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PYOCYANIN, A VIRULENCE FACTOR PRODUCED BY SEPSIS-CAUSING 
PSEUDOMONAS AERUGINOSA, PROMOTES ADIPOSE WASTING AND 
CACHEXIA 
 
 
 
Sepsis is a leading cause of death among critically ill patients that 
results in metabolic alterations including hypercatabolism, lipoatrophy, and 
muscle wasting, contributing to the development of cachexia. Septic 
cachexia is associated with loss of body weight, fat mass, and lean mass 
and dysregulated immune function. There are currently no efficacious 
treatment strategies for septic cachexia, and nutritional interventions have 
limited success in preventing hypercatabolic wasting. Pyocyanin is a 
virulence factor produced by sepsis-causing Pseudomonas aeruginosa that 
has been shown to activate the aryl hydrocarbon receptor (AhR), increase 
inflammation, and produce reactive oxygen species. Thus, pyocyanin 
represents a novel mechanistic target in the development of septic cachexia. 
In Aim 1, we hypothesized that pyocyanin reduces adipocyte 
differentiation and activates AhR in vitro and in vivo. In vitro, pyocyanin 
reduced differentiation of 3T3-L1 cells to adipocytes and promoted 
expression of proinflammatory cytokines. These effects were associated with 
activation of AhR. We established an in vivo model of pyocyanin-induced 
cachexia using repeat intraperitoneal exposure to pyocyanin in male and 
female C57BL/6J mice. Acutely, pyocyanin reduced differentiation of stem 
cells isolated from adipose stromal vascular tissue and augmented 
expression of proinflammatory cytokines. Chronically, pyocyanin reduced 
body weight and fat mass, which was associated with adipose-specific AhR 
activation. Pyocyanin had sexually dimorphic effects on lipolysis and 
adipocyte inflammation. These data suggest a role of pyocyanin in adipose 
cachexia associated with sepsis. 
 In Aim 2, we hypothesized that pyocyanin activates adipocyte AhR to 
promote adipose tissue wasting and cachexia. To test this hypothesis, we 
used a mouse model of adipocyte-specific deficiency of AhR and chronically 
administered pyocyanin to male and female mice. In male mice with 
adipocyte AhR deficiency, effects of pyocyanin to promote adipose wasting 
and cachexia were attenuated. In contrast, female adipocyte AhR deficient 
mice had an augmented response to pyocyanin to decrease body weight. 
Results suggest divergent mechanisms of pyocyanin to regulate adiposity 
and body weight through adipocyte AhR between male and female mice.  
These data support a role for pyocyanin in the development of 
adipose cachexia associated with Pseudomonas aeruginosa sepsis that is 
partially regulated by adipocyte AhR. Targeting pyocyanin’s effects on 
adipocytes represents a potentially novel therapeutic approach for septic 
cachexia that could mitigate septic cachexia, a condition associated with 
increased risk of mortality in this population. 
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Chapter 1 Literature Review 
 
1.1 Sepsis: Overview and Evolving Definitions 
In 2016, a task force convened by the European Society of Intensive Care 
Medicine and the Society of Critical Care Medicine published the Third 
International Consensus Definitions for Sepsis and Septic Shock (Sepsis-3). The 
new consensus defines sepsis as life-threatening organ dysfunction caused by a 
dysregulated host response to infection [1]. Infection is identified using the 
classifications of a systemic inflammatory response syndrome (SIRS), defined as 
the presence of two or more of the following: temperature >38oC or <36 oC, heart 
rate >90 beats/min, respiratory rate >20 breaths/min or PaCO2 <32 mmHg (4.3 
kPa), or white blood cell count >12,000/mm3 or <4000/mm3 or >10% immature 
bands [1]. Organ dysfunction is defined by a Sequential Organ Failure 
Assessment (SOFA) score of 2 points or higher, with higher scores associated 
with greater mortality in sepsis [1, 2]. However, because SOFA definition requires 
laboratory tests that may be time-consuming, the task force also suggested the 
use of quick SOFA (qSOFA) to quickly identify organ dysfunction using the 
following definitions: a respiratory rate > 22/min, altered mentation, and systolic 
blood pressure >100mmHg [1].  
Septic shock represents a more severe and lethal subcategory of sepsis. 
The definition of septic shock was broadened from “a state of acute circulatory 
failure” to “a subset of sepsis in which underlying circulatory and cellular 
metabolism abnormalities are profound enough to substantially increase 
mortality” [1, 3]. The clinical criteria of septic shock now incorporate both 
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hyperlactemia and hypotension, identified clinically by a serum lactate level >2 
mmol/L (18mg/dL) and the required use of vasopressors to maintain a mean 
arterial pressure (MAP) > 65 mmHg despite adequate fluid resuscitation [1]. 
Septic shock can be divided into the ebb and flow phases. The ebb phase is 
characterized by hyper-dynamic shock, decreased systemic vascular resistance, 
and hypovolemia [4]. After stabilization, the patient enters the hyper-catabolic 
flow phase with activation of the innate immune system and increased energy 
expenditure [4, 5]. Lastly, the task force also approved a lay definition of sepsis 
to increase awareness and understanding of the syndrome. 
The new definition of sepsis aims to encapsulate the dichotomous 
pathobiology of sepsis, involving both pro- and anti-inflammatory responses [1, 
6]. Furthermore, while these inflammatory responses are triggered by the 
presence of an exogenous pathogen, the milieu of sepsis is heavily impacted by 
endogenous factors and the host’s immune system [1, 7, 8]. The first definition of 
sepsis was released in 1992 and derived the definition of sepsis from the 
presence of SIRS in the host [9]. In 2001, a second definition was released that 
expanded the diagnostic criteria for sepsis by adding organ injury but was largely 
the same as the 1992 guidelines [3]. Until Sepsis-3, the definition of sepsis had 
been largely unchanged for over two decades. The new definition of sepsis 
incorporates the use of patient health records and is based on the current 
understanding of the pathobiology of sepsis, including changes of organ function, 
biochemistry, and circulation. Furthermore, Sepsis-3 aims to encompass the 
heterogeneous and complex nature of sepsis, including the diverse effects that 
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age, sex, existing conditions, and source of infection play in incidence and 
progression of affected patients [1, 10].  
As can be seen from evolving definitions, sepsis is a syndrome that 
currently lacks a standard diagnostic test and is, therefore, difficult to define and 
diagnose. As such, the new definition of sepsis aimed to differentiate sepsis from 
uncomplicated infection, update the definition to reflect new knowledge of sepsis 
pathobiology, promote early recognition of sepsis, and produce a more simple 
and consistent identification of sepsis. Furthermore, adding “life-threatening 
organ dysfunction” to the definition emphasizes the potential lethality and 
necessity of early diagnosis and treatment of sepsis [1]. Under this new 
definition, “severe sepsis” becomes “superfluous” and has been removed from 
the definition [1]. Additionally, the task force believed that the similar 
characteristics of “sepsis” and “severe sepsis” contributed to confusion amongst 
clinicians and patients [1].   
The previous use of two or more SIRS criteria to diagnose sepsis was 
deemed “unhelpful” by the 2016 task force [1]. The SIRS criteria do not 
accurately distinguish a normal inflammatory response from dysregulated 
inflammatory response and life-threatening sepsis; for example, a bad cold could 
be diagnosed as sepsis using SIRS criteria, which could lead to unnecessary 
antibiotic use contributing to antibiotic resistance. Furthermore, the SIRS criteria 
failed to capture the dynamic pro- and anti-inflammatory responses of sepsis. 
However, SIRS is still helpful in identifying an infection.  
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The task force recognized that the clinical criteria for sepsis should allow 
for prompt diagnosis of sepsis, as early recognition and treatment of sepsis can 
improve patient outcomes. The new definition sought to increase uniformity in 
definitions of sepsis, which would lead to fewer variations in reported incidences 
and mortality rates. Increased standardization allows for more accurate 
epidemiological reporting of sepsis and allows for more accurate coding in 
hospitals. As opposed to the previous definitions, which were based on expert 
opinion, Sepsis-3 is based on objective data and large databases of patient 
records.  
However, the new definition of sepsis is not without flaws. SOFA is not 
well known outside of the critical care community, and the data required for 
qSOFA criteria may not be available in hospitals outside of the U.S. [11]. Neither 
SOFA nor SIRS determine the cause of the dysfunction [12]. The task force 
acknowledged the need for an updated SOFA scoring system or implementation 
of a superior scoring system for organ dysfunction in future definitions [1]. 
Furthermore, by removing the progression from sepsis to severe sepsis to septic 
shock in place of a more severe definition of sepsis, there have been concerns 
these stringent guidelines may delay recognition and intervention in patients [13]. 
However, despite these weaknesses of Sepsis-3, revised definitions are 
necessary to update diagnostic criteria to reflect current advances in the 
understanding of the mechanisms and pathophysiology of sepsis.  
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1.1.1 Global Burden of Sepsis 
      Sepsis remains a leading cause of death in critically ill patients, with global 
estimates of 31.5 million cases resulting in 5.3 million deaths annually [14]. In the 
United States (US), the prevalence of sepsis is estimated at 1.7 million cases 
resulting in 265,000 deaths per year [15]. The prevalence of sepsis has 
increased 13.7% per year from 1979 to 2000, with 659,935 recorded cases in 
2000 [16]. During this 22-year period, sepsis incidence also increased 8.7% 
annually [16]. Sepsis incidence has risen precipitously to 535 hospitalized cases 
per 100,000 US residents [17], placing sepsis incidence far higher than 
myocardial infarction (208 cases per 100,000 person-years) [18] and the 
combination of lung, breast, and prostate cancer (129, 124, and 115 per 100,000, 
respectively [19]). Despite the shockingly high incidence rates of sepsis, it often 
receives far less attention than heart disease and cancer. This increase in sepsis 
incidence can be explained, in part, by augmentations in antibiotic resistance, 
elderly populations, diseases and treatments that cause immune suppression, 
transplantation surgeries and other invasive procedures, and nosocomial 
infections [16]. 
Sepsis mortality rates are high despite advances in critical care, and 1 in 3 
hospital deaths are due to sepsis [20]. Septic patients face a 25-30% mortality 
rate that rises to 40-50% in cases of septic shock [21]. Globally, mortality rates 
are highest in the Middle East, Eastern Europe, and South America and lowest in 
North America [21]. Among sepsis decedents, the most common listed causes of 
death were unspecified septicemia, septicemia caused by other gram-negative 
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bacteria, and septicemia caused by Staphylococcus aureus [22]. Sepsis 
particularly affects the elderly population. Of sepsis mortalities, 49% of patients 
were 65-84 years old, 26% were >85 years old, and 25% were 25-64 years old; 
patients <25 years old accounted for 1% of decedents [22].  
These increases in sepsis incidence and prevalence are placing a heavy 
burden on the US healthcare system. Sepsis is the most expensive condition 
treated in hospitals in the US, accounting for $24 million in aggregate hospital 
costs [23, 24]. Costs of sepsis are estimated at $22,000 to 50,000 per patient 
[25, 26] with total costs at $17 billion annually [25]. The length of hospital stays 
has increased from 1979 to 2000 [16], with median ICU and hospital stays of 5 
days and 10 days, respectively [15]. Increased hospital stays are problematic, as 
mortality is higher among patients who contract sepsis after hospital admittance 
(25.5%) as compared to patients who present with sepsis upon admission 
(13.4%) [16]. Moreover, fewer patients diagnosed with sepsis are discharged to 
home while a growing number are discharged to long-term care or other health 
care facilities [16]. Therefore, sepsis represents a growing and ponderous 
chronic critical health issue.  
Sex differences exist in the incidence, prevalence, and mortality from 
sepsis. Prevalence of sepsis is higher among males than females [15, 16]. From 
1979 to 2000, sepsis incidence increased in both sexes; however, incidence 
increased more rapidly in females [16]. Sepsis incidence occurs later in life for 
females than males, with a mean age of 62.1 years in females and 56.9 years in 
males [16]. Furthermore, mortality rates are higher for males than females [15]. 
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These sex differences result from the influence of sex hormones on inflammation 
and energy and lipid metabolism [27]. Therefore, females appear to be slightly 
protected from sepsis as compared to males. 
 
1.1.2 Pathogenesis of Sepsis: Cytokine Cascade 
The immune response of the host and the resulting pathogenesis of 
sepsis depend on the location of infection, type of infection, and existing immune 
status of the host. Sepsis most often originates from infections in the lungs 
(40%), abdominal organs (30%), and urinary tract (10%) [28, 29]. In 2000, the 
leading causes of sepsis were gram-positive bacteria (52.1% of cases) and 
gram-negative bacteria (37.6% of cases), with polymicrobial infections, 
anaerobes, and fungi accounting for the remaining cases [16]. Among gram-
positive bacteria, Staphylococcus aureus and Streptococcus pneumoniae 
dominate. On the other hand, Escherichia coli, Klebsiella species, and 
Pseudomonas aeruginosa account for the majority of gram-negative bacterial 
infections [30, 31]. Bacterial components and toxins produced by these 
microorganisms play a pivotal role in the pathogenesis of sepsis. 
Recognition of microorganisms by pattern recognition receptors (PRRs) 
triggers activation of the innate immune system. PRRs recognize exogenous 
pathogen-associated molecular patterns (PAMPs), inherent microbial 
components of bacteria, fungi, parasites, or viruses, or endogenous damage-
associated molecular patterns (DAMPs) [32]. The toxins released by the 
microorganism combined with the cytokines released by the host’s immune 
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response ultimately result in cell death activation of DAMPs. Therefore, activation 
of both exogenous and endogenous activation cascades results in an amplified 
inflammatory response.  
Common PRRs in sepsis include Toll-like receptors (TLRs), nucleotide-
binding oligomerization domain (NOD)-like receptors, and retinoic acid-inducible 
gene (RIG)-like receptors. TLRs, perhaps the most studied PRR in sepsis, can 
detect bacterial components. For example, TLR4 recognizes lipopolysaccharide 
(LPS), a potent immunostimulant contained the in the cell walls of Gram-negative 
bacteria [32]. Interestingly, septic patients possess leukocytes bearing higher 
expression levels of TLR4 [33, 34]. Upon binding to exogenous and/or 
endogenous ligands, PRRs induce signaling cascades that ultimately lead to 
inflammation. PRR binding to PAMPs and DAMPs can result in activation of 
mitogen-activated protein kinase (MAPKs), Janus kinases (JAKs) or signal 
transducers and activators of transcription (STATs), or nuclear factor kappa-light-
chain-enhancer of activated B cells (NF-), triggering the production of an 
inflammatory “cytokine storm [35].” 
Cytokines are small cell signaling proteins (<40 kDa) that play an 
important role in immunomodulation via autocrine, paracrine, and endocrine 
signaling to promote inflammation [36]. Cytokines, including tumor necrosis factor 
(TNF), interleukins (IL), chemokines, and interferons, constitute a delicate 
balance between pro- and anti-inflammatory processes. The pro-inflammatory 
cytokines TNF-, interleukin (IL)-1, and IL-6 are commonly studied in sepsis; on 
the other hand, anti-inflammatory IL-10 and IL-1 receptor antagonist (IL-1Ra) 
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play an immunosuppressive role in sepsis. IL-10 blocks the production of 
inflammatory cytokines by immune cells in an attempt to dampen the 
inflammatory process [6, 37, 38]. Cytokine production occurs rapidly after micro-
organismal insult, with peak levels of TNF-, IL-6, IL-1, and IL-10 reached 1.5-2 
hours after infection and rapidly decreased after 6 hours [39-42]. This cytokine 
cascade contributes to activation and recruitment of leukocytes, namely 
monocytes/macrophages, neutrophils, eosinophils, basophils, and natural killers 
(NKs) [42, 43]. Recruitment of leukocytes to the site of infection aims to resolve 
the infection by clearing microorganisms and dead cells and generating 
inflammation; however, this inflammation becomes problematic when it spreads 
systemically.  
Paradoxically, while systemic inflammation is the hallmark of sepsis, anti-
inflammatory cytokines are also heavily produced, resulting in immune 
suppression. Anti-inflammatory cytokines, such as IL-10 and transforming factor-
 (TGF-) suppress immune function, which increases the risk of opportunistic 
infection, positive blood cultures, and re-activation of latent viruses in septic 
patients [44-46]. These anti-inflammatory cytokines are produced by 
immunosuppressive immature polymorphonuclear leukocytes (PMNs), myeloid-
derived suppressor cells (MDSCs), and M2 macrophages, which are increased 
as a consequence of sepsis [47]. Expansion of T regulatory cells and anergic 
(unresponsive) T cells, a shift towards an immunosuppressive T helper 2 (TH2) T 
cell phenotype, and apoptosis of T cells, B cells, and dendritic cells further drives 
the immunosuppression of chronic sepsis [47-49]. Ultimately this dichotomy 
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between inflammation and immunosuppression in chronic sepsis leads to 
persistent inflammation/immunosuppression and catabolism syndrome (PICS) 
[50-53]. PICS, characterized by persistent inflammation, immunosuppression, 
organ failure, poor wound healing, and cachexia, is a growing problem among 
chronic critically ill patients and contributes to complications of sepsis, difficulties 
in treatment strategies, and poor outcomes. 
 
1.1.3 Pseudomonas Aeruginosa 
Pseudomonas (P.) aeruginosa is one of the main organisms responsible 
for nosocomial infections. This opportunistic bacterium commonly afflicts 
immunocompromised patients, such as intensive care unit (ICU) patients, burn 
victims, septic patients, and individuals with cystic fibrosis (CF). Among bacteria 
isolated from blood cultures, P. aeruginosa is the third most frequent gram-
negative pathogen and seventh most frequent among all pathogens [54, 55]. 
Risk of P. aeruginosa infection is increased with presence of a central venous or 
urinary catheter, previous bacteremia or antibiotic therapy, mechanical 
ventilation, and neutropenia [56]. P. aeruginosa is associated with a higher 
fatality rate than other gram-negative bacterial infections, likely due to its high 
propensity for bacterial resistance [54, 57-60]. Of cultures positive for P. 
aeruginosa among hospital patients, 29.6% were resistant and 33.3% were multi 
drug resistant [61]. The rates of drug resistance to this pathogen have been 
steadily growing [54], indicating a need for new therapeutic strategies to treat 
conditions that result from P. aeruginosa infection, including sepsis. 
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P. aeruginosa is an important cause of gut-derived sepsis. Although 
intestinal colonization of P. aeruginosa is low in healthy individuals, studies have 
shown that up to 36% of hospitalized patients have P. aeruginosa in their 
intestinal flora [62, 63], and 21% of these individuals have sepsis [64]. No studies 
have identified a role of P. aeruginosa in cachexia of gut-derived sepsis; 
however, P. aeruginosa is the most common infection in CF patients, a chronic 
lung condition that is associated with growth failure and chronic malnutrition [65, 
66]. Moreover, lung infection with P. aeruginosa in mice is associated with 
significant loss of body weight that correlates with expression of TNF- and IL-1 
in bronchoalveolar lavage fluid [67]. Infections with P. aeruginosa are followed by 
an influx of neutrophils, which release ROS and proteases upon activation [68-
70]. The pervasive nature of P. aeruginosa infection is attributable to is 
production of virulence factors, antibiotic resistance due to an impermeable outer 
membrane, and formation of biofilms [71]. 
Bacteria communicate with each other using secreted signaling 
compounds through a process called quorum sensing (QS). The gram-negative 
P. aeruginosa contains three QS systems: Las, Rhl, and the Pseudomonas 
quinolone signal (PQS) [72]. The activation of PQS leads to the production of 
virulence factors such as the heterocyclic, redox-active phenazines [73]. P. 
aeruginosa releases at least four phenazines: pyocyanin, 1-hydroxyphenazine 
(1-HP), and phenazine-1-carboxamide (PCN), which are derived from the 
common precursor phenazine-1-carboxylic acid (PCA) [74]. In addition to the 
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blue-pigmented pyocyanin, P. aeruginosa also produces pyoverdine (yellow-
green), pyomelanin (light-brown), and pyorubin (red-brown) [75, 76].  
 
1.1.4 Complications and Treatment Strategies  
The cytokine storm of sepsis leads to deleterious effects on organ 
systems, particularly neurological, pulmonary, cardiovascular, renal, 
hematological, and hepatic dysfunction. Globally, common sepsis comorbidities 
include chronic obstructive pulmonary disease (COPD), cancer, type II diabetes 
mellitus, heart failure, chronic renal failure, and immunosuppression [15, 21]. The 
complex paradox of inflammation and immune suppression in sepsis has created 
challenges for treatment strategies as well as clinical applications of inflammatory 
research findings. Moreover, chronic critical illness and intensive care unit (ICU) 
stays can also lead to long-term reductions in quality of life and cognitive 
impairments [77, 78]. Chronic critical illness (CCI) is defined as an ICU stay of > 
8 days plus the presence of one of the following: sepsis, severe wounds, 
prolonged mechanical ventilation, tracheotomy, stroke, or traumatic brain injury 
[79]. Advances in critical care have increased survival through the acute 
inflammatory stage of sepsis; however, new issues in treatment strategies have 
arisen as septic patients progress to CCI and face metabolic alterations, such as 
hyper-catabolism, for which current nutrition therapies are ineffective.  
There is currently no FDA-approved medication to treat sepsis. Infection 
control, hemodynamic management, and regulation of the cytokine storm form 
the basis of sepsis treatment. The frontline of treatment involves identification of 
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the source of infection and antibiotic administration. Antibiotic therapy should be 
initiated as soon as possible following sepsis diagnosis to reduce the risk of 
mortality [80, 81]. Sepsis can be caused by different kinds of bacteria, which are 
best killed by different types of antibiotics. However, because identifying the type 
of bacteria causing the infection can be time-consuming, physicians usually 
begin treatment with broad-spectrum antibiotics, such as ceftriaxone, 
azithromycin, ciprofloxacin, vancomycin, and piperacillin-tazobactam, which 
cover a wide range of common sepsis culprits. Often, combination antibiotic 
treatment is preferred [82, 83]. Once the type of bacteria is identified, a more 
targeted antibiotic treatment protocol should be utilized to reduce costs and the 
development of antibiotic resistance.  
Hemodynamic stabilization involves the use of fluids to prevent dangerous 
hypotension, organ injury, and shock. Fluid resuscitation in sepsis occurs in four 
stages: salvage, optimization, stabilization, and de-escalation [84]. Intravenous 
fluid administration allows the medical team to track the amount and types of 
fluids the patient receives. Fluids can also help prevent dehydration and kidney 
failure. Current guidelines recommend commencing treatment with initial fluid 
resuscitation with 30mL/kg of crystalloid within the first three hours [85]; however, 
the guidelines for fluid resuscitation in sepsis are an area of controversy [86]. 
Mechanical ventilation is also used to correct hypoxemia and prevent lung injury 
[87].  
Lastly, drug development has focused largely on targeting the cytokine 
storm and early pro-inflammatory phase of sepsis. However, over 150 clinical 
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trials targeting PRRs, PAMPs, or cytokines have not been successful in 
improving patient outcomes [47]. In fact, some of these anti-inflammatory 
therapies actually increased patient mortality [88, 89]. These clinical trials may 
not have been successful due to improper timing of drug administration or poor 
identification of target sepsis patient population for treatment [90]. The failure of 
these clinical trials and lack of identification of a treatment for sepsis highlight the 
complexity of the pathogenesis of sepsis and the need for novel mechanisms to 
target for sepsis therapeutic development. However, advancements on this front 
have been complicated by several drawbacks in the study of sepsis, largely 
performed in animal models of research. 
Animal studies of sepsis utilize host-barrier disruption models, toxemia 
models, and bacterial infection models to replicate sepsis. Cecal ligation and 
puncture (CLP), a host-barrier disruption model, is considered the gold standard 
for experimental sepsis research. This model involves midline laparotomy 
followed by ligation and puncture of the cecum in order to replicate the human 
conditions of ruptured appendicitis or perforated diverticulitis [91, 92]. CLP results 
in a polymicrobial infection as a result of extrusion of fecal contents into the 
peritoneum; furthermore, the ligated cecum is a necrotic source of inflammation 
[91]. In toxemia models, exogenous administration of a toxin to induce sepsis 
allows researchers to tightly control the experimental model and investigate the 
effects and mechanisms of particular compounds. Common chemical mediators 
used include TLR4 activators (i.e. LPS) or TLR9 activators (i.e. 
immunostimulatory CpG DNA) [91]. This model is popular due to its simplicity. 
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Bacterial infection involves administration (often injection) of pure or mixed 
bacterial flora and can provide important insights on the mechanisms of host 
response to specific pathogens. Furthermore, various sites of infection can be 
examined, with the peritoneal compartment, lung, and blood being common 
routes of inoculation. Additionally, bacterial strains can be tested in isolation, and 
the severity of sepsis can be adjusted by altering the bacterial load used for 
infection. 
Overall, the models presented above represent useful, rapid, and 
reproducible methods of studying sepsis. The animal models used, such as mice, 
are small and cost-effective. Furthermore, various strains of mice, including those 
with knockdown of certain genes either in specific tissues or whole body, allows 
for valuable mechanistic elucidation of the pathophysiology of sepsis. However, 
there are major drawbacks to the utilization of animal models for the examination 
of human sepsis. Namely, the timeline of disease progression is far more rapid in 
animal models, with animals succumbing to sepsis and organ failure within hours 
to days as compared to days to weeks in human patients [91]. Furthermore, mice 
and humans differ in their immune responses, compounding difficulties for clinical 
translation. Additionally, human sepsis patients usually receive some forms of 
supportive care (i.e. antibiotics, mechanical ventilation, and enteral/parenteral 
nutrition); however, these methods are rarely employed in animal studies, and 
certain forms of supportive care, such as use of antibiotics, may confound the 
ability to study the effect of pathogen (i.e. in the bacterial infection models) [93]. 
Lastly, sepsis patients represent a heterogeneous population of different ages, 
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sex, race, immune function, type of infection, and location of infection that are not 
easy to replicate in animal studies.  
The current treatment strategies for sepsis discussed above merely 
attempt to control the symptoms of sepsis. The complexity of treating sepsis is 
evident by the lack of an FDA-approved medication for the treatment or 
prevention of sepsis. Failure of anti-inflammatory treatments that target the 
cytokine storm indicate that these endogenous inflammatory pathways may be 
essential for immunity against sepsis. While these drugs reduce inflammation, 
they also suppress immune function, thus increasing susceptibility to secondary 
infection. Identification of efficacious therapies is further complicated by the use 
of animal models in research that often cannot replicate the complex and 
dynamic nature of sepsis. Therefore, a growing number of patients are 
progressing to chronic critical illness and face changes in metabolism that 
ultimately lead to cachexia. As such, there is a gap in the research for sepsis 
treatment development, representing a need to identify novel mechanisms of 
therapeutically targetable sepsis pathogenesis.  
 
1.2 Cachexia in Chronic Critical Illness 
Cachexia is a serious complication of sepsis, necessitating the 
development of novel therapeutic approaches. In addition to sepsis, cachexia is 
present in cancer, chronic heart failure (CHF), chronic renal failure (CRF), 
chronic obstructive pulmonary disease (COPD), and human immunodeficiency 
virus infection/acquired immune deficiency syndrome (HIV/AIDS) [94]. Cachexia 
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is a complex metabolic syndrome characterized by weight loss, weakness, and 
fatigue as a result of muscle wasting with or without fat loss [95]. This wasting, 
associated with increased morbidity and mortality, is often associated with 
inflammation, anorexia, and insulin resistance as a result of chronic critical illness 
[95]. As previously discussed, there are currently no FDA approved medications 
for the treatment of sepsis. Current treatment strategies, such as antibiotics and 
fluid resuscitation, have increased acute sepsis survival; however, a growing 
number of septic patients are progressing to chronic critical illness (CCI), falling 
victim to the weight loss, hyper-catabolism, and increased risk of mortality 
associated with cachexia.   
Cachexia is diagnosed as edema-free weight loss of at least 5% in 12 
months or less, or a BMI <20 kg/m2 plus 3 of the 5 following conditions: low fat-
free mass, decreased muscle strength, fatigue, anorexia, or abnormal 
biochemistry indicating increased inflammation, anemia, or low serum albumin 
[95]. Weight loss is consistently associated with poor outcomes and mortality in 
cancer [96, 97], chronic heart failure [98], HIV [99, 100], and the elderly [101]. 
Cachexia is often misdiagnosed as malnutrition as it is often associated 
with reductions in appetite. Malnutrition is distinct from cachexia as it can be 
overcome with adequate nutrition and proper absorption and utilization of 
nutrients [102]. Furthermore, during starvation, metabolism attempts to preserve 
body composition, particularly lean mass, while the inflammation associated with 
cachexia contributes to hyper-catabolism and wasting of fat and lean mass [103]. 
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While anorexia is common in chronic critical illness, the loss of muscle and fat 
mass often precedes a drop in food intake [104, 105].  
Due to the deleterious effects on quality of life and patient outcomes, the 
muscle wasting of cachexia has been extensively studied. In skeletal muscle, the 
accelerated loss of muscle mass contributes to fatigue and distinguishes 
cachexia from weight loss caused by reduced intake [106]. The wasting of 
muscle is attributed to increased protein breakdown and reduced protein 
synthesis [107, 108], with breakdown of the actin and myosin proteins as the 
primary mechanism [109, 110]. Inflammatory markers such as NF-κb have been 
shown to increase protein breakdown [111]. The weakness and fatigue created 
by muscle cachexia necessitates the use of mechanical ventilation, prolonging 
hospital stays and increasing risk of lung injury and mortality [107]. In septic 
cachexia, pro-inflammatory cytokines, glucocorticoids, and the ubiquitin-
proteasome system result in increased muscle wasting [112, 113]. While muscle 
wasting is similar between males and females in moderate weight loss cachexia, 
severe weight loss results in a sexually dimorphic effect on muscle function, with 
males losing more muscle function than females [114, 115]. 
While the wasting of muscle has been extensively studied in cachexia 
[107, 108, 112, 113, 116], the loss of fat mass in cachectic patients is poorly 
understood [95]. Furthermore, the loss of fat may precede muscle wasting of 
cachexia, and lipolysis contributes to reductions in muscle mass [117, 118]. 
Increases in lipolysis [119-124] and fatty acid oxidation [122, 125, 126] in 
cachexia result in fat loss that is predictive of poor survival [127-129]. 
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Furthermore, increased thermogenesis in brown adipose [130, 131] and 
browning of white adipose tissue [132-135] have been reported in mouse models 
of cancer cachexia and may further augment the wasting of adipose tissue.  
White adipose tissue (WAT) plays a critical role in the regulation of 
cachexia [136]. In cancer, adipose cachexia has been associated with increased 
lipolysis [123, 124, 137], reduced lipogenesis [138], alterations in adipogenesis 
genes [139, 140], and altered remodeling of the extracellular matrix [139, 141, 
142]. In both human and mouse cancer cachexia, WAT had increased 
expression of nuclear factor  (NF-), inflammatory cytokines TNF-), IL-1, 
and IL-6, and NACHT, LRR and PYD domains-containing protein 3 (NLRP3) 
inflammasome activation [136, 143]. Furthermore, cachectic adipose tissue was 
apoptotic as measured by Caspase-3 and -9 cleavage as well as remodeling of 
the extracellular matrix [142]. Clinical studies of cachectic cancer patients 
demonstrated increased mRNA abundance of adiponectin, TNF-, and IL-6 in 
subcutaneous adipose tissue [143]. Interestingly, these changes in gene 
expression were exclusive to subcutaneous adipose and were absent in visceral 
fat [143]; therefore, subcutaneous adipose tissue potentially has a greater 
contribution to the inflammation and progression of cancer cachexia. Even within 
visceral fat, different depots (i.e. retroperitoneal fat and mesenteric fat) respond 
differently to atrophy, inflammation, and changes in adipocyte size in cancer 
cachexia [140, 142, 144]. 
It is evident that understanding early mechanisms of adipose cachexia is 
essential for the development of potential therapies. In a study of early cancer 
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cachexia in mice, increased basal lipolysis and phosphorylation of hormone 
sensitive lipase (HSL) were associated with reductions in body weight, muscle 
mass, and the mass of epididymal, inguinal, and interscapular brown fat [119]. 
Indirect calorimetry of mice with early cancer cachexia revealed elevations in 
total energy expenditure (TEE) and rectal temperature and decreased locomotor 
activity and respiratory exchange ratio (RER) [119]. However, studies in cancer 
cachexia have revealed normal [145], reduced [146], or elevated [147] TEE 
depending on the type of cancer. Reductions in RER indicate greater oxidation of 
fat as an energy source. Moreover, fatty acid oxidation and thermogenesis were 
increased in brown adipose tissue from cachectic mice [119].  
 
1.2.1 Fat Metabolism in Sepsis 
Cachexia is associated with hyper-catabolism and metabolic alterations 
including increased lipolysis, hyperglycemia, hyperlactatemia, and 
hypoaminoacidemia, which ultimately contribute to the wasting of fat and lean 
mass [148]. Hypoaminoacidemia is a result of increased utilization of amino acids 
that cannot be compensated by muscle catabolism [149, 150]. Increases in 
plasma lactate can augment the Cori cycle to convert lactate to glucose in the 
liver during cachexia [151]. Since the Cori cycle is energy-consuming, this 
increase in glucose flux may contribute to weight loss [151]. 
After consuming dietary fat, lipid triglycerides (TGs) are hydrolyzed to free 
fatty acids (FFAs) and glycerol by intestinal lipases. In the enterocyte, the FFAs 
are re-esterified with glycerol, forming TGs that enter the lymphatic circulation as 
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chylomicrons. These TGs can be hydrolyzed by lipoprotein lipase (LPL) to 
release fatty acids that can be stored as energy in adipose tissue. In the 
postprandial period, this stored energy can be liberated via lipolysis by hormone-
sensitive lipase (HSL), producing non-esterified fatty acids (NEFAs) and glycerol 
[152]. Catecholamines, which are increased in sepsis, activate HSL and 
stimulate lipolysis [153]. 
Adipose tissue can be divided into subcutaneous and visceral fat. 
Subcutaneous fat is found under the skin, while visceral fat is found in the 
abdomen and around organs. Visceral fat is more vascular and innervated than 
subcutaneous fat, and its blood drains through the portal vein, providing the liver 
with direct access to free fatty acids and adipokines [154]. Visceral adipose 
tissue contains more glucocorticoid receptors involved in the metabolic regulation 
[155, 156] and more adrenergic receptors, indicating a greater capacity for 
catecholamine-induced lipolysis during sepsis [157, 158]. 
Fat is the preferred energy fuel source of sepsis [120, 159, 160]. The 
increase in fat oxidation and resting energy expenditure of septic patients is 
associated with an increase in lipid cycling and plasma NEFAs that cannot be 
suppressed with glucose infusion [161-164]. In sepsis, increased plasma NEFAs 
are reflective of augmented lipolysis [165, 166]. The cytokine storm of sepsis can 
contribute to lipolysis, as TNF- can directly increase lipolysis [167]. Increases in 
TNF- may increase circulating lipid by inhibiting lipoprotein lipase, preventing 
uptake of circulating fatty acids for storage in adipose tissue [168]. Furthermore, 
catecholamines, which can trigger lipolysis, are elevated in septic patients [169]. 
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Glucagon is also elevated in sepsis and can drive lipolysis and catabolism [148, 
170]. Increased plasma NEFAs results in greater fatty acid oxidation, which is 
reflected by a lower respiratory quotient in sepsis [159]. Additionally, increased 
circulating NEFAs can augment proteolysis and exacerbate wasting of lean mass 
[171]. 
 
1.2.2 Septic Cachexia 
The metabolic alterations of sepsis, including insulin resistance, 
hyperlactatemia, hypercatabolism, muscle wasting, and lipoatrophy [94, 172, 
173], contribute to cachexia pathogenesis (Figure 1.1). The relationship between 
inflammation and altered metabolism in sepsis is described as the metabolic 
inflammatory complex or immunometabolism [174]. Mitochondrial dysfunction 
leads to the release of mitochondrial DNA, which triggers activation of the NLRP3 
inflammasome, production of ROS, and release of mitochondrial DAMPs, 
ultimately contributing to increased systemic inflammation and multiple organ 
dysfunction [94, 175-177]. Metabolic dysfunction and inflammatory pathways, 
such as NF-B and hypoxia-inducible factor 1-alpha (HIF-1), enhance each 
other in a feed forward mechanism [175-177]. 
High levels of plasma lactate, or hyperlactatemia, is a “hallmark of sepsis” 
linked to increased mortality [178]. Increased production as opposed to reduced 
clearance of lactate is implicated in hyperlactatemia. The increased production of 
lactate is believed to result from cytopathic hypoxia, the shift from mitochondrial 
oxidative phosphorylation to anaerobic glycolysis for the production of adenosine 
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triphosphate (ATP), even in the presence of oxygen [179, 180]. This metabolic 
shift has also been established in cancer as the Warburg effect and in diabetes 
as pseudohypoxia [181]. Studies have suggested that adipose tissue may be the 
site of lactate generation in sepsis [182]. In septic patients, increased lactate 
clearance in the blood [183, 184] and in adipose tissue [182] is associated with 
improved clinical outcomes.  
Rates of obesity have grown at an alarming rate, and obesity is 
independently associated with increased all-cause mortality [185]. However, the 
obesity paradox indicates that fat mass may play a protective role in sepsis. 
Obese and overweight septic patients have improved outcomes as compared to 
normal-weight patients [186-188]. In mice, high fat feeding prior to sepsis 
induction by CLP stabilized body temperature, improved immune response, and 
increased survival [189]. Another study in mice using CLP found that obese mice 
lost more fat mass but less lean mass than lean mice, which was associated with 
improved hepatic fatty acid and glycerol metabolism and reduced serum fatty 
acids in obese mice [190]. Furthermore, the authors of this study suggest obese 
mice may have a different metabolic response to sepsis, as body fat was more 
reduced in obese mice while muscle protein and triglycerides in muscle and liver 
were preserved [190]. Greater fat depots of obese individuals allow more fatty 
acids and glycerol to be released and subsequently utilized, thus protecting vital 
organs. Interestingly, while the loss of body weight, fat mass, and lean mass 
were not affected by parenteral nutrition, obesity appeared to protect against 
muscle wasting and weakness [190].  
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There is a growing appreciation that adipose tissue is an endocrine organ 
that can secrete adipokines. Adipocytes produce monocyte chemoattractant 
protein-1 (MCP-1), triggering the infiltration of macrophages into fat depots that 
then secrete inflammatory cytokines [154]. These adipokines, which are 
implicated in cachexia pathogenesis, include IL-6, TNF-, leptin, adiponectin, 
and C-reactive protein (CRP) [154]. Moreover, visceral adipose tissue is capable 
of producing these inflammatory adipokines to a greater extent than 
subcutaneous fat [191-193] and is more susceptible to weight loss [194].  
Very few studies have investigated adipose cachexia in sepsis. In one 
study investigating the catabolic state of sepsis, C57BL/6 mice that underwent 
cecal ligation and puncture (CLP) had reduced body weight within 24 hours with 
peak body weight reductions at 2-4 days [195]. While mice undergoing sham 
surgery were able to restore their body fat mass to normal by day 10, mice with 
CLP-sepsis failed to replete their white adipose tissue [195]. This acute reduction 
in body weight was associated with increased endoplasmic reticulum (ER) stress, 
apoptosis, proteasome activity, increased NLRP3 inflammasome activation, and 
lipolysis as well as decreased adipose lipogenesis [195].  
Similarly, in humans injected with lipopolysaccharide, early endotoxemia 
was associated with increased lipolysis and glycerol release from adipose tissue 
[196]. The recovery phase of experimental sepsis was associated with increased 
global protein synthesis independent of mTORC1, increased autophagy, NLRP3 
inflammasome activation, ER stress, and decreased lipolysis and lipogenesis in 
WAT [195]. TNF-α remained elevated in both eWAT and plasma of mice 
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recovering from sepsis, but the elevation of IL-1β only persisted in eWAT [195]. 
These results indicate that adipose tissue is an important contributor to septic 
cachexia; however, further studies are needed to elucidate the mechanisms of 
adipose wasting during acute and chronic sepsis. 
 
1.2.3 Current Treatment Strategies for Cachexia 
Cachexia, unlike malnutrition, cannot be successfully treated with nutrition 
therapy alone. The inflammation associated with cachexia impairs nutrient 
utilization [197]. The wasting of lean and fat mass and metabolic dysregulation of 
cachexia cannot be treated by adequate feeding, even in cases of total 
parenteral nutrition [198]. Overfeeding does not have any additional benefit for 
nitrogen balance and can actually contribute to increased mortality [199]. Studies 
utilizing total parenteral nutrition (TPN) or appetite stimulants such as Megace® 
have demonstrated that any weight gain that occurs from these treatments is a 
result of increases in fat or body fluid [200-202]. Treating cachexia involves not 
only meeting nutrient needs but also necessitates addressing the underlying 
inflammation, as much of the energy supplied will be used to synthesize acute-
phase proteins [103]. Treatment should commence as soon as possible, as a 
“window of anabolic potential” to slow or prevent cachexia exists early in the 
disease trajectory [203]. Unfortunately, nutritional assessment is often not a 
clinical priority [204]. 
Lipid emulsions provide fatty acids at a high energy content and low 
osmolarity to help meet the increased energy demands of sepsis [205, 206]. A 
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mix of long-chain and medium triglycerides (LCTs and MCTs, respectively) is 
recommended, and there is a growing understanding of the benefit of omega-3 
polyunsaturated fatty acids in septic patients. For example, omega-3 fatty acids 
have been shown to stimulate protein synthesis and prevent catabolism in cancer 
cachexia [207]. Omega-3s are believed to be beneficial in treating cachexia by 
inhibiting TNF- and IL-1 by blocking cyclooxygenase (COX) and lipoxygenase 
(LO) pathways and inhibiting the acute phase response [208-210].   
Either enteral nutrition (EN) or parenteral nutrition (PN) can be used to 
provide lipids to septic patients. EN involves feeding the patient orally and is 
associated with fewer complications than PN because it helps maintain gut 
function, a healthy microbiome, and proper immune function [211]. On the other 
hand, PN utilizes intravenous administration of nutrition that can be tightly 
controlled. While PN may be useful in gut-derived sepsis to bypass a 
dysfunctional gut, PN can result in gut mucosal atrophy that can contribute to 
increased inflammation and secondary sepsis [212].  
In addition to nutrition therapies, anti-cytokine agents, anti-inflammatories, 
and anabolic agents, such as androgen receptor modulators, growth hormone, 
and testosterone derivatives represent potential pharmacological treatments for 
the management of weight loss in cachexia [208-210]. However, evidence of the 
efficacy of these interventions is limited, and there remains no standard 
treatment for septic patients with cachexia. Therefore, there is a need for a better 
understanding of cachexia mechanisms, leading to combination therapies 
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involving nutrition support coupled with anti-inflammatory pharmacologics to 
target the underlying causes of cachexia.  
 
1.3 The Aryl Hydrocarbon Receptor (AhR) 
     AhR is a ligand-activated transcription factor belonging to the basic helix-
loop-helix/Per-Arnt-Sum (bHLH/PAS) family. Unstimulated AhR in the cytoplasm 
is in a complex bound to heat shock protein 90 (Hsp90), X-associated protein 2 
(XAP2), and p23 [213]. Upon ligand binding, AhR undergoes a conformational 
change resulting in the exposure of a nuclear localization signal and translocation 
to the nucleus where AhR forms a heterodimer with the AhR nuclear transporter 
(ARNT) and binds to specific AhR response elements upstream of target genes 
[213] (Figure 1.2). In its classical role in drug and xenobiotic metabolism, AhR 
binds to xenobiotic response elements in the promoter regions of genes such as 
cytochrome P450 (CYP) genes CYP1a1, CYP1a2, and CYP1b1 [214]. These 
phase I metabolic enzymes assist in the clearance of xenobiotic AhR ligands, 
such as environmental pollutants.  
AhR exhibits promiscuous ligand binding to many drug and xenobiotic 
exogenous ligands. Environmental persistent organic pollutants (POPs), such as 
the halogenated and polycyclic aromatic hydrocarbons, are AhR ligands [213], 
including 2,3,7,8-Tetrachlorodibenzodioxin (TCDD) and coplanar polychlorinated 
biphenyls (PCBs) [213]. AhR detoxifies these lipophilic compounds by 
hydroxylation, increasing their water solubility and excretion [215]. Although 
much of the AhR has focused on detoxification and biological effects of 
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xenobiotics, there is growing interest in physiological roles of this highly-
conserved protein [216], as studies in AhR knockout mice have produced 
phenotypes in the absence of xenobiotics [217-219]. Furthermore, AhR has 
demonstrated roles in endogenous processes including immunity [220-222], 
inflammation [223, 224], and adipocyte biology [219, 225, 226], as discussed in 
further detail below. AhR also exhibits non-canonical activation, including 
interactions with NF-B [227, 228] and estrogen receptor signaling [229, 230].   
AhR signaling can be terminated by proteasome degradation and negative 
feedback from the AhR repressor (AhRR). Upon dissociation from ARNT, a 
nuclear export sequence is revealed, which permits AhR to be transported back 
to the cytoplasm [231]. Once in the cytoplasm, AhR undergoes in-mediated 
receptor protein degradation by the 26S proteasome [232-235]. The AhR 
response is also regulated by AhRR, another member of the bHLH/PAS family of 
transcription factors localized to the nucleus [236]. AhRR bears structural 
similarity to AhR and is able to form heterodimers with ARNT and bind to AhR 
response elements [237]. However, AhRR is believed to act independently of 
ligands as it lacks a proper ligand-binding domain and cannot bind TCDD [238, 
239]. AhR activation regulates transcription of AhRR [240-242]; therefore, AhR 
binding to ligand activates AhR and leads to transcriptional upregulation of both 
CYP1a1 and AhRR. AhRR then exerts negative feedback on AhR-induced 
transcription by either competitive binding or trans-repression [237, 238]. In the 
first instance, AhRR binds to ARNT and prevents DNA-binding of AhR-ARNT 
heterodimers; thus, AhRR competes with AhR for ARNT binding and AhRR-
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ARNT dimers compete with AhR-ARNT for DNA binding [238]. Additionally, 
AhRR may act as a trans-repressor, affecting protein-protein interactions without 
direct binding to DNA [237, 243].  
 
1.3.1 Ligands of the AhR 
AhR ligands can be categorized as agonists, antagonists, selective 
modulators, and indirect regulators. AhR agonists, which act in the canonical 
pathway to bind AhR and activate transcription of downstream target genes, are 
the most extensively studied AhR ligands and include both exogenous and 
endogenous agonists. As previously mentioned, exogenous ligands include the 
synthetic environmental agonists halogenated and polycyclic aromatic 
hydrocarbons, such as TCDD and PCBs [213] (Figure 1.3). Additionally, natural 
exogenous ligands, such as the plant flavonoids quercetin, galangin, and indole-
3-carbinol have demonstrated AhR agonist activity [244-246]. 
In addition to the well-researched exogenous ligands of AhR, studies have 
suggested the presence of endogenous ligands of AhR, indicated by AhR 
activation in the absence of exogenous ligands [247-250]. The most heavily 
studied of these putative endogenous ligands are the indoles, tryptophan 
metabolites such as kynurenine, kynurenic acid, and 6-formylindolo[3,2-
b]carbazole (FICZ) [251-254]. Indigo and indirubin, also tryptophan metabolites, 
were recently reported to have more potent AhR agonism than TCDD in yeast 
cell systems [255]. The tetrapyroles bilirubin and its precursor biliverdin have 
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demonstrated AhR agonism [256-258]. Lastly, arachidonic acid metabolites, such 
as lipoxin A4 and prostaglandins, have weak agonist activity [259, 260].  
In contrast, AhR antagonists inhibit nuclear translocation of the receptor 
by competitive binding to the AhR ligand-binding domain. Potent and reliable 
AhR antagonists have been difficult to find, as many antagonists possess partial 
agonist activity [261]. For example, - naphthoflavone is an AhR antagonist with 
partial AhR agonist activity that is able to antagonize AhR at high concentrations 
by competing with AhR ligands [262]. 6,2’,4’-trimethoxyflavone (TMF) is an AhR 
antagonist; however, prolonged exposure to TMF results in weak partial agonism 
[261]. On the other hand, CH-223191 is a potent, pure competitive antagonist of 
AhR [263-265].  
Less is known about indirect regulators and selective AhR modulators. 
Indirect regulators of AhR are poorly understood and influence AhR signaling 
without binding to the receptor’s ligand-binding domain. The polyphenol 
epigallocatechin gallate (EGCG), found in green tea, antagonizes AhR without 
binding to the ligand-binding domain [266]. On the other hand, selective AhR 
modulators do bind to the AhR ligand-binding domain, triggering translocation of 
the receptor into the nucleus and dimerization with ARNT [267, 268]. However, 
these ligands are able to act as agonists or antagonists through non-canonical 
pathways without binding to DNA AhR response elements [267-269]. 
As the list of novel putative ligands of AhR grows, so does the 
understanding of the myriad of physiological roles downstream of AhR activation. 
While AhR sensing of exogenous environmental toxins and subsequent 
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activation pathways has been well studied, there is growing interest in 
endogenous and dietary ligands of AhR, many of which may play a role in 
immunity [253, 270, 271]. Notably, Moura-Alves et al. recently demonstrated 
AhR’s ability to detect and potentially detoxify pathogen-associated molecular 
patterns (PAMPs), including the pigmented bacterial virulence factors pyocyanin 
(PYO), 1-hydroxyphenazine (1-HP), phenazine-1-carboxylic acid (PCA), and 
phenazine-1-caboxamide (PCN) from Pseudomonas aeruginosa as well as the 
napthoquinone phthiocol (Pht) produced by Mycobacterium tuberculosis [270]. 
Therefore, AhR appears to play a role in bacterial defense by clearing bacterial 
virulence factors and activating innate immunity.   
 
1.3.2 Role of the AhR in Adipocyte Biology 
AhR is involved in the development of several different cell types including 
adipocytes. The functions of adipocyte AhR are of particular interest due to the 
lipophilicity of AhR ligands, including POPs, which results in their accumulation in 
adipose tissue in close contact to adipocyte AhR [272]. Several studies have 
demonstrated POP-mediated regulation of adipocyte differentiation [219, 225] 
and increased production of inflammatory cytokines such as TNF-α through an 
AhR-dependent mechanism in mature adipocytes [225].  
In murine 3T3-L1 cells differentiated to adipocytes, AhR expression 
decreases throughout adipocyte differentiation [273, 274]. Expression of the 
ARNT protein also decreases during differentiation [273]. Furthermore, when 
eWAT was excised from C57BL/6J mice and digested into a stromal vascular 
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fraction (SVF) and an adipocyte fraction, the SVF fraction possessed higher 
mRNA abundance of AhR as compared to adipocytes [274]. AhR’s inhibitory 
control of adipocyte differentiation is independent of the presence of exogenous 
AhR ligands added to the experimental system. The downregulation of AhR 
during adipocyte differentiation is sufficient to yield the loss of function response 
to xenobiotics, including the inhibitory effect of TCDD [273]. Moreover, 
overexpression of AhR inhibits adipocyte differentiation as indicated by reduced 
oil red O staining and mRNA abundance of aP2 and CCAAT/enhancer-binding 
proteins (C/EBPs) [275]. On the other hand, 3T3-L1 cells expressing antisense 
AhR mRNA had slightly increased adipocyte differentiation compared to controls 
[275].  
The downregulation of AhR during adipocyte differentiation occurs at the 
transcriptional level, and inhibition of the 26S proteasome responsible for 
degrading AhR had no effect on AhR cellular protein levels [274]. AhR’s inhibitory 
effect on adipocyte differentiation was facilitated by hyper-activation of the 
p42/p44 MAP kinase [275]. Interestingly, AhR overexpression had no effect on 
PPAR mRNA abundance, and addition of PPAR activators restored the ability 
of cells overexpressing AhR to differentiate to adipocytes [275]. Together, these 
results suggest AhR inhibits adipocyte differentiation during early stages of clonal 
expansion before the activation of PPAR.  
Exogenous AhR ligands also exert effects on adipocyte differentiation. 
Specifically, exposure of 3T3-L1 cells to TCDD (10 nM) reduced adipocyte 
differentiation [225, 226]. However, the timing of TCDD exposure was critical for 
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a negative effect on differentiation. When 3T3-L1 cells were exposed to TCDD 
within 24 hours of the induction of differentiation, adipocyte differentiation was 
reduced [273]; however, if TCDD was added 48 hours after the induction of 
differentiation, normal adipocyte differentiation was observed [226, 273]. These 
results lend further support that AhR’s inhibitory control occurs early in the 
differentiation process. Previous studies in our laboratory demonstrated the 
ability of another AhR ligand, PCB-77, to alter adipocyte differentiation of 3T3-L1 
adipocytes and induce the expression of TNF- in differentiated adipocytes [225]. 
While the early effects of TCDD impacted inflammation and differentiation, 
treatment of mature 3T3-L1 adipocytes with TCDD induced lipolysis [276].  
Moreover, in vivo exposures to TCDD resulted in a wasting syndrome associated 
with weight loss, lean and fat mass loss, decreased lipoprotein lipase (LPL) 
activity, and hyperlipidemia in guinea pigs [277]. Development of TCDD wasting 
syndrome could be explained by inhibition of adipocyte differentiation and 
activation of inflammatory cytokines observed in vitro [225]. 
Consequently, our laboratory demonstrated a role of AhR and 
endogenous AhR ligands in the regulation of body weight, using a mouse model 
of adipocyte-specific AhR deficiency (AhRAdQ) using the Cre-LoxP system under 
control of the adiponectin promoter (AhRAdQ) (mice were on a C57BL/6J genetic 
background) [247]. When challenged with a high fat diet for 12 weeks, AhRAdQ 
mice had greater increases in body weight, increased fat mass, decreased lean 
mass, and increased adipocyte size compared to floxed littermate controls [247]. 
Together, these results suggest a role for AhR in the regulation of body weight.  
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1.3.3 Immune Function 
AhR has been implicated in endogenous regulation of immunity and 
inflammation [278-281]. The generation of AhR knockout (KO) mice revealed a 
role of AhR in development and immunity. In the postnatal period, AhR KO mice 
had higher rates of mortality and slower growth [282, 283]. Furthermore, AhR KO 
mice had organ abnormalities, including alterations in the structure and function 
of the liver, spleen, and lymph nodes [282-284]. These initial findings have 
provoked an expansive study of AhR’s role in immune function, particularly at 
barriers that serve as the frontline defense against toxins and infections, such as 
the gut, skin, and lung.  
AhR regulates the development of immune cells, including T cells, B cells, 
and hematopoietic stem cells. Among T cells, AhR is expressed in IL-17-
producing T (TH17) cells, FoxP3+ regulatory T (Treg) cells, and Type 1 regulatory 
T (TR1) cells but not in T helper Th1 or Th2 cells [224]. Studies have 
demonstrated AhR’s contribution to the differentiation of TH17 cells, which are 
implicated in autoimmunity and produce proinflammatory cytokines such as IL-
17, IL-21, IL-22, and granulocyte-macrophage colony-stimulating factor (GM-
CSF) [223, 224, 285-288]. AhR also plays a role in the regulation of Treg cells and 
TR1 cells; however, the mechanisms of AhR signaling in these cell types remain 
to be fully elucidated. TCDD has repeatedly been shown to result in an increased 
population of Treg cells in mice [220, 221, 286, 289, 290]. However, it remains 
unclear if the increase in numbers of Treg cells is due to increased proliferation or 
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decreased apoptosis [287]. Interestingly, endogenous ligands, namely the 
tryptophan metabolites kynurenine and FICZ have opposing effects on Treg cell 
populations [222]. AhR also promoted differentiation of TR1 cells that produced 
the anti-inflammatory cytokine IL-10, which plays a crucial role in resolving 
inflammatory responses [291]. Therefore, AhR plays a diverging role in immunity 
that can either be pro-inflammatory or anti-inflammatory based on the target 
immune cell population. B cells express AhR, and AhR activation by TCDD 
suppressed differentiation and inhibited humoral immunity [292, 293]. However, 
the mechanisms of AhR’s contribution to B cell regulation and development are 
not well understood. Lastly, AhR plays a functional role in hematopoietic stem 
cell differentiation. Antagonism or knockout of AhR reduced differentiation and 
expansion of hematopoietic stem cells [294, 295].  
Innate lymphoid cells (ILCs) are lymphocytes expressed highly at mucosal 
sites, such as the gut. ILC3s express AhR and are capable of producing IL-17 
and IL-22 [296]. Studies have demonstrated AhR’s role in the development of 
ILC3 cells as well as their production of IL-22 [281, 297, 298]. AhR maintains ILC 
as well as intraepithelial lymphocytes (IELs) in the gut [271, 281, 297-299], 
indicating an important function of AhR in intestinal barrier maintenance, which 
can ultimately influence bacterial translocation.  
AhR is implicated in the regulation of pattern recognition receptors (PRRs) 
such as the NACHT, LRR and PYD domains-containing protein 3 (NLRP3) 
inflammasome. The NLRP3 inflammasome is formed upon exposure to stimuli 
during infection or metabolic dysregulation, including bacterial toxins and 
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extracellular ATP; therefore, NLRP3 plays an important role in innate immunity 
by facilitating in the production of IL-1 and IL-18 via activation of caspase-1 
[300, 301]. AhR suppressed NLRP3 inflammasome activation [302] and also 
inhibited NF-B transcription, which are essential for NLRP3 expression [303-
305]. Therefore, AhR is able to impact inflammation by suppressing NF-B 
transcription of IL-6 and TNF- [306] and inhibiting NLRP3 activation of caspase-
1 and IL-1 secretion [302].  
Furthermore, recent studies have shown that AhR binds and senses 
pathogen-associated molecular patterns (PAMPs) and directly senses pigmented 
bacterial virulence factors [270], including those produced by the gram-negative 
bacteria Pseudomonas (P.) aeruginosa, one of the main organisms responsible 
for nosocomial infections. Therefore, it is highly likely that AhR activation by 
bacteria-derived factors contributes to sepsis pathogenesis. Specifically, AhR KO 
mice were more susceptible to LPS-induced septic shock compared to wild type 
control mice [306, 307]. This increased susceptibility was attributed to AhR’s 
effect on macrophages, believed to be mediated by a reduction in expression of 
plasminogen activator inhibitor-2 (Pai-2) [307]. Both whole body and 
macrophage-specific AhR KO mice had increased mortality following LPS 
challenge, which was accompanied by increased plasma concentrations IL-1, 
IL-18, TNF-, and IL-6 [307].  
Moura-Alves et al. investigated the role of AhR in sensing bacterial 
pigments in P. aeruginosa infection. Following intratracheal infection with P. 
aeruginosa, mice developed respiratory distress and severe disease [270]. AhR 
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KO mice (AhR-/-) had higher bacterial loads of P. aeruginosa in their lungs, 
greater tissue damage, and succumbed more quickly to infection compared to 
wild-type controls [270]. AhR-/- mice had reduced neutrophil numbers and 
expression of neutrophil chemoattracts CXCLI and CXCL2 after infection, 
indicating a role of neutrophil recruitment in host defense against P. aeruginosa 
[270]. Additionally, AhR played a role in the cytokine response to P. aeruginosa 
infection, as the ability or P. aeruginosa infection to increase IL-1, IL-1, and 
RANTES/CCL5 was attenuated in AhR-/- mice [270]. Furthermore, AhR sensing 
of bacterial phenazines facilitated host resistance to infection by reducing 
bacterial burden, which is potentially linked to the clearance of pyocyanin [270]. 
Therefore, AhR can be viewed as a PRR that can recognize and potentially 
metabolize bacterial pigments, a new class of PAMPs. Overall, AhR plays a 
critical role in immune function and diseases of inflammation, such as sepsis; 
therefore, interventions targeted at AhR may provide a novel treatment strategy 
for patients with inflammatory disorders, including sepsis caused by bacteria that 
produce AhR-activating phenazines. 
 
1.4 Pyocyanin: An Overview 
The tricyclic phenazine pyocyanin is a blue-pigmented virulence factor 
released by Pseudomonas (P.) aeruginosa. Pyocyanin is a low molecular weight 
zwitterion believed to easily cross cell membranes [308-310]. With a pKa of 4.9, 
pyocyanin is weakly acidic [311-314]. While pyocyanin is a neutral, blue molecule 
at physiological pH, protonation at one of the central nitrogens in acidic 
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environment causes pyocyanin gain charge turning it red in color (Figure 1.4) 
[308-310]. Pyocyanin is synthesized from the common phenazine precursor 
phenzine-1-carboxylic acid (PCA) by the phzM and phzS enzymes [315]. PCA is 
first converted to 5-methylphenazine-1-carboxylic acid betaine by phzM, which 
then undergoes hydroxylative decarboxylation by phzS to become pyocyanin 
(Figure 1.4) [316].  
P. aeruginosa releases pyocyanin via a type II secretion system [317], and 
infected patients have been demonstrated to have concentrations of pyocyanin 
up to 130M in bodily secretions, including sputum, urine, wounds, and ear 
secretions [318-320]. Only recently has pyocyanin been quantified systemically. 
Arora et al. detected pyocyanin (10 nM) in the plasma of mice exposed to 50 
g/L of pyocyanin via intranasal delivery [321].  
 Pyocyanin possesses antibacterial activity that allows it to kill off 
competitors of P. aeruginosa. Pyocyanin antibacterial activity impedes the ability 
of the competitor bacteria to perform active transport by acting on the cell 
membrane respiratory chain [310, 315, 322]. Pyocyanin negatively impacted 
active transport in organisms and produced deleterious reactive oxygen species 
(ROS) [315, 323]. Studies have also shown pyocyanin has anti-fungal activity 
against Aspergillus fumigatus and Candida albicans [324]. Pyocyanin also 
promoted the formation of biofilms by increasing the release of extracellular DNA 
[325], which increased longevity of infection by P. aeruginosa. 
A recent study by Moura-Alves and colleagues demonstrated the ability of 
pyocyanin to activate AhR in a dose-dependent manner in pneumocytes and 
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macrophages  [270]. Pyocyanin also increased expression of CYP1a1, a marker 
of AhR activation, which was attenuated when AhR was silenced in these cell 
types [270]. When macrophages were treated with various strains of P. 
aeruginosa, the strains overproducing pyocyanin had consistently higher AhR 
activation as compared to bacterial strains that lacked phenazine production 
[270]. In pneumocytes, pyocyanin degradation was observed and appeared to be 
mediated by AhR [270]. Studies in A549 alveolar epithelial cells suggest 
pyocyanin has a half-life of ~12 hours [326]. 
 
1.4.1 Physiological Effects 
Oxidative Stress 
 Pyocyanin is a redox-active compound capable of producing reactive 
oxygen species (ROS), namely superoxide and hydrogen peroxide [312, 327-
329]. ROS are produced when pyocyanin undergoes non-enzymatic, cyclic 
reduction by NAD(P)H, oxidizing intracellular pools of NADPH and GSH directly 
by accepting electrons [312, 327, 330, 331]. This reduced form of pyocyanin then 
donates electrons to oxygen to produce superoxide [312, 327, 330]. Superoxide 
dismutase (SOD) can subsequently transform superoxide to hydrogen peroxide 
[327].  
P. aeruginosa infection reduces the protective antioxidant enzymes 
superoxide dismutase (SOD), catalase (CAT), and glutathione peroxidase (GSH-
Px) in mice [332], and pyocyanin alone can decrease CAT activity in alveolar 
epithelial cells [326]. Furthermore, studies have suggested pyocyanin can directly 
oxidize GSH to GSSG and produces hydrogen peroxide in the process [311]. In 
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human tracheobronchiolar epithelial cells, pyocyanin increased the production of 
superoxide and hydrogen peroxide, which led to increased mucin synthesis and 
mucin (MUC) and MUC2 gene expression [333]. Furthermore, as indicators of 
oxidative stress, SOD2 and growth differentiation factor (GDF)-15 were 
increased while catalase was decreased in epithelial cells treated with pyocyanin 
[333].  
The redox-active nature of pyocyanin is thought to be responsible for most 
of its effects described on host cells [330]. Together, these ROS can cause free 
radical damage and oxidative stress to cells and DNA. Production of oxidative 
stress is a major contributor to pyocyanin’s cytotoxicity. Pyocyanin’s induction of 
oxidative stress affects calcium homeostasis, inhibits cellular respiration, 
prostacyclin release, and release of nitric oxide [315]. Strains of P. aeruginosa 
that overproduce pyocyanin exhibit greater oxidative stress, cell lysis, and 
extracellular DNA (eDNA) levels than wild-type strains [325]. Increased eDNA 
contributes to the formation of biofilms, which augment the persistence of P. 
aeruginosa infections [325]. 
Inflammation and Immunomodulation 
The generation of reactive oxygen species contributes to augmented 
inflammation and immunomodulatory effects of pyocyanin. For example, in 
murine bone marrow derived macrophages, pyocyanin inhibited activation of the 
NLRP3 inflammasome, therefore blocking Caspase-1 maturation and IL-1 
release [334]. This inhibition of the NLRP3 inflammasome was the result of 
reactive oxygen and reactive nitrogen species by pyocyanin [334]. These results 
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suggest that anti-inflammatory effects of pyocyanin may help P. aeruginosa 
evade detection, allowing for more persistent and pervasive infections [334].  
Pyocyanin also increases inflammatory cytokine production. P. aeruginosa 
infections are marked by recruitment of neutrophils, which is facilitated by IL-8 
[335]. Pyocyanin has been shown to increase IL-8 release from human airways 
epithelial cells in a dose-dependent manner, potentially through a mechanism 
involving oxidants and signaling through protein tyrosine kinases (PTKs) and 
MAP kinases (MAPKs) [336, 337]. Furthermore, in these same airway samples, 
pyocyanin inhibited RANTES expression [336, 337]. The thiol antioxidant N-
acetyl cysteine (NAC) is able to scavenge oxidants formed in response to 
pyocyanin and reduced pyocyanin’s ability to increase IL-8 release, indicating a 
role of ROS in pyocyanin’s ability to regulate cytokines [336]. Furthermore, 
pyocyanin (100M) has been demonstrated to increase IL-6 release from 
urothelial cells to a greater extent than LPS [338]. In human tracheobronchiolar 
epithelial cells (TBECs), pyocyanin increased inflammatory cytokine expression 
of  IL-1, IL-1, IL-6, IL-8, TNF-, as well as the inflammatory mediators G-CSF, 
GM-CSF, CXCL1, CXCL2, CXCL3, CCL20, CXR4, IL-22, Serum amyloid A 1 
(SAA1) and SAA2 [333].  
Pyocyanin also influences neutrophil function as a means of prolonging P. 
aeruginosa infection. Normally, resolution of acute inflammation involves 
apoptosis of recruited inflammatory cells such as neutrophils. Pyocyanin has 
been shown to induce apoptosis of human neutrophils but not epithelial cells or 
macrophages in a dose-dependent manner in concentrations up to 100M even 
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in the presence of anti-apoptotic LPS [339]. Pyocyanin also increased generation 
of reactive oxygen intermediates and reduced intracellular CAMP and ATP as 
mechanisms preceding this increase in neutrophil apoptosis [339]. Pyocyanin 
has consistently been shown to produce superoxide and hydrogen peroxide [340, 
341]; however, P. aeruginosa is protected from pyocyanin’s effects and escapes 
oxidative injury [342]. The increased production of reactive oxygen intermediates 
and oxidative stress caused by pyocyanin plays a role in neutrophil apoptosis 
because the antioxidant NAC can block pyocyanin-induced cell death [339]. 
In mice infected intra-tracheally with P. aeruginosa, pyocyanin was also 
found to increase neutrophil apoptosis and decrease neutrophil recruitment [343]. 
In these mice, pyocyanin appeared to suppress the increase of neutrophil 
chemokines MKC/CXCLI and MIP-2 typically seen upon infection [343]. 
Furthermore, pyocyanin plays a role in P. aeruginosa clearance, as mutant 
strains of the bacterium that lack pyocyanin production are cleared much faster 
than wild-type P. aeruginosa strains that produce pyocyanin [343]. As such, 
pyocyanin contributes to the longevity of P. aeruginosa infection. In fact, this 
same mutant strain of P. aeruginosa with reduced pyocyanin production had 
reduced mortality in a murine sepsis model [73]. 
Neutrophil apoptosis typically promotes the resolution of inflammation by 
impairing proinflammatory neutrophil processes and promoting production of anti-
inflammatory cytokines while suppressing proinflammatory cytokines [339]. 
Premature neutrophil apoptosis induced by pyocyanin may contribute to 
pathogen evasion of host defense [344]. However, excessive neutrophil 
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apoptosis may overwhelm phagocytosing macrophages, increasing 
proinflammatory processes [345]. 
Pyocyanin also helps P. aeruginosa evade the immune system by 
inhibiting T cell lymphocyte proliferation as a result of decreased IL-2 [346]. While 
pyocyanin had little effect on IL-1 and tumor necrosis factor (TNF) production by 
monocytes, it enhanced the production of these monokines by lipopolysaccharide 
(LPS) in peripheral blood mononuclear cells (PBMCs) [347].  
These effects of pyocyanin to increase oxidative stress and inflammation, 
which are summarized in Table 1.1, have largely been studied in the respiratory 
system due to the frequency of P. aeruginosa infections in patients with cystic 
fibrosis and lung injury [319]. While these studies have largely looked at in vitro 
effects, a small number of in vivo studies have revealed deleterious effects of 
pyocyanin on the respiratory tract, including increased neutrophil migration in 
sheep [348] and mice [349]. A small number of studies have investigated 
pyocyanin’s effects on the urological, central nervous, vascular, and hepatic 
system [331]. However, no studies have explored pyocyanin’s effects on adipose 
tissue.  
Oxidative stress in 3T3-L1 adipocytes has been shown to dysregulate 
adipokines, including adiponectin, plasminogen activator inhibitor-1 (PAI-1), IL-6, 
and monocyte chemotactic protein-1 (MCP-1) [350]. Obese mice with oxidative 
stress had reduced PPAR and adiponectin mRNA and increased TNF- 
expression in white adipose tissue [350]. As such, there appears to be a 
relationship between body weight and adipose inflammation that is linked to 
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oxidative stress. These findings indicate that oxidative stress in adipose tissue 
may be a therapeutic target for diseases of metabolic dysregulation. Moreover, 
oxidative stress has been identified as a mechanism in cancer cachexia [351]. 
Lastly, superoxide and hydrogen peroxide contribute to mitochondrial 
dysfunction, leading to sepsis pathogenesis and mortality [352].  
As a producer of oxidative stress and inflammation, pyocyanin should be 
studied in the context of adipocyte in regulation of body weight. Furthermore, 
pyocyanin has been shown to activate AhR [270], a receptor that has 
demonstrated roles in the regulation of adipocyte differentiation and immune 
function. Moreover, due to the frequency of P. aeruginosa infections in sepsis, 
the physiological role of pyocyanin in sepsis pathogenesis warrants exploration. 
Specifically, adipose cachexia in sepsis represents a gap in the literature. 
Identifying compounds, such as pyocyanin, that are present in sepsis infections 
and can regulate oxidative stress, inflammation, and receptor signaling pathways 
involved in adipocyte differentiation and immune function could lead to a better 
understanding of the mechanisms of adipose cachexia and, ultimately, novel 
therapeutic treatment strategies for septic patients.  
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Table 1.1 Reported in vitro and in vivo effects of pyocyanin. 
Effect of Pyocyanin System Model 
Activates AhR and CYP1a1 in vitro THP-1 cells [270], A549 cells 
[270] 
Inhibits SOD, CAT, and GSH-Px 
activity  
in vivo,  
in vitro  
Rats [332], yeast cells [353], 
A549 cells [353], A549 cells 
[326], H292 cells [333] 
Depletes GSH in vitro HUVECs [327], HBE [311] 
Increases ROS hydrogen peroxide 
and superoxide  
in vitro HUVECs [327], HBE [311], 
A549 [326], H292 cells [333] 
 
Increases neutrophil migration  in vivo Sheep [348], mice [349] 
Increases neutrophil apoptosis  in vitro,  
in vivo 
Human neutrophils [339], 
mice [343] 
Inhibits T cell production in vitro MNCs [346, 347] 
Low concentrations increase, high 
concentration decrease: T and B 
cell proliferation, immunoglobulin 
production by B cells, B cell 
differentiation 
in vitro MNCs [347] 
Inhibits NLRP3 inflammasome and 
IL-1 
in vitro BMDMs [334] 
Increases IL-8, decreases 
RANTES 
in vitro Lung cells [336] 
Increases IL-6 in vitro RT4 urothelial cells [338] 
Inhibits IL-2  in vitro MNCs [346, 347] 
Increases IL-1, TNF-a in vitro MNCs [347], H292 cells [333] 
Increases inflammatory cytokines: 
IL-1a, IL-1B, IL-6, IL-8, TNF- 
in vitro H292 cells [333] 
Increases inflammatory mediators: 
G-CSF, GM-CSF, CXCLI, CXCL2, 
CXCL3, CCL20, CXCR4, IL-23, 
SAA1, SAA2  
in vitro H292 cells [333] 
Increases mucin synthesis 
(MUC5AC and MUC2) 
in vitro H292 cells [333] 
Reduces intracellular cAMP and 
ATP 
in vitro A549 cells [326], lung cells 
[354] 
 
Abbreviations:  
AhR, aryl hydrocarbon receptor; SOD, superoxide dismutase; CAT, catalase; 
GSH-Px, glutathione peroxide; GSH, glutathione; ROS, reactive oxygen species; 
HUVECs, human umbilical vein endothelial cells; MNC, mononuclear cells; HBE,  
human bronchial epithelial; BMDM, bone marrow derived macrophages. 
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Figure 1.1. Pathogenesis of adipose cachexia in sepsis  
 
 
Figure 1.1. Pathogenesis of adipose cachexia in sepsis. In sepsis, infection 
results in systemic inflammation and metabolic alterations that contribute to 
cachexia. Mechanisms of adipose cachexia in white adipose tissue include 
increases in apoptosis, lipolysis, inflammasome activation, and inflammatory 
cytokines, coupled with decreased adipocyte size and lipogenesis.  
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Figure 1.2. Ligand binding of AhR. AhR is a cytoplasmic ligand-activated 
transcription factor that, when unstimulated, is bound in a complex with heat 
shock protein 90 (Hsp90), X-associated protein 2 (XAP2), and p23. Upon 
ligand binding, AhR translocates into the nucleus and forms a heterodimer with 
the AhR nuclear transporter (ARNT). The AhR-ARNT heterodimer can then 
bind to AhR response elements upstream of target genes such as cytochrome 
P450 (CYP) gene CYP1a1. The receptor then undergoes ubiquitin-mediated 
receptor protein degradation by the 26S proteasome. Adapted from Denison 
and Nagy, 2003 [213].  
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Figure 1.3. Representative AhR ligands  
 
 
Figure 1.3. Representative AhR ligands. Depiction of selected ligands of the 
aryl hydrocarbon receptor (AhR), including the persistent organic pollutants 
TCDD and PCB-77, the bacterial phenazine pyocyanin, and the natural 
compounds FICZ, EGCG, and quercetin. 
  
TCDD PCB-77 Pyocyanin
FICZ EGCG Quercetin
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Figure 1.4. Biosynthesis of pyocyanin 
 
Figure 1.4. Biosynthesis of pyocyanin. Phenazine-1-carboxylic acid (PCA) is a 
common precursor for many phenazines. PCA is converted to the dark red 5 
methyl phenazine-1-carboxylic acid betaine by the PhzM enzyme, which then 
undergoes hydroxylative decarboxylation by PhzS to become pyocyanin. At 
physiological pH, pyocyanin is a neutral, blue molecule. In acidic environments, 
the central nitrogen is protonated, causing pyocyanin to gain charge and become 
red in color. 
Pyocyanin (Red) Pyocyanin (Blue)5 methyl phenazine-1-carboxylic acid betainePhenazine-1-carboxylic acid
pKa = 4.9
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Figure 1.5. Generation of reactive oxygen species by pyocyanin  
 
 
Figure 1.5. Generation of reactive oxygen species by pyocyanin. As a redox-
active compound, pyocyanin is able to induce oxygen stress through the creation 
of reactive oxygen species (ROS). Adapted from Muller, 2002 [327]. 
Abbreviations: SOD, superoxide dismutase; H2O2, hydrogen peroxide; GSH, 
glutathione; GSSG, glutathione disulfide; NADP+, NADPH, nicotinamide adenine 
dinucleotide phosphate.  
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1.5 Statement of the problem and scope of the dissertation 
1.5.1 Statement of the problem 
Sepsis is a growing clinical problem associated with significant morbidity 
and mortality, with no effective therapeutics. Patients surviving sepsis suffer from 
cachexia, which does not respond to nutritional therapies aimed at simply 
replacing nutrients. Cachexia associated with sepsis arises from losses of both 
lean and fat mass, but there is little known about mechanisms contributing to 
septic-cachexia. Our laboratory, as well as others, have demonstrated that 
activation of AhR, either by endogenous or exogenous ligands, regulates the 
differentiation of adipocytes and inflammatory adipokine production. Recent 
studies demonstrated that pyocyanin, a virulence factor produced by the gram-
negative sepsis-inducing bacteria, P. aeruginosa, is an AhR ligand. These results 
raise the possibility that P. aeruginosa-derived pyocyanin activates adipocyte 
AhR to regulate adipocyte differentiation and function, an intriguing hypothesis 
that could mechanistically contribute to septic-cachexia.  The purpose of this 
dissertation research was to define effects of pyocyanin on adipocytes, whether 
these effects were AhR-mediated, and to determine if pyocyanin regulates body 
weight in mice as an experimental model of septic cachexia.   
1.5.2 Aims of dissertation 
The overall objective of this project was to elucidate the effects of 
pyocyanin, a virulence factor produced by the sepsis-inducing bacteria P. 
aeruginosa, on adipocyte differentiation, function (ex vivo lipolysis), and 
expression of inflammation-regulating cytokines. Moreover, we defined effects of 
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pyocyanin on body weight regulation and developed an experimental mouse 
model of pyocyanin-induced cachexia. 
The central hypothesis of this dissertation is that pyocyanin, released by 
P. aeruginosa during sepsis, acts at adipocyte AhR to reduce adipocyte 
differentiation and promote adipocyte inflammation, thereby contributing to the 
development of septic cachexia (Figure 1.4). We tested our central hypothesis 
using the following specific aims:   
Specific Aim 1. Define the role of pyocyanin in adipocyte differentiation and 
inflammation in vitro using 3T3-L1 cells and use this information to establish an in 
vivo mouse model of pyocyanin-induced cachexia. 
Specific Aim 2. Define the role of adipocyte AhR on pyocyanin-induced 
regulation of adipocyte differentiation and on pyocyanin-induced cachexia in 
mice.  
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Figure 1.6. Graphical abstract of central hypothesis 
 
Figure 1.6. Graphical abstract of central hypothesis 
.  
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Chapter 2 Pseudomonas aeruginosa-derived pyocyanin is a novel 
mediator of the wasting and inflammation of adipose in septic cachexia 
  
2.1 Synopsis 
Pseudomonas aeruginosa, a leading cause of sepsis, produces pyocyanin, 
a blue-pigmented virulence factor. Recent studies demonstrated affinity of 
pyocyanin for the aryl hydrocarbon receptor (AhR). Adipocytes express AhR, 
where activation has been shown to reduce adipocyte differentiation, while 
adipocyte deficiency of AhR increased body weight. Effects of pyocyanin at 
adipocyte AhR are unknown, but may contribute to septic cachexia, a problem 
with no effective therapeutics. This study examined in vitro and in vivo effects of 
pyocyanin on adipocyte differentiation and body weight regulation. In 3T3-L1 
preadipocytes, pyocyanin reduced adipocyte differentiation and activated AhR 
and its downstream marker CYP1a1. Similarly, pyocyanin reduced adipocyte 
differentiation from stem cells isolated from naïve C57BL/6J mice. Intraperitoneal 
injection of pyocyanin to male C57BL/6J mice acutely (over 24 hours) reduced 
body temperature with altered locomotion but caused sustained (7 days) weight 
loss associated with reduced stem cell differentiation to adipocytes. Following 
three weekly injections of pyocyanin to male and female C57BL/6J mice, body 
weight and fat mass were reduced for 4 weeks, and AhR was activated in 
adipose tissue, but not liver. Pyocyanin-treated male mice had decreased energy 
expenditure, reduced physical activity, and increased adipose explant lipolysis. In 
females, pyocyanin caused more robust reductions in body weight, adipose-
specific AhR activation, and increased expression of inflammatory cytokines in 
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adipocytes differentiated in vitro from pyocyanin-treated mice. These results 
demonstrate that pyocyanin reduces adipocyte differentiation and decreases 
body weight and fat mass in male and female mice through divergent 
mechanisms. Moreover, pyocyanin may play a role in septic cachexia. 
 
2.2 Introduction 
Sepsis is a life-threatening condition characterized by dysregulated host 
response to infection and multiple organ dysfunction [1]. Sepsis pathogenesis 
includes metabolic alterations such as hypercatabolism, muscle wasting, and 
lipoatrophy [94], leading to cachexia characterized by decreased body weight, 
lean body mass, and fat mass as well as metabolic disruption and systemic 
inflammation [95, 355, 356]. Sepsis remains a leading cause of death in critically 
ill patients, with global estimates of 31.5 million cases resulting in 5.3 million 
deaths annually [14]. While advances in critical care have increased survival from 
acute sepsis, a growing number of patients progress to chronic critical illness that 
includes septic cachexia, a condition for which nutritional therapies have limited 
efficacy. Furthermore, there is currently no FDA-approved medication that 
specifically targets sepsis [94]. Anti-inflammatory strategies are used to manage 
acute sepsis; however, no therapeutic approaches improve septic cachexia, and 
wasting of adipose tissue in sepsis has been largely unexplored [107, 108, 195]. 
Although adipose cachexia in sepsis is an understudied area, white adipose 
tissue (WAT) is known to be an important regulator of cachexia associated with 
cancer, with increases in WAT apoptosis, lipolysis, NLRP3 inflammasome 
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activation, inflammatory cytokine expression, and decreases in adipogenesis and 
adipocyte size [136, 142, 143]. Similarly, a recent study found that septic mice 
lost more weight than controls and failed to replete their fat mass even when 
body weight returned to baseline [195]. This state of septic adipose cachexia was 
associated with increases in inflammation, apoptosis, and lipolysis, and 
decreases in lipogenesis of WAT [195]. These results suggest that adipose 
tissue is a site where cachexia from sepsis is manifest, but mechanisms for 
adipose tissue wasting during acute or chronic sepsis are not well defined. 
Pseudomonas aeruginosa (P. aeruginosa), a Gram-negative bacterium, is a 
leading cause of sepsis that commonly colonizes the lung and gut with a high 
propensity for antibiotic resistance. P. aeruginosa produces pyocyanin, a blue-
pigmented toxin that is a major virulence factor for this organism. The toxic and 
inflammatory properties of pyocyanin are due, in part, to its ability to increase 
production of reactive oxygen species, induce neutrophil apoptosis, and facilitate 
the formation of biofilms [315, 331, 357]. Pyocyanin possesses both antibiotic 
and antifungal properties, which allow it to kill off competitors of P. aeruginosa. 
The majority of studies on pyocyanin have focused on its ability to facilitate the 
virulence of P. aeruginosa. 
Recent studies demonstrated that pyocyanin binds the aryl hydrocarbon 
receptor (AhR) and results in AhR activation in macrophages and pneumocytes 
[270]. Pyocyanin has structural similarity to 2,3,7,8-tetrachlorodibenzodioxin 
(TCDD), a prototypical ligand of AhR, and similar to TCDD, easily crosses the 
cell membrane as a low molecular weight zwitterion [1]. AhR-deficient mice are 
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more susceptible to P. aeruginosa lung infection than wild type mice, indicating a 
role of AhR in resistance against P. aeruginosa that is potentially related to 
clearance of pyocyanin [270]. In its classical role in drug and xenobiotic 
metabolism, AhR binds to xenobiotic response elements in the promoter regions 
of genes such as cytochrome P450 CYP1a1, CYP1a2, and CYP1b1 [214]. AhR 
exhibits promiscuous ligand binding to many drug and xenobiotic ligands, 
including persistent organic pollutants (POPs), such as TCDD and coplanar 
polychlorinated biphenyls (PCBs) [213]. AhR has been implicated in the 
differentiation and functional regulation of several different cell types, including 
adipocytes. The functions of adipocyte AhR are of particular interest due to the 
lipophilicity of AhR ligands, including POPs, which results in their accumulation in 
adipose tissue in close proximity to adipocyte AhR [272]. 
Pyocyanin has been detected in sputum, wounds, and urine in 
concentrations up to 130µM [319, 320]. While there are several studies 
demonstrating pyocyanin promotes the virulence of P. aeruginosa, levels of 
pyocyanin released by the bacteria may also regulate the function of mammalian 
cells, including activation of AhR in adipocytes, a cell type potentially related to 
cachexia of chronic sepsis. In this study, we defined effects of the novel AhR 
ligand pyocyanin on in vitro adipocyte differentiation and inflammation. We then 
used this information to establish an in vivo model of pyocyanin-induced 
cachexia in male and female C57BL/6J mice to elucidate possible mechanisms 
of pyocyanin’s effects on the development of septic cachexia. 
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2.3 Materials and Methods 
 
2.3.1 Growth and differentiation of 3T3-L1 cells 
3T3-L1 mouse adipocytes were purchased from ATCC (catalogue number 
CL-173, ATCC, Manassas, VA). Cells were plated into 6-well plates at a seeding 
density of 10,000 cells/cm2 and grown in pre-adipocyte expansion medium 
containing 90% Dulbecco’s modified Eagle’s medium (DMEM; Invitrogen, 
Carlsbad, CA), 10% Newborn Calf Serum (NCS, Gemini Bio-Products, Carlsbad, 
CA), and 1% penicillin/streptomycin. Cells (passage number 6 or lower) were 
grown to 100% confluence at 37°C in a humidified 5% CO2 atmosphere and 
culture media was changed every 48 hours. Two days after cells reached 100% 
confluence, differentiation was initiated (day 0) with media containing 90% 
DMEM, 10% fetal bovine serum (FBS; Gemini Bio-Products, Woodland, CA), 1% 
penicillin/streptomycin, 0.2 µM insulin, 0.5 mM IBMX and 1.0 µM 
dexamethasone. Forty-eight hours later (day 2), media was changed to adipocyte 
maintenance media containing 90% DMEM, 10% FBS, 1% 
penicillin/streptomycin, and 0.2 µM insulin. Following day 2, media was changed 
every 48 hours (day 4 and day 6) using maintenance media containing 90% 
DMEM, 10% FBS, and 1% penicillin/streptomycin. On day 8, cells were 
considered fully differentiated adipocytes. 
 
2.3.2 Pyocyanin treatment in 3T3-L1 cells 
Pyocyanin was purchased from Sigma-Aldrich (catalogue number P0046, 
Sigma-Aldrich, St. Louis, MO) and dissolved in DMSO. For treatment during 
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differentiation, 3T3-L1 cells were grown to confluence in preadipocyte expansion 
medium in 6-well plates. Two days after reaching confluence, cells were treated 
with 0 (DMSO, 0.02%), 10, 50, or 100 µM pyocyanin, with fresh media containing 
vehicle or pyocyanin added on days 0, 2, 4, and 6. On day 8, cells were 
harvested for RNA extraction and gene expression analysis, or Oil Red O (ORO) 
staining as a marker of adipocyte differentiation. For post-differentiation 
treatment of mature adipocytes, fully differentiated 3T3-L1 adipocytes (day 8 
cells) were treated with 0, 10, 50, or 100 µM pyocyanin for 24 hours and then 
harvested for RNA extraction or ORO staining. Cells were scraped using 175 µL 
of RNA lysis buffer (Maxwell, catalogue # MC501C, Promega, Madison, WI), and 
stored at -80⁰C. Oil Red O staining was performed on separate plates on day 8 
or 9 using the ORO Staining Kit from Lifeline Cell Technology (catalogue number 
LL-0052, Frederick, MD). Stained cells were imaged at 10x. After imaging, water 
was removed from the stained cells, 500 µL of isopropanol was added to each 
well for 1 minute to extract ORO from the cells, and 200 µL was removed from 
each well and absorbance measured in a 96-well plate at 510nm in a 
spectrophotometer. 
2.3.3 Animal treatments and sample collection 
All experiments met the approval of the Animal Care and Use Committee 
of the University of Kentucky.  Mice were housed in micro-isolator, polystyrene 
cages with a 14 hr light/10 hr dark cycle. Room temperature was at a range of 
20-21ºC, and humidity ranged from 30-70%. Male and female mice C57BL/6J 
mice were purchased from The Jackson Laboratories (Bar Harbor, MA) and aged 
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6 months to have sufficient fat mass to assess adipose cachexia. All mice were 
fed standard murine diet (Harlan Teklad 2918 Global Rodent Diet, irradiated; 
Harlan Laboratories, Indianapolis, IN) ad libitum for the duration of the study 
design. Body weights were quantified daily. At study end point, mice were 
anesthetized [ketamine/xylazine, 10/100 mg/kg, by intraperitoneal (ip) injection] 
for exsanguination and tissue harvest (liver, subcutaneous adipose (SubQ), 
retroperitoneal adipose (RPF), epididymal adipose (EF)/periovarian fat (POF), 
interscapular brown adipose tissue (BAT), heart, lung, and soleus)). 
2.3.4 Isolation of the stromal vascular fraction (SVF) from adipose 
SubQ and EF tissue was aseptically excised from C57BL/6J mice, 
minced, and incubated in basal medium (Zenbio, Research Triangle Park, NC) 
supplemented with collagenase (1 mg/mL) and penicillin (100 
U/mL)/streptomyocin (100 µg/mL) for 1 hour with shaking at 37°C, as previously 
described in 12-well plates at a seeding density of 50,000 cells/cm2 [358]. Two 
days after SVF cells had reached 100% confluence (day 0), the medium was 
changed to differentiation media and then replaced every other day with fresh 
media for 8 days. Cells were harvested at day 8 after differentiation for ORO 
staining and RNA isolation using Maxwell RSC simplyRNA Cell Kit; cDNA 
synthesis and real-time PCR were performed as described below. 
2.3.5 Pyocyanin treatment in stromal vascular cells (SVF) 
SVF cells were harvested from naïve 10-month old male C57BL/6J mice 
and plated onto 12-well plates at a seeding density of 50,000 cells/cm2. Cells 
were treated with vehicle (DMSO, 0.02%) or pyocyanin (100 µM) beginning on 
  62 
day 0 and every 48 hours thereafter until cells were collected for ORO staining 
and RNA extraction on day 8. 
2.3.6 Dose escalation pyocyanin pilot study in C57BL/6J mice 
Male C57BL/6J mice, aged to 6 months as adults with significant adipose 
tissue mass, were administered vehicle (phosphate buffered saline, PBS) or 
escalating doses (2, 6, 19, and 50 mg/kg) of pyocyanin by intraperitoneal (IP) 
injection separated by 3-4 days. Body weights were recorded daily, and body 
composition was quantified by EchoMRI as described below. Study endpoint 
occurred 3 weeks after the final injection of 50 mg/kg pyocyanin. 
2.3.7 Dose response pyocyanin pilot study in C57BL/6J mice 
Male C57BL/6J mice (6 months of age) received a total of three IP 
injections, at weeks 0, 3 or 13, of either PBS VEH control or pyocyanin at 30, 40, 
or 50 mg/kg. Body weights were recorded daily, and body composition was 
measured by EchoMRI as described below. Study endpoint occurred 24 hours 
after the final injection. 
2.3.8 Repeated pyocyanin administration to male C57BL/6J mice with tissue 
harvest 1 day following the last dose 
Male C57BL/6J mice (6 months of age) were administered IP injections of 
PBS VEH control or pyocyanin (40 mg/kg, ip) on day 0 and 7, with study endpoint 
24 hours after the last dose. Body weights were quantified daily and EchoMRI 
was performed prior to each injection as described below. After each injection, 
body temperature was quantified using a subcutaneously implantable 
programmable temperature transponder (IPTT) and Bio Medic Data Systems 
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(BMDS) transponder (product numbers IPTT 300 and DAS-7007, Bio Medic Data 
Systems Inc, Seaford, DE). At study endpoint, EF explants were prepared 
(described below) and SVF cells were isolated from both EF and SubQ for 
adipocyte differentiation.  
 
2.3.9 Repeated pyocyanin administration to male and female C57BL/6J mice 
with tissue harvest 2 weeks following the last dose 
Male and female C57BL/6J mice (6 months of age) were administered IP 
injections of PBS VEH control or pyocyanin (40 mg/kg, ip) on days 0, 7 and 14, 
with study endpoint two weeks after the final dose. Body weights were taken 
daily and EchoMRI was performed each week prior to the next injection. Male 
mice received their first two injections while in indirect calorimetry chambers 
(LabMaster TSE Systems Inc., Chesterfield, MO). After one week of acclimation 
to the chamber system, baseline measurements were recorded for one week.  
Mice received two injections of PBS or pyocyanin, separated by one week, while 
recordings continued for 7 days beyond the last injection. Data from three 24-
hour periods after each injection were adjusted for lean mass and averaged. For 
both sexes, study endpoint occurred two weeks following the third injection, at 
which point EF explants were used to quantify lipolysis (described below) and 
SVF cells were isolated from SubQ for adipocyte differentiation. 
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2.3.10 Measurement of body composition 
Body composition (fat and lean mass) of conscious mice was determined 
by nuclear magnetic resonance spectroscopy [EchoMRI (magnetic resonance 
imaging)] as described previously [247]. 
 
2.3.11 Extraction of RNA and quantification of mRNA abundance by real-time 
PCR (RT-PCR) 
Total RNA was extracted from tissues and cells using the Maxwell RSC 
simplyRNA Cell or Tissue Kit (Promega Corporation, Madison, WI) according to 
the manufacturer’s instructions. RNA concentrations were determined using a 
NanoDrop 2000 spectophotometer (ThermoScientific, Wilmington, DE). cDNA 
was synthesized from 0.4 µg total RNA with qScript cDNA SuperMix (Quanta 
Biosciences, Gaithersburg, MD) in the following reaction:  25°C for 5 minutes, 
42°C for 30 minutes, and 85°C for 5 minutes. The cDNA was diluted to 0.4 ng/µL 
and amplified with an iCycler (Bio-Rad, Hercules, CA) and the Perfecta SYBR 
Green Fastmix for iQ (Quanta Biosciences, Gaithersburg, MD). Using the 
difference from GAPDH cDNA (reference gene) and the Ct method, the 
relative quantification of mRNA abundance in each sample was calculated. The 
PCR reaction was as follows: 94°C for 5 minutes, 40 cycles at 94°C for 15 
seconds, 60°C or 64°C (based on tested primer efficiency) for 40 seconds, 72°C 
for 10 minutes, and 100 cycles from 95°C to 45.5°C for 10 seconds. Primer 
sequences were as follows: AhR, forward 5’- 
GACCAAACACAAGCTAGACTTCACACC, reverse 5’- 
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CAAGAAGCCGGAAAACTGTCATGC; AhR, forward 5’-
AGTAAAGCCCATCCCCGCTGAAGG-3’, reverse 5’-
CATCAAAGAAGCTCTTGGCCC-3’;  CYP1A1 (cytochrome P450 1A1), forward 
5’-AGTCAATCTGAGCAATGAGTTTGG-3’, reverse 5’-
GGCATCCAGGGAAGAGTTAGG-3’; GAPDH, forward 5’-
GCCAAAAGGGTCATCATCTC-3’, reverse 5’-GGCCATCCACAGTCTTCT-3’; 
TNF-α, forward 5’-CCCACTCTGACCCCTTTACTC-3’, reverse 5’-
TCACTGTCCCAGCATCTTGT-3’; aP2, forward 5’- 
GGAACCTGGAAGCTTGTCTC-3’, reverse 5’- TGATGCTCTTCACCTTCCTG-3’; 
PPARγ, forward 5’- GATGGAAGACCACTCGCATT-3’, reverse 5’- 
AACCATTGGGTCAGCTCTTG-3’; β-catenin, forward 5’-
ATGGACTGCCTGTTGTGGTT-3’, reverse 5’- AAAGGCGCATGATTTGCTGG-3’; 
RANTES, forward 5’- CCCTCACCATCATCCTCACT-3’, reverse 5’- 
CCTTCGAGTGACAAACACGA-3’; F4/80, forward 5’- 
CTTTGGCTATGGGCTTCCAGTC-3’, reverse 5’- 
GCAAGGAGGACAGAGTTTATCGTG-3’. 
 
2.3.12 Quantification of lipolysis in adipose tissue explants 
Epididymal adipose tissue was cut into 25-50 mg explants. A single EF 
explant was placed into one 24-well plate containing Krebs buffer (1 mL). 
Explants were washed with fresh buffer, which was removed and replaced with 
Krebs buffer (0.5 mL) containing 2% fatty acid free bovine serum albumin, and 
the plates were incubated at 37°C. A 30 uL sample of buffer was removed from 
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each well at 60, 120, 180, and 240 minutes after the start of the incubation. The 
glycerol concentration of the samples was quantified using the Glycerol 
Colorimetric Assay Kit (Item # 10010755, Caymen Chemicals, Ann Arbor, MI) per 
the manufacturer’s instructions. The remaining EF explants were washed three 
times with Krebs buffer (1 mL/each) and frozen for protein determination. For 
protein determination, tissue samples were suspended on ice in PBS (0.5 mL) 
containing EDTA (2 mM) and protease cocktail inhibitor (cOmplete Mini, Roche 
Diagnostics, Indianapolis, IN). Tissue was homogenized using a Geno/Grinder 
(Spex SamplePrep, Metuchen, NJ) set to 1,350 rpm x 1.5 minutes. After 
homogenization, samples were centrifuged at 14,000 rpm x 10 minutes at 4°C 
and the supernatants transferred to clean tubes. Protein concentrations of the 
supernatants were determined using the Pierce BCA protein assay kit (Dallas, 
TX). Lipolysis is reported as amount of glycerol produced/mg protein/hour. 
 
2.3.13 Quantification of plasma concentrations of inflammatory cytokines 
Mouse plasma (25 µL) was collected in EDTA and diluted 1:2 in Assay 
Buffer (Milliplex, Item #L-AB, Millipore Sigma, Burlington, MA) to quantify plasma 
inflammatory cytokine concentrations using the Mouse Cytokine/Chemokine 
Magnetic Bead Panel as per the manufacturer’s instructions (Item 
#MCYTOMAG-70K-PMX, Millipore Sigma, Burlington, MA). The 96-well magnetic 
bead assay was read using a Luminex 200 (R&D Systems, Minneapolis, MN).  
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2.3.14 Quantification of pyocyanin concentrations in biological samples 
Sample preparation: Plasma (50 µL) or adipose homogenate (200 mg/ml) 
was added to a 1.5 mL microcentrifuge tube. Internal standard solution (10 µL; 
caffeine-d3, 100 ng/mL in ethanol) and ethanol (10 µL) were added (for 
calibration samples, 10 uL of ethanol containing pyocyanin in a concentration 
range of 2.5-625 ng/ml) to each tube. After briefly vortex-mixing, methanol (50 
uL) and 10% perchloric acid solution (150 uL) were added and the contents 
mixed for 5 min. Tubes were centrifuged for 5 minutes at 11, 000 x g. The 
supernatant was recovered and transferred to an autosampler vial. 
LC-MS/MS analysis: Analysis was performed on an AB Sciex 4000 Q Trap 
coupled with an Exion LC system. The Analyst software package was used for 
data collection and analysis. Chromatography was carried out with a C8 reverse-
phase column (Waters ACQUITY UPLC BEH C8, 2.1 X 50 mm, 1.7 μm) 
maintained at 40℃ and the flow rate was set to 0.3 mL/min. Solvent A is 100% 
water with 0.1 % formic acid and ammonium carbonate (5 mM) and solvent B is 
90% methanol with 0.1 % formic acid and ammonium carbonate. A gradient 
program was used as follow (T min/%A): 0/95, 1.0/95, 2.5/75, 5.0/75, 5.1/0, 
6.6/0, 6.7/95, 9.0 /95. The injection volume was 5.0 μL. Mass spectrometer was 
equipped with an electrospray ionization (ESI) source and operated in positive 
mode under the following operating parameters: IonSpray Voltage 5.5 kV, 
Desolvation temperature 500℃, Ion Source Gas 1 40 psi, Ion Source Gas 2 40 
psi, Curtain Gas 30 psi, Collision Gas Medium, Declustering Potential 80 V, 
Entrance Potential 10.0 V, and Collision Energy 27.0 V for caffeine and 45.0 V 
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for pyocyanin. Quantitative analysis was conducted by monitoring the precursor 
ion to production ion transitions of m/z 211.2/168.2 for pyocyanin and m/z 
198.2/138.0 for caffeine-d3 with a dwell time of 0.15 s. 
 
2.3.15 Metabolite identification of pyocyanin in mouse urine 
Urine samples were extracted using methanol, and the supernatant was 
dried under nitrogen. After reconstituting in 90% acetonitrile, sample (2 μL) was 
injected for LC-MS analysis. A Q-Exactive mass spectrometer equipped with an 
Ultimate 3000 ultra high performance liquid chromatography system (Thermo 
Fisher Scientific, San Jose, CA) was used for sample detection. 
Chromatographic separation was performed on a reversed phase Kinetex C18 
column (2.6 mm × 100 mm, 2.1 μm, Phenomenex, USA). Mobile phases were 
composed of acetonitrile (A) and water (B), both containing 0.1% formic acid. 
The column temperature was maintained at 40°C, and the flow rate was set to 
0.25 ml/min. Mass spectrometric detection was performed by electrospray 
ionization in positive ionization mode with source voltage maintained at 4.3 kV. 
The capillary temperature, sheath gas flow and auxiliary gas flow were set at 
330°C, 35 arb and 12 arb, respectively. Full-scan MS spectra (mass range m/z 
75 to 1000) were acquired with resolution R = 70,000 and AGC target 1e6. 
MS/MS fragmentation was performed using high-energy C-trap dissociation with 
resolution R = 35,000 and AGC target 2e5. The stepped normalized collisional 
energy scheme was set at 30, 40, and 50. Raw data files acquired in full scan-
ddMS2 mode were imported into Compound Discoverer™ software (v. 2.1; 
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Thermo Fisher Scientific) to identify pyocyanin metabolites. The software detects 
chromatographic peaks, and the mass of the corresponding compound is 
compared with a list of generated theoretical metabolites. Potential metabolites 
were proposed based on exact mass, MS2 fragmentation, isotopic pattern and 
retention time with respect to the parent compound. 
 
2.3.16 Statistical analysis 
Data are represented as mean + SEM. Data were tested for normality using 
the Shapiro-Wilk test, and equal variance was tested using the Brown-Forsythe 
test. Outlier detection was performed using Grubbs’ or extreme studentized 
deviate method where alpha = 0.05. If data did not pass normality using these 
approaches, data were logarithmically transformed. One-way analysis of 
variance (ANOVA; SigmaPlot, version 13.0; Systat Software Inc., Chicago, IL) 
was used to define effects of pyocyanin treatment in vitro. Dunnett’s method was 
used for post-hoc analyses. T-tests were used to analyze in vivo comparisons 
between pyocyanin (PYO) and vehicle (VEH) treated animals. Body weights and 
body composition were analyzed by repeated measure. Body temperature 
analyses were performed in SAS 9.4 (SAS Institute Inc.; Cary, NC, USA). For 
each mouse, temperature was plotted against log-transformed time and the area 
under the curve (AUC) was calculated for each of the two injections. A full 
factorial two-way repeated measures ANOVA was performed on the AUC values, 
analyzing differences between across treatment and injection number. A 
Kenward and Roger adjustment was used to correct for small-sample bias. Post-
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hoc two-sample t-tests were performed at each timepoint, separated by injection 
number. Statistical significance was defined as p < 0.05. 
 
2.4 Results 
 
2.4.1 Pyocyanin reduces differentiation of 3T3-L1 cells to adipocytes 
Previous studies demonstrated that activation of AhR reduced 
differentiation of 3T3-L1 cells to adipocytes [219, 225, 226]. Pyocyanin has been 
demonstrated to bind to AhR [270]. Thus, we first defined concentration-
dependent effects of pyocyanin (0 – 100 µM) on differentiation of 3T3-L1 cells to 
adipocytes. Pyocyanin (100 M) reduced significantly ORO absorbance and 
staining as a marker of adipocyte differentiation compared to vehicle controls 
(Figure 2.1A,B; P<0.05). Similarly, mRNA abundance of Ap2 and PPARγ, genes 
associated with a mature adipocyte phenotype [359], were reduced significantly 
by pyocyanin (100 M; Figure 2.1C; P<0.05). As an index of AhR activation, 
pyocyanin resulted in robust increase in mRNA abundance of AhR and its 
downstream marker, CYP1a1 (Figure 2.1C, P<0.05). When incubated with 
differentiated adipocytes, pyocyanin (50, 100 µM) reduced significantly ORO 
absorbance and staining (Figure 2.1D,E; P<0.05). However, in mature 
adipocytes, while pyocyanin at high concentrations (100 µM) increased mRNA 
abundance of AhR, there was a non-monotonic, inverted-U shape dose response 
for effects of pyocyanin on mRNA abundance of CYP1a1 and TNF-α (Figure 
2.1F). Pyocyanin, at any concentration examined, did not significantly influence 
cell viability as quantified by trypan blue staining (data not shown). 
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2.4.2 Pyocyanin reduces differentiation of mouse adipose stromal vascular cells 
to adipocytes and promotes lipolysis of mouse white adipose explants 
We isolated the stromal vascular fraction (SVF) from adipose tissue to 
obtain stem cells as an alternative in vitro model of adipocyte differentiation. 
Similar to effects of pyocyanin to reduce differentiation of 3T3-L1 cells to 
adipocytes, pyocyanin (100 µM) reduced significantly ORO absorbance 
compared to vehicle controls after 8 days of the differentiation protocol (Figure 
2.2A, P<0.05). Since pyocyanin reduced ORO absorbance when incubated with 
mature adipocytes (Figure 2.1D), we defined effects of pyocyanin on lipolysis 
using epididymal (EF) white adipose explants from naïve male C57BL/6J mice. 
Following a 4 hour incubation, pyocyanin (100 M) increased significantly 
glycerol release from adipose tissue explants (Figure 2.2B, P<0.05).  
 
2.4.3 Development of an in vivo model of pyocyanin-induced cachexia 
We developed an in vivo model of pyocyanin-induced cachexia using adult 
male C57BL/6J mice (aged to 6 months to have sufficient fat mass to quantify 
adipose cachexia). Intraperitoneal (IP) injection of pyocyanin was chosen as a 
mode of delivery to replicate gut-derived sepsis. Initial dose escalation studies, 
initiated at 2 mg/kg of pyocyanin, had no effect on body weight, and thus doses 
were escalated to a maximum of 50 mg/kg of pyocyanin, which resulted in a 
reduction in body weight within 48 hours after administration (34.1 ± 0.9 g at 
baseline versus 31.9 ± 1.2g, P<0.05). We then performed dose response studies 
testing effects of repeated exposures (two injections separated by one week) to 
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30, 40, and 50 mg/kg pyocyanin. During the course of these studies, we found 
that there is an effect of repeated exposures to pyocyanin, with greater losses in 
body weight and fat mass following a second injection of pyocyanin (Figure 
2.7A,B). Furthermore, upon second injection with pyocyanin, mice exhibited 
changes in behavior, including lethargy, trembling, and poor motor control, which 
persisted for several hours after injection but returned to normal function within 
12 hours. We detected pyocyanin in plasma 24 hours following the second 
injection of each dose (Figure 2.7C). 
 
2.4.4 Pyocyanin acutely reduces body temperature and chronically decreases 
body weight, fat mass, and adipocyte differentiation in male C57BL/6J 
mice 
Based on results from pilot studies, we administered two injections (IP) of 
pyocyanin (40 mg/kg) separated by one week. Moreover, because of the 
behavioral effects of the virulence factor in pilot studies, we quantified body 
temperature during the first 24 hours after administration of each dose of 
pyocyanin, and then subsequently for 7 days at the same time each day. Both 
first and second injection of pyocyanin resulted in a rapid and robust decrease in 
body temperature (Figure 2.3B, P<0.05) that was accompanied by lethargy, 
trembling, and poor motor control. Calculation of the area under the curve for 
body temperature reductions during the 24 hours following pyocyanin exposure 
demonstrated significant reductions compared to vehicle controls (data not 
shown). Pyocyanin-induced acute reductions in body temperature were not 
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maintained beyond 24 hours (Figure 2.3B, P<0.05), and body temperature was 
not significantly influenced by pyocyanin on subsequent days (Figure 2.3A).  
Normalization of body temperature coincided with a return to normal 
behavior and motor control. Acute body temperature-regulating effects of 
pyocyanin occurred prior to reductions in body weight (illustrated as % weight 
loss compared to baseline body weight) of pyocyanin-treated mice compared to 
vehicle controls (Figure 2.3C). However, while body temperature quickly returned 
to normal within 24 hours after injection (Figure 2.3A,B), weight loss following 
pyocyanin was sustained throughout the 7 day time course (Figure 2.3C). 
Pyocyanin was detected in the plasma 24 hours following the second injection 
(PYO: 4.5 + 1.0 ng/mL; VEH: none detected). We also quantified pyocyanin and 
associated metabolites in the urine of mice from this study. Pyocyanin was 
detected in urine (45 and 60 minutes post-injection) as the parent compound and 
five major metabolites (N-demethylation + glucorindation and oxidation + 
glucoronidation conjugates; (Figure 2.9). Peak areas for each conjugate 
decreased from 45 to 60 minutes, indicating pyocyanin is rapidly metabolized. 
Additionally, while pyocyanin levels were non-detectable in adipose tissue from 
vehicle-treated animals, pyocyanin (4 ng/g) was detected in EF and RPF at 24 
hours after the last dose (Figure 2.3D, P<0.05). 
EF explants removed from animals 24 hours after the last dose of 
pyocyanin did not exhibit differences in basal lipolysis (See supplemental 
material, Figure 2.8). Concentrations of the pro-inflammatory cytokine interleukin-
6 (IL-6) were increased in plasma of mice administered pyocyanin compared to 
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vehicle controls, while concentrations of the anti-inflammatory cytokine 
interleukin-13 (IL-13) were decreased compared to controls (Table 2.2; P<0.05). 
There was a trend toward reduced plasma concentrations of interleukin-1 alpha 
(IL-1) and increased concentrations of chemokine (C-X-C motif) ligand 1 
(CXCL1) (Table 2.2). In adipose tissue, mRNA abundance of the T-cell marker, 
RANTES, was increased significantly 24 hours after the last dose of pyocyanin 
(See supplemental material, Figure S2; P<0.05). However, there was no effect of 
pyocyanin on mRNA abundance of CYP1a1, PPARγ, aP2, TNF-α, F4/80, 
RANTES, or interleukin-10 (IL-10) in EF, RPF, or liver compared to vehicle 
controls (Figure 2.8).  
We harvested SVF from subcutaneous and EF adipose tissue of mice 
administered vehicle or pyocyanin and differentiated stem cells in vitro to 
adipocytes. On day 8 of the differentiation protocol, ORO absorbance was 
decreased significantly in adipocytes differentiated from stem cells isolated from 
both adipose depots of pyocyanin-treated mice compared to vehicle controls 
(Figure 2.3E, P<0.05).  
 
2.4.5 Pyocyanin chronically decreases body weight and fat mass of male 
C57BL/6J mice 
In this study, we administered three injections (IP) of vehicle or pyocyanin 
(40 mg/kg) one week apart and harvested tissues 14 days after the last dose. 
Our goal was to determine if effects of pyocyanin to decrease body weight and 
fat mass of male mice were sustained two weeks after the last dose. Moreover, 
to resolve mechanisms for effects of pyocyanin, we quantified measures of 
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whole-body metabolism following the first two injections of pyocyanin. We 
quantified food intake, indirect calorimetry, and physical activity for 3 consecutive 
days at baseline (prior to exposure) and the 3 days following both the first and 
second injections of pyocyanin while mice were within the recording chambers. 
There were no changes in any measured parameter of vehicle-treated mice at 
any time point (data not shown). Thus, data are illustrated for pyocyanin-treated 
mice only. The first injection of pyocyanin resulted in significant reductions in 
respiratory exchange ratio (RER, as quantified by VCO2/VO2, Figure 2.4A; 
P<0.05), energy expenditure (kcal expended; Figure 2.4B; P<0.05), physical 
activity (counts/30 min; Figure 2.4C; P<0.05), and food intake (kcal consumed; 
Figure 2.4D, P<0.05) on day 1 of recording. With the exception of physical 
activity and energy expenditure, reductions in these parameters (RER, EE, food 
intake) returned to baseline levels by the second day following the initial injection 
of pyocyanin. Following the second injection of pyocyanin, there were more 
pronounced and sustained reductions in RER, EE, activity, and food intake 
(Figure 2.4A-D, P<0.05).  
Male mice began losing weight following the second injection of pyocyanin 
and weighed significantly less than vehicle controls following the third injection of 
pyocyanin (Figure 2.5A, P<0.05). Similarly, lean mass (as a percentage of body 
weight) of pyocyanin-treated mice was increased significantly compared to 
vehicle controls, while fat mass was decreased significantly following the second 
injection of pyocyanin (Figure 2.5B,C; P<0.05). 
  76 
At 14 days following the final dose, pyocyanin-treated mice had significant 
reductions in the mass (adjusted to body weight) of EF, retroperitoneal fat (RPF), 
and interscapular brown fat (isBAT) compared to vehicle controls (Table 2.1; 
P<0.05). Liver mass was also reduced significantly in mice administered 
pyocyanin compared to vehicle controls (Table 2.1; P<0.05). Lipolysis of EF 
explants was increased significantly at 14 days after the last injection of 
pyocyanin compared to vehicle controls (Figure 2.5D, P<0.05). Concentrations of 
IL-10 were reduced significantly in plasma from mice administered pyocyanin 
compared to vehicle controls (Table 2.2). Notably, pyocyanin resulted in a 
significant increase in mRNA abundance for CYP1a1 in EF and RPF, but not in 
liver (Figure 2.5E; P<0.05). Moreover, mRNA abundance of TNF-α was reduced 
significantly in RPF from mice administered pyocyanin compared to vehicle 
controls (Figure 2.5E; P<0.05). However, other markers of adipocyte 
differentiation (aP2, PPARγ), inflammation (TNF-α), macrophage infiltration 
(F4/80), or T-cell infiltration (RANTES) were not altered in adipose tissue from 
pyocyanin-treated mice. Moreover, absorbance of ORO in adipocytes 
differentiated from stem cells isolated from subcutaneous adipose tissue of mice 
administered pyocyanin was not significantly different from control (Figure 2.5F), 
nor were there any differences in mRNA abundance of adipocyte markers in 
differentiated adipocytes (Figure 2.5G). Effects of pyocyanin to promote basal 
lipolysis of adipose explants and activate CYP1a1 expression in adipose tissue 
were observed despite an inability to detect pyocyanin in plasma or adipose at 14 
days after the last injection.  
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2.4.6 Pyocyanin chronically decreases body weight and fat mass of female 
C57BL/6J mice 
Studies have demonstrated sex differences in sepsis incidence between 
males and females [27, 28]. Thus, we repeated chronic pyocyanin exposures 
using the same experimental design as the above described in males (with the 
exception of indirect calorimetry) in adult female C57BL/6 mice. In contrast to 
males, female mice began losing body weight after the first injection of pyocyanin 
compared to vehicle controls, and weight loss was maintained throughout the 
study protocol (Figure 2.6A, P<0.05). Body weight reductions were associated 
with increased lean mass and decreased fat mass compared to baseline levels 
within each treatment group, or compared to vehicle controls (Figure 2.6B,C, 
P<0.05). In females, pyocyanin’s effect to reduce fat mass exhibited similar 
trends as seen in males, with modest reductions in weights of some fat pads 
compared to vehicle controls (Table 2.1). However, in contrast to males, liver 
mass of pyocyanin-treated female mice was increased significantly compared to 
vehicle controls (Table 2.1; P<0.05). Moreover, in females, there was no 
significant effect of pyocyanin on lipolysis of adipose tissue explants compared to 
vehicle controls (Figure 2.6D, P<0.05). Similar to males, pyocyanin resulted in a 
significant increase in mRNA abundance of CYP1a1 in adipose tissue but not in 
livers of female mice compared to vehicle controls, with no changes in mRNA 
abundance of aP2 or PPAR (Figure 2.6E, P<0.05). Pyocyanin resulted in a 
significant decrease in RANTES mRNA abundance in periovarian adipose tissue 
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compared to vehicle controls (Figure 2.6E, P<0.05). Moreover, pyocyanin 
resulted in a significant decrease in RANTES plasma concentrations of females 
compared to vehicle controls (Table 2.2, P<0.05).  
Notably, while there were no significant differences in ORO absorbance 
when SVF cells isolated from pyocyanin-treated females were differentiated in 
vitro to adipocytes (Figure 2.6F), adipocytes differentiated from pyocyanin-
treated females exhibited significant elevations in mRNA abundance of AhR and 
TNF-α (Figure 2.6G, P<0.05). These effects were observed in cells isolated two 
weeks after the last injection, when pyocyanin levels in plasma and adipose were 
below the detectable limit.   
 
2.5 Discussion 
Results from these studies demonstrate that pyocyanin, a virulence factor 
released by the sepsis-causing bacteria P. aeruginosa, regulates adipocyte 
formation and function in vitro, and regulates body weight in vivo of male and 
female mice. Specifically, we found that (1) pyocyanin reduces differentiation of 
adipocytes, promotes expression of inflammatory cytokines in differentiated 
adipocytes, and augments basal lipolysis of adipose tissue explants, (2) 
pyocyanin results in reductions in body weight and fat mass when administered 
in vivo to both male and female mice, (3) there are sex differences in 
mechanisms related to effects of pyocyanin on adipose tissue. While there has 
been a growing interest in the role of the virulence-promoting effects of 
pyocyanin in sepsis following P. aeruginosa infection, the role of pyocyanin at 
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mammalian cells such as adipocytes in the wasting and cachexia associated with 
sepsis has been largely unexplored. Our results suggest that pyocyanin exerts 
long-lasting effects to regulate body weight, adipose mass, and adipocyte 
function. These findings may have relevance to the wasting associated with 
chronic sepsis.  
Using 3T3-L1 cells, we found that pyocyanin stimulated expression of 
CYP1a1 as an index of AhR activation at concentrations (100 µM) that resulted in 
a 50% reduction in adipocyte differentiation. Notably, this concentration of 
pyocyanin has been detected in human samples [319, 320]. Our laboratory has 
reported previously an ability of AhR ligands, including coplanar PCBs and dioxin 
(TCDD), to reduce adipocyte differentiation [225]. In agreement with these 
findings, pyocyanin reduced several indices of adipocyte differentiation at 
concentrations that induced markers of AhR activation in 3T3-L1 adipocytes. 
While pyocyanin elicited downstream markers of AhR activation in adipocytes, it 
is unclear if the effects of pyocyanin on adipocytes were AhR-mediated.  
In mature adipocytes, pyocyanin also reduced ORO staining and 
promoted expression of TNF-α. Elevations in mRNA abundance for 
proinflammatory adipokines in response to pyocyanin is in agreement with 
previous findings of AhR activation in differentiated 3T3-L1 adipocytes [225]. 
However, in the current study, pyocyanin also reduced neutral lipid staining when 
incubated with differentiated adipocytes. A reduction in ORO staining of mature 
adipocytes exposed to pyocyanin may represent an increase in lipolysis, 
potentially related to induction of TNF-α [360, 361]. Indeed, using adipose tissue 
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explants from mice, we demonstrated that pyocyanin increased basal lipolysis. In 
a parallel adipocyte differentiation system using stem cells harvested from naïve 
mice, pyocyanin, at similar concentrations, decreased markers of adipocyte 
differentiation. It is interesting to note pyocyanin’s effect on CYP1a1 and TNF-α 
mRNA abundance in mature adipocytes appears to follow a non-monotonic, 
inverted-U shaped dose response, with the greatest inductions of gene 
expression occurring at intermediate concentrations of pyocyanin. We have 
previously reported that AhR ligands, namely environmental pollutants, exhibit 
non-monotonic and inverted U-shaped associations with disease outcomes 
[362].Therefore, it appears pyocyanin might have contrasting effects on pre-
/differentiating adipocytes versus mature adipocytes, representing an important 
consideration when interpreting in vivo data and defining future therapeutic 
targets.   
Based on these in vitro findings, we developed an in vivo model of 
pyocyanin-induced cachexia that did not include use of P. aeruginosa as a 
confounding factor, as our interest was the effects of pyocyanin on mammalian 
cells. Utilizing IP injection to replicate potential pyocyanin exposures from gut-
derived sepsis, pyocyanin dose-dependently elicited sustained weight loss upon 
repeated exposures. Moreover, while an initial injection of pyocyanin had no 
effects in male mice, upon second injection, several effects were noted, including 
behavioral effects that were short-lived. Our findings are in agreement with 
previous studies indicating that intranasal exposure to pyocyanin resulted in 
reduced spontaneous locomotor activity and increased immobility time in forced 
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swim [321]. Hypothermia is a known symptom of sepsis [363]. Our results 
demonstrate that behavioral effects of pyocyanin, including lethargy, trembling, 
and poor motor control, were associated with a rapid decrease in body 
temperature that returned to baseline levels 17 hours after injection, when 
behavioral effects were no longer evident. These results suggest that these 
symptoms associated with sepsis from P. aeruginosa may result from release of 
pyocyanin from the bacteria. However, since weight loss from pyocyanin 
exposure was sustained and did not coincide with the timeframe for behavioral or 
temperature-regulating effects of the compound, these results suggest that other 
mechanisms contribute to pyocyanin’s effects on body weight. 
To elucidate mechanisms contributing to body weight-regulating effects of 
pyocyanin, we studied its effects on adipocyte differentiation and adipose 
inflammation. Remarkably, when stem cells were harvested 24 hours after the 
last dose of pyocyanin and differentiated over an 8 day experimental protocol, 
markers of adipocyte differentiation were reduced, suggesting long-lasting effects 
of pyocyanin. It is noteworthy that mice injected with pyocyanin begin 
metabolizing and excreting the compound through their urine within 45 minutes 
of injection; however, pyocyanin was still detectable in the plasma at 24 hours, 
when stem cells were harvested for in vitro adipocyte differentiation. Plasma 
concentrations of the pro-inflammatory cytokine IL-6 were increased 24 hours 
after the last dose of pyocyanin, while concentrations of the anti-inflammatory 
cytokine IL-13 were decreased in pyocyanin-treated mice. Elevations in systemic 
IL-6 concentrations have been demonstrated in patients with sepsis [6, 364, 365], 
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with high IL-6 levels associated with poor outcomes in sepsis [42, 366-369]. 
Previous studies have demonstrated pyocyanin’s ability to increase IL-6 in airway 
epithelial or urothelial cells [333, 338]. By increasing pro-inflammatory 
concentrations of IL-6, pyocyanin may augment the acute phase reaction to P. 
aeruginosa infection. It is possible that reductions in plasma concentrations of IL-
13, an anti-inflammatory cytokine produced by T helper 2 (Th2) cells that has 
been shown to inhibit secretion of IL-6, TNF- and other inflammatory cytokines, 
contribute to an overzealous inflammatory response to pyocyanin [370-373]. 
Conversely, IL-13 has been shown to play a protective role in cecal ligation and 
puncture (CLP) models of sepsis [374], and reductions in IL-13 were associated 
with increases in the neutrophil recruiter CXCL1 [374], which was also modestly 
elevated in the plasma of pyocyanin-treated mice. Therefore, by blocking the 
protective anti-inflammatory processes of IL-13, pyocyanin may contribute to the 
longevity of P. aeruginosa survival. These changes in plasma concentrations of 
factors involved in inflammation may contribute to pyocyanin’s ability to regulate 
body weight. However, since adipose tissue expression of several inflammatory 
modulators was not altered by pyocyanin, the source of these systemic factors is 
unclear.  
Though advances in anti-inflammatory strategies have increased survival 
through the acute phase of sepsis, a growing number of patients are progressing 
to chronic critical illness [94]. Cachexia, with no known therapeutic strategies, is 
a complication of chronic survivors of sepsis [94]. We quantified measures of 
whole-body metabolism in male mice exposed to pyocyanin to define 
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mechanisms for the observed reductions in body weight and fat mass. 
Interestingly, while both injections of pyocyanin lowered RER, EE, activity, and 
food intake of male mice, reductions were more robust and sustained upon 
repeated exposure. A shift towards a lower RER indicates that fat is being 
utilized as the predominant fuel source of pyocyanin-treated male mice. Similarly, 
fat is the preferred fuel of septic patients [199]. Increased fat utilization and 
oxidation is further supported by an observed increase in basal lipolysis of fat 
explants, which coupled with greater fat oxidation may contribute to a loss of fat 
mass in male pyocyanin-treated mice. Reductions in energy expenditure of male 
pyocyanin-treated mice may relate to the observed reductions in physical activity. 
While food intake declined acutely in response to pyocyanin, these effects were 
not sustained and thus did not appear to contribute to sustained reductions in 
body weight. 
Since sex differences in sepsis incidence and survival have been reported 
previously [15, 16], we contrasted effects of chronic pyocyanin exposures on 
body weight and fat mass in male and female mice. While both male and female 
mice exhibited sustained weight loss in response to pyocyanin, female mice lost 
weight after the first pyocyanin exposure and exhibited more robust responses to 
pyocyanin. An important finding of the present study was an ability of pyocyanin 
to activate expression of CYP1a1 as a marker of AhR activation in adipose 
tissue, but not in liver of both sexes. This result was surprising in light of a much 
larger expression level of AhR in liver compared to adipose tissue [375-377]. 
Moreover, induction of CYP1a1 in adipose tissue was maintained two weeks 
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after the last exposure to pyocyanin, supporting sequestration of lipophilic 
pyocyanin in adipose tissue. Indeed, pyocyanin was detected in adipose tissue 
24 hours after the last dose in male mice. However, we were not able to detect 
pyocyanin in adipose tissue of male or female mice at 2 weeks after the last 
dose. In addition to differences in the timing and degree of weight loss between 
males and females, results from this study suggest sex differences in the 
mechanisms of action of pyocyanin on adipose tissue biology. For example, 
adipose explants from males, but not females, exhibited increased basal 
lipolysis, while adipocytes differentiated from stem cells of pyocyanin-treated 
females had increased expression of TNF-α and AhR. Notably, changes in 
expression of these markers of inflammation and AhR activation in differentiated 
adipocytes occurred three weeks following the last exposure of female mice to 
pyocyanin. Other differences between sexes included levels of pro- or anti-
inflammatory cytokines and/or markers of immune cell activation in plasma of 
male versus female pyocyanin-treated mice. The sexually dimorphic effects of 
pyocyanin may be due, in part, to sex differences in AhR responsiveness [378-
380].  Regardless, our results suggest that in both sexes, changes in plasma 
concentrations of inflammatory mediators and/or immune cells that were 
sustained for several weeks after the last exposure to pyocyanin may contribute 
to poor outcomes associated with chronic sepsis from P. aeruginosa.  
In conclusion, results from this study demonstrate that pyocyanin reduced 
the differentiation of adipocytes in vitro, and decreased body weight and fat mass 
when administered to male and female mice in vivo. Effects of pyocyanin to 
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decrease body weight and fat mass were sustained for several weeks after the 
last exposure and appeared to involve different mechanisms in male versus 
female mice. These results indicate a potential role of pyocyanin in adipose 
wasting and cachexia associated with sepsis from P. aeruginosa. Future studies 
should elucidate the role of AhR in pyocyanin’s sexual dimorphic effects on 
adipose cachexia in sepsis. Understanding pyocyanin’s mechanisms of action 
could lead to novel therapeutic targets for septic cachexia produced by P. 
aeruginosa. 
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Table 2.1 Plasma cytokine concentrations in male and female mice administered 
vehicle or pyocyanin 
Tissue 
Tissue weight (g)/Body weight (g) 
Acute Males Chronic Males Chronic Females 
Vehicle Pyocyanin Vehicle Pyocyanin Vehicle Pyocyanin 
EF 0.043 ± 0.008 0.042 ± 0.01 0.028 ± 0.007 0.019 ± 0.007 * 0.025 ± 0.0112 0.017 ± 0.003 
SubQ 0.019 ± 0.008 0.019 ± 0.006 0.009 ± 0.002 0.008 ± 0.003 0.011 ± 0.0033 0.011 ± 0.0022 
RPF 0.015 ± 0.003 0.013 ± 0.002 0.010 ± 0.003 0.006 ± 0.003 * 0.005 ± 0.003 0.003 ± 0.0006 
isBAT 0.006 ± 0.002 0.007 ± 0.002 0.006 ± 0.0008 0.005 ± 0.0003 * 0.005 ± 0.00097 0.004 ± 0.0007 
Liver 0.046 ± 0.002 0.045 ± 0.006 0.056 ± 0.003 0.051 ± 0.003 * 0.041 ± 0.0061 0.048 ± 0.0028 * 
Lung 0.006 ± 0.003 0.006 ± 0.002 0.006 ± 0.002 0.006 ± 0.0009 0.006 ± 0.0015 0.008 ± 0.0031 
Heart 0.004 ± 0.001 0.004 ± 0.001 0.005  0.0003 0.005  0.0004 0.005 ± 0.0009 0.005 ± 0.0003 
Soleus 
0.0006 ± 
0.0001 
0.0006 ± 0.0001 -- -- 0.0006 ± 0.0001 0.0007 ± 0.0001* 
Values are mean + SEM from n=5-15/group. *, P<0.05 compared to vehicle. 
Abbreviations: EF, epididymal fat; SubQ, subcutaneous fat; RPF, retroperitoneal 
fat; isBAT, interscapular brown fat. 
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Table 2.2 Plasma cytokine concentrations in male and female mice administered 
vehicle or pyocyanin 
 
Plasma Cytokine Concentration (pg/mL) 
Acute Males Chronic Males Chronic Females 
Vehicle Pyocyanin Vehicle Pyocyanin Vehicle Pyocyanin 
IL-1α 67.20 ± 35.05 31.21 ± 12.91 31.22 ± 32.82 21.91 ± 9.41 35.31 ± 22.75 19.87 ± 15.29 
IL-6 8.14 ± 5.52 33.03 ± 18.69* 0.65 ± 0.48 0.93 ± 1.13 0.78 ± 0.86 1.65 ± 1.97 
IL-13 27.34 ± 8.15 9.54 ± 8.61* 18.36 ± 12.74 13.94 ± 9.72 15.75 ± 13.04 49.07 ± 71.13 
IL-10 2.68 ± 2.51 2.32 ± 1.98 5.59 ± 3.68 3.41 ± 0.93* 3.73 ± 3.83 4.24 ± 3.64 
IP-10 148.95 ± 72.50 130.57 ± 45.74 139.73 ± 32.86 115.89 ± 11.81 105.62 ± 23.03 124.39 ± 40.94 
CXCL1 44.94 ± 21.11 132.63 ± 102.54 27.58 ± 11.61 41.09 ± 30.87 25.14 ± 12.21 17.28 ± 10.99 
RANTES 17.91 ± 10.48 9.86 ± 5.47 5.02 ± 4.99 6.46 ± 3.34 11.93 ± 5.33 5.21 ± 3.56* 
Values are mean + SEM from n=5-15/group. *, P<0.05 compared to vehicle 
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Figure 2.1. Pyocyanin reduces in vitro adipocyte differentation and activates AhR 
in 3T3-L1 adipocytes 
 
 
Figure 2.1. Pyocyanin reduces in vitro adipocyte differentiation and 
activates AhR in 3T3-L1 adipocytes. (A) Oil Red O (ORO) absorbance (510 
nm, day 8 of differentiation protocol) of 3T3-L1 adipocytes treated with vehicle (0 
µM) or pyocyanin. (B) Representative images of cells (day 8 from (A)) incubated 
with vehicle or pyocyanin (PYO). (C) mRNA abundance of AhR, CYP1a1, aP2, 
PPAR, or -catenin in 3T3-L1 adipocytes incubated with vehicle (0 µM) or 
pyocyanin during the differentiation protocol. (D) ORO absorbance of 
differentiated (day 8) 3T3-L1 adipocytes incubated with vehicle (0 µM) or 
pyocyanin for 24 hours. (E) Representative images of differentiated 3T3-L1 
adipocytes from (D) incubated with vehicle or pyocyanin. (F) mRNA abundance 
of AhR, CYP1a1, or TNF- mRNA abundance in differentiated 3T3-L1 
adipocytes incubated with vehicle (0 µM) or pyocyanin for 24 hours. Scale bar in 
  89 
(B) and (E) is 200 μm. Data are mean + SEM from n = 3-8 wells/treatment. *, 
P<0.05 compared to 0 M (VEH). 
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Figure 2.2. Pyocyanin reduces adipocyte differentiation from murine stem cells 
and induces ex vivo lipolysis of mouse adipose explants 
 
Figure 2.2 Pyocyanin reduces adipocyte differentiation from murine stem 
cells and induces ex vivo lipolysis of mouse adipose explants. (A) Oil Red O 
(ORO) absorbance (510 nm) of adipocytes, incubated with vehicle (VEH) or 
pyocyanin (PYO, 100 µM), differentiated from the stromal vascular fraction (SVF) 
of mouse adipose tissue. (B) Ex vivo lipolysis (glycerol release) of epididymal 
adipose tissue explants incubated with vehicle (VEH) or pyocyanin (100 µM). 
Data are mean + SEM from n = 9-10 mice/group. *, P<0.05 compared to VEH. 
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Figure 2.3. Pyocyanin results in an acute reduction in body temperature and 
sustained reductions in body weight of male C57BL/6 mice 
 
Figure 2.3. Pyocyanin results in an acute reduction in body temperature 
and sustained reductions in body weight of male C57BL/6 mice. Mice 
received two IP injections of vehicle (VEH) or pyocyanin (PYO, 40 mg/kg) one 
week apart with study endpoint occurring 24-hours after the second injection. (A) 
Subcutaneous body temperature measured at the same time of day for 7 days. 
(B) Subcutaneous body temperature measured over a 24-hour period following 
the first or second IP injection. (C) Percent weight loss (original weight – current 
weight / original weight x 100) over 7 days. (D) Pyocyanin concentration in 
adipose tissues (epididymal, EF or retroperitoneal, RPF) 24 hours after second 
injection. (none detected, N.D.) (E) Oil Red O absorbance (510 nm) of 
adipocytes (day 8) differentiated from SVF of subcutaneous (SubQ) or EF tissue 
(right) of mice administered vehicle or pyocyanin. , indicates timing of IP 
injection. Data are mean + SEM from n = 5-12 mice/group. *, P<0.05 compared 
to VEH. 
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Figure 2.4. Pyocyanin regulates indices of whole body metabolism in male mice 
 
Figure 2.4. Pyocyanin regulates indices of whole body metabolism in male 
mice. Indirect calorimetry collected over three days of baseline and the first three 
days following the first and second injection of pyocyanin (PYO) measuring (A) 
Respiratory exchange ratio (RER, VCO2/VO2/lean mass), (B) energy 
expenditure (kcal expended/hr/lean mass), (C) physical activity (counts/30 
min/lean mass), or (D) energy intake (kcal consumed/lean mass). Data are mean 
+ SEM from n = 15 mice/timepoint. *, P<0.05 compared to baseline PYO. 
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Figure 2.5. Pyocyanin results in sustained reductions in body weight, lean and 
fat mass of male C57BL/6J mice 
 
Figure 2.5. Pyocyanin results in sustained reductions in body weight, lean 
and fat mass of male C57BL/6J mice. Male mice received three IP injections of 
vehicle (VEH) or pyocyanin (40 mg/kg) one week apart with study endpoint 
occurring 2 weeks after the third injection. (A) Body weights (g). (B) Percent lean 
mass (lean mass (g) / body weight (g) x 100)). (C) Percent fat mass (fat mass (g) 
/ body weight (g) x 100)). (D) Ex vivo lipolysis of EF explants as quantified by 
glycerol release. (E) mRNA abundance of target genes in EF, RPF, and liver. (F) 
Oil Red O (ORO) absorbance (510 nm) of adipocytes differentiated from SVF 
cells of male mice administered vehicle (VEH) or pyocyanin (PYO). (G) mRNA 
abundance of target genes in adipocytes differentiated from (F). , indicates 
timing of IP injection. Data are mean + SEM from n = 5-15 mice/group. *, P<0.05 
compared to VEH. #, P<0.05 as compared to baseline pyocyanin. 
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Figure 2.6. Pyocyanin results in sustained and robust reductions in body weight, 
lean and fat mass of female C57BL/6J mice 
 
Figure 2.6. Pyocyanin results in sustained and robust reductions in body 
weight, lean and fat mass of female C57BL/6J mice. Female mice received 
three IP injections of vehicle (VEH) or pyocyanin (PYO, 40 mg/kg) one week 
apart with study endpoint occurring 2 weeks after the third injection. (A) Body 
weights (g). (B) Percent lean mass (lean mass (g) / body weight (g) x 100)). (C) 
Percent fat mass (fat mass (g) / body weight (g) x 100)). (D) Ex vivo lipolysis of 
EF explants as quantified by glycerol release. (E) mRNA abundance of CYP1a1, 
PPAR, aP2, TNF-, F4/80, or RANTES in EF, RPF, and liver. (F) Oil Red O 
(ORO) absorbance (510 nm) of adipocytes differentiated from SVF cells of male 
mice administered vehicle (VEH) or pyocyanin (PYO). (G) mRNA abundance of 
target genes in adipocytes differentiated from (F). , indicates timing of IP 
injection. Data are mean + SEM from n = 5 mice/group. *, P<0.05 compared to 
VEH. #, P<0.05 as compared to baseline pyocyanin. 
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Figure 2.7 Dose response study indicates priming effect of pyocyanin exposure 
via intraperitoneal (IP) injection 
 
Figure 2.7. Dose response study indicates priming effect of pyocyanin 
exposure via intraperitoneal (IP) injection. Mice received a total of three IP 
injections of 30, 40, or 50 mg/kg pyocyanin or PBS VEH control with study 
endpoint occurring 24-hours after the third injection. (A) Percent weight loss 
(original weight – current weight / original weight x 100) two days after the first 
and second injection. (B) Fat loss (original fat mass – current fat mass / original 
fat mass x 100) two days after the first and second injection. (C) Plasma 
concentrations of pyocyanin 24 hours after the third injection. Data are mean + 
SEM from n = 5/group. *, P<0.05 compared to VEH. 
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Figure 2.8 Acute effects of intraperitoneal (IP) injection of pyocyanin on lipolysis 
and gene expression 
 
Figure 2.8. Acute effects of intraperitoneal (IP) injection of pyocyanin on lipolysis 
and gene expression of adipose tissue from male mice administered vehicle 
(VEH) or pyocyanin (40 mg/kg, two ip injections separated by one week, tissue 
harvest 24 hours after last injection). (A) Lipolysis of EF explants as quantified by 
glycerol release. (B) AhR, CYP1a1, PPAR, aP2, TNF-, F4/80, RANTES, and 
IL-10 mRNA abundance in EF, RPF, and liver.  Data are mean ± SEM from n = 
5-12 mice/group. *, P<0.05 compared to VEH. 
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Figure 2.9 Pyocyanin is rapidly metabolized and excreted in the urine of injected 
mice 
 
Figure 2.9. Pyocyanin is rapidly metabolized and excreted in the urine of 
injected mice. Metabolites detected in urine of treated animals 45 and 90 
minutes after injection with 40 mg/kg pyocyanin. 
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Chapter 3 Defining the role of the aryl hydrocarbon receptor in 
pyocyanin-induced adipose cachexia 
 
3.1 Synopsis 
Pyocyanin, a blue-pigmented virulence factor produced by sepsis-causing 
Pseudomonas aeruginosa, is a ligand of the aryl hydrocarbon receptor (AhR). 
Previous studies demonstrated that pyocyanin activates AhR and reduces 
adipocyte differentiation. Activation of AhR by pyocyanin (as evidenced by 
CYP1a1 induction) occurred in adipose tissue, but not in livers from male and 
female C57BL/6J mice, and coincided with weight loss, fat loss, increased 
adipose explant lipolysis, and changes in whole body metabolism. In this study, 
we defined effects of AhR antagonism on pyocyanin-induced reductions in the 
differentiation of 3T3-L1 adipocytes. Using male and female mice with adipocyte-
specific deficiency of AhR, we determined effects on pyocyanin-induced 
regulation of body weight and fat mass. In 3T3-L1 cells, CH-223191, an AhR 
antagonist, reduced pyocyanin-induced stimulation of CYP1a1 mRNA 
abundance, but had no effect on pyocyanin-induced inhibition of adipocyte 
differentiation. In male mice, adipocyte AhR deficiency attenuated pyocyanin-
induced weight loss and adipose-specific stimulation of CYP1a1 mRNA 
abundance. In contrast, in female mice, adipocyte AhR deficiency potentiated 
pyocyanin-induced weight loss, but attenuated pyocyanin-induced stimulation of 
adipose explant lipolysis and induction of CYP1a1 expression. These results 
reinforce the sexually dimorphic effect of pyocyanin on cachexia and 
demonstrate that several of these cachectic outcomes are adipocyte AhR-
mediated. 
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3.2 Introduction 
The aryl hydrocarbon receptor (AhR) is a ligand-activated transcription 
factor that exists in the cytoplasm in its unbound state. Upon binding to ligand, 
AhR translocates to the nucleus where it forms a heterodimer with the AhR 
nuclear transporter (ARNT) [213]. This heterodimer can then bind to AhR 
response elements on DNA and regulate transcription of target genes, such as 
the cytochrome P450 gene, CYP1a1 [213]. AhR has been studied in its classical 
role in drug metabolism and detoxification of xenobiotics. Environmental 
persistent organic pollutants (POPs), including halogenated and polycyclic 
aromatic hydrocarbons, are well-known AhR ligands [213]. 2,3,7,8-
Tetrachlorodibenzodioxin (TCDD) and coplanar polychlorinated biphenyls 
(PCBs), perhaps the most extensively studied AhR ligands, are hydroxylated by 
CYP1a1 and subsequently excreted [215], limiting their toxicity. However, whole 
body elimination of lipophilic POPs is complicated because of accumulation in 
adipose lipids, which limits their access to detoxifying enzymes such as CYP1a1 
[362].  
The accumulation of toxicant AhR ligands in adipose tissue may have 
physiological implications on adipocyte biology, as AhR is expressed on 
preadipocytes with expression levels decreasing over the course of adipocyte 
differentiation [273, 274]. Studies indicate that AhR controls adipocyte 
differentiation in the early stages of clonal expansion prior to activation of PPAR 
[226, 273, 275]. Furthermore, exogenous AhR ligands, including TCDD and 
PCBs, reduced adipocyte differentiation and induced inflammation when cells 
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were exposed to toxicants during the early stages of differentiation [225, 226, 
273]. Exposure to TCDD is known to cause a wasting syndrome leading to loss 
of body weight, fat mass, and lean mass [277]. Previously, we demonstrated a 
role of AhR in the regulation of body weight using a mouse model with adipocyte-
specific AhR deficiency (AhRAdQ) on a C57BL/6J genetic background. After 12 
weeks of high fat feeding, AhRAdQ mice had greater increases in body weight and 
fat mass, decreased lean mass, and increased adipocyte size compared to 
floxed littermate controls [247].  
In addition to its role in adipocyte differentiation and inflammation that is 
potentially linked to regulation of body weight, AhR also influences immune 
function. The development of immune cells such as T cells, B cells, and 
hematopoietic stem cells is regulated by AhR [220, 221, 223, 224, 285-288, 290-
295]. Furthermore, AhR regulates pattern recognition receptors (PRRs), including 
the NACHT, LRR and PYD domains-containing protein 3 (NLRP3) 
inflammasome [302-305]. Recently, results demonstrated AhR’s ability to bind 
and sense pathogen-associated molecular patterns (PAMPs), including 
pigmented bacterial virulence factors produced by the sepsis-causing bacteria, 
Pseudomonas (P.) aeruginosa [270].  
P. aeruginosa produces pyocyanin, a blue-pigmented virulence factor with 
both antibiotic and antifungal properties that kill off competitors of P. aeruginosa 
[310, 315, 322, 324]. In biological fluids from patients infected with P. aeruginosa, 
pyocyanin has been detected at concentrations of 130M [331]. In mammalian 
cells (e.g., neutrophils), pyocyanin has been reported to increase production of 
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reactive oxygen species and trigger apoptosis [1, 315, 331, 357], but 
mechanisms for these effects, namely whether they are receptor-mediated, have 
not been defined. As described in chapter 2, pyocyanin activated AhR and 
CYP1a1 in 3T3-L1 adipocytes. Furthermore, pyocyanin reduced the 
differentiation of adipocytes using two different model systems. When male and 
female mice were administered pyocyanin, body weight and fat mass decreased, 
supporting a potential role for pyocyanin in sepsis-associated cachexia. Notably, 
these effects of pyocyanin were associated with higher mRNA abundance of 
CYP1a1 in adipose tissue, but not in liver of male and female mice, supporting 
AhR activation that was selective to adipose tissue. In this study, we defined the 
role of AhR on the in vitro (regulation of adipocyte differentiation, expression 
levels of CYP1a1) and in vivo (regulation of body weight, fat mass) effects of 
pyocyanin. Since previous studies identified sex differences in effects of 
pyocyanin in mice, we examined effects of adipocyte-specific AhR deficiency on 
pyocyanin administration to male and female C57BL/6J mice.   
 
3.3 Materials and Methods 
 
3.3.1 Growth and differentiation of 3T3-L1 cells 
3T3-L1 mouse adipocytes were purchased from ATCC (catalogue number 
CL-173). Cells were plated into 6-well plates at a seeding density of 10,000 
cells/cm2 and grown in pre-adipocyte expansion medium containing 90% 
Dulbecco’s modified Eagle’s medium (DMEM; Invitrogen, Carlsbad, CA), 10% 
Newborn Calf Serum (NCS, Gemini Bio-Products, Carlsbad, CA), and 1% 
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penicillin/streptomycin. Cells (passage number 6 or lower) were grown to 100% 
confluence at 37°C in a humidified 5% CO2 atmosphere and culture media was 
changed every 48 hours. Two days after cells reached 100% confluence, 
differentiation was initiated (day 0) with differentiation medium containing 90% 
DMEM, 10% fetal bovine serum (FBS; Gemini Bio-Products, Woodland, CA), 1% 
penicillin/streptomycin (VWR, Radnor, PA), 0.2 µM insulin (Novo Nordisk A/S, 
Bagsvaerd, Denmark), 0.5 mM IBMX (Sigma, catalogue #15879), 1.0 µM 
dexamethasone (Sigma, catalogue #D4902). Forty-eight hours later (day 2), the 
medium was changed to adipocyte maintenance medium containing 90% DMEM, 
10% FBS, 1% penicillin/streptomycin, and 0.2 µM insulin. Following day 2, the 
medium was changed every 48 hours (day 4 and day 6) with maintenance 
medium containing 90% DMEM, 10% FBS, and 1% penicillin/streptomycin only. 
On day 8, adipocyte differentiation was quantified. 
 
3.3.2 Use of AhR antagonists against pyocyanin in 3T3-L1 cells  
  Pyocyanin (Sigma, catalogue number P0046) and the AhR antagonists 
CH-223191 (catalogue number C8124), -naphthoflavone (-NF) (catalogue 
number N5757), and 6, 2’, 4’- trimethoxyflavone (TMF) (catalogue number 
T4080) were purchased from Sigma and dissolved in DMSO. As a positive 
control for AhR activation, 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD) 
(Accustandard, catalogue number D-404N) was dissolved as 1 mg in 3.1 mL 
DMSO for a 1 mM stock. To examine effects during differentiation, 3T3-L1 cells 
were grown to confluence in preadipocyte expansion medium in 6-well plates. 
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Two days after reaching confluence, cells were pretreated with antagonist (20 μM 
TMF, 20 μM -NF, or 10 μM CH-223191) for one hour and subsequently treated 
with pyocyanin (100 µM) or TCDD (10 nM). Fresh media with treatments was 
replaced every 48 hours. On day 8, cells were harvested for RNA or fixed and 
stained with Oil Red O (ORO). RNA was collected using RNA lysis buffer (175 
µL; Promega, catalogue number MC501C) and scraping the cells. Samples were 
stored at -80⁰C until RNA extraction was performed. Oil Red O staining was 
performed on separate plates on day 8 or 9 using the Oil Red O Staining Kit from 
Lifeline Cell Technology (catalogue number LL-0052). Stained cells were imaged 
at 100x. After imaging, all water was removed from the stained cells, and 
isospropanol (500 µL) was added to each well for 1 minute to extract the Oil Red 
O from the cells. Two hundred µL was removed from each well and absorbance 
was measured in a 96-well plate at 510 nm using a spectrophotometer. 
 
3.3.3 Animal treatments and sample collection 
All experiments met the approval of the Animal Care and Use Committee 
of the University of Kentucky. Mice were housed in micro-isolator, polystyrene 
cages with a 14 hr light/10 hr dark cycle. Room temperature was at a range of 
68-70ºC, and humidity ranged from 30-70%. AhR-floxed (AhRfl/fl) mice on a 
C57BL/6J background with loxP sites flanking exon 2 were a generous gift from 
M. Walker (University of Mexico) [381]. Female AhRfl/fl mice were bred to 
hemizygous transgenic male Cre mice under the control of the adiponectin 
promoter/enhancer as described previously [247]. Both male and female AhRfl/fl 
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littermate controls and AhRAdQ mice were randomly assigned to treatment groups 
for each study. The two genotypes of mice displayed no overt alterations in 
appearance, behavior, or health at baseline. A total of 37 male mice were used in 
these experiments, of which n=8 were AhRfl/fl pyocyanin-treated, n= 8 AhRfl/fl 
vehicle-treated, n=10 AhRAdQ pyocyanin-treated, and n=11 AhRAdQ vehicle-
treated. A total of 41 female mice were used in these experiments, of which n=10 
were AhRfl/fl pyocyanin-treated, n=9 AhRfl/fl vehicle-treated, n=12 AhRAdQ 
pyocyanin-treated, and n=10 AhRAdQ vehicle-treated. All mice were fed standard 
murine diet (Harlan Teklad 2918 Global Rodent Diet, irradiated; Harlan 
Laboratories) ad libitum for the course of the studies. At study end point, mice 
were anesthetized [ketamine/xylazine, 10/100 mg/kg, by intraperitoneal (ip) 
injection] for exsanguination and tissue harvest (liver, subcutaneous adipose 
(SubQ), retroperitoneal adipose (RPF), epididymal adipose (EF)/periovarian fat 
(POF), interscapular brown adipose tissue (BAT), heart, lung, and soleus). 
 
3.3.4 Model validation by detection of β-galactosidase activity in tissues  
Female ROSA26 Cre reporter mice were bred with AhRAdQ males, and 
transgenic mice expressed lacZ in all cells driven by the adiponectin (AdQ) 
promoter. Removal of the floxed STOP cassette by recombinase results in the 
expression of the lacZ reporter gene coding for beta-galactosidase. Organs from 
AhRfl/fl and AhRAdQ male mice resulting from the ROSA26 cross were fixed in 
formalin at 4°C for 1 hour, then rinsed three times with buffer (100 nM sodium 
phosphate, 2 mM MgCl2, 0.01% sodium deoxycholate, 0.02% NP-40). Organs 
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underwent overnight incubation in 5-bromo-4-chloro-3-indoyl-beta-D-
galactopyranoside (X-gal) staining buffer (above rinse buffer with 5 mM 
potassium ferricyanide, 5 mM potassium ferrocyanide, 1 mg/mL X-gal). A dark 
blue precipitate is formed when X-gal is cleaved by -galactosidase, which can 
be visualized at tissue level.  
 
3.3.5 Administration of pyocyanin to male and female mice  
Male and female mice (aged to 7 months to increase fat mass) received 
three injections (i.p.) of vehicle (VEH) or pyocyanin (40 mg/kg) separated by one 
week. Body weight was quantified daily and EchoMRI was performed weekly 
prior to each injection to quantify fat and lean mass. One week following the third 
injection, a glucose tolerance test was performed as described below. Study 
endpoint occurred two weeks following the third injection. 
 
3.3.6 Measurement of body composition by EchoMRI 
Body composition (fat and lean mass) of conscious mice was determined 
by nuclear magnetic resonance spectroscopy [EchoMRI (magnetic resonance 
imaging)] as described previously [247].  
 
3.3.7 Glucose tolerance tests (GTT) 
GTT were performed during week 3 of the study design in male and 
female mice of each genotype that were fasted for 6 hours. Mice were injected 
(i.p.) with D-glucose (Sigma; 15% in saline, 10 L/g of body weight) and blood 
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glucose concentrations were quantified using a handheld glucometer (Accu-
Check Aviva Plus, Roche Diagnostics, Indianapolis, IN) at 0, 15, 30, 60, 90, and 
120 min using tail vein puncture. Calculations for the total area under the curve 
(AUC) were performed by adjusting the baseline to the fasting blood glucose 
concentration at time 0 for each mouse. Using GraphPad Prism, the total 
incremental area (between times 0 and 120 min) above baseline was calculated 
and represented as arbitrary units. 
 
3.3.8 Extraction of RNA and quantification of mRNA abundance  
The Maxwell RSC simplyRNA Cell or Tissue Kit (Promega Corporation, 
Madison, WI) was used to extract total RNA from tissues and cells using 
according to the manufacturer’s instructions. RNA concentrations were 
determined using a NanoDrop 2000 spectophotometer (ThermoScientific, 
Wilmington, DE). qScript cDNA SuperMix (Quanta Biosciences, Gaithersburg, 
MD) was used to synthesize cDNA from 0.4 µg total RNA with in the following 
reaction:  25°C for 5 minutes, 42°C for 30 minutes, and 85°C for 5 minutes. The 
cDNA was diluted to 0.4 ng/µL and amplified with an iCycler (Bio-Rad, Hercules, 
CA) and the Perfecta SYBR Green Fastmix for iQ (Quanta Biosciences, 
Gaithersburg, MD). The relative quantification of mRNA abundance in each 
sample was calculated using the Ct method and the difference from GAPDH 
cDNA (reference gene). The PCR reaction was as follows: 94°C for 5 minutes, 
40 cycles at 94°C for 15 seconds, 60°C or 64°C (based on tested primer 
efficiency) for 40 seconds, 72°C for 10 minutes, and 100 cycles from 95°C to 
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45.5°C for 10 seconds. Primer sequences were as follows: AhR, forward 5’- 
GACCAAACACAAGCTAGACTTCACACC, reverse 5’- 
CAAGAAGCCGGAAAACTGTCATGC; AhR, forward 5’-
AGTAAAGCCCATCCCCGCTGAAGG-3’, reverse 5’-
CATCAAAGAAGCTCTTGGCCC-3’;  CYP1A1 (cytochrome P450 1A1), forward 
5’-AGTCAATCTGAGCAATGAGTTTGG-3’, reverse 5’-
GGCATCCAGGGAAGAGTTAGG-3’; GAPDH, forward 5’-
GCCAAAAGGGTCATCATCTC-3’, reverse 5’-GGCCATCCACAGTCTTCT-3’. 
 
3.3.9 Quantification of lipolysis in epididymal (EF) adipose explants 
EF were cut into 25 to 50 mg explants, with one explant placed into one 
24-well plate containing Krebs buffer (1 mL). Explants were washed with fresh 
buffer, which was removed and replaced with Krebs buffer (0.5 mL) containing 
2% fatty acid free bovine serum albumin, and the plates were incubated at 37°C. 
A 30 uL sample of buffer was removed from each well at 60, 120, 180, and 240 
minutes after the start of the incubation. The glycerol concentration of the 
samples was quantified using the Glycerol Colorimetric Assay Kit (Cayman 
Chemicals, Item # 10010755) per the manufacturer’s instructions. At the end of 
the incubation, EF explants were washed three times with Krebs buffer (1 
mL/each) and frozen for protein determination. For protein determination, tissue 
samples were suspended on ice in PBS (0.5 mL) containing EDTA (2 mM) and 
protease cocktail inhibitor (cOmplete Mini, Roche Diagnostics, Indianapolis, IN). 
Tissue was homogenized using a Geno/Grinder (Spex SamplePrep, Metuchen, 
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NJ) set to 1,350 rpm x 1.5 minutes. After homogenization, samples were 
centrifuged at 14,000 rpm x 10 minutes at 4°C and the supernatants transferred 
to clean tubes. Protein concentrations of the supernatants were determined using 
the Pierce BCA protein assay kit. Lipolysis is reported as amount of glycerol 
produced/mg protein/hour. 
 
3.3.10 Statistical analyses 
Data are represented as mean + SEM. Data were tested for normality 
using the Shapiro-Wilk test, and equal variance was tested using the Brown-
Forsythe test. Outlier detection was performed using Grubbs’ or extreme 
studentized deviate method where alpha = 0.05. Data were logarithmically 
transformed if data did not pass normality using these approaches. Two-way 
analysis of variance (ANOVA; SigmaPlot, version 13.0; Systat Software Inc., 
Chicago, IL) was used to define effects of pyocyanin and CH-223191 treatment 
in vitro. Holm-sidak was used for post-hoc analyses to test for interactions. Two-
way Repeated Measure ANOVAs (for body weight and blood glucose) and Two-
Way ANOVAs (for lipolysis and mRNA abundance) were used to analyze in vivo 
comparisons between pyocyanin (PYO) and vehicle (VEH) treated animals. To 
analyze body composition, for each outcome variable of interest (fat mass and 
lean mass), two separate full factorial three-way repeated measures ANOVAs 
were performed, one for males and one for females, analyzing differences across 
time, genotype, and treatment. In each model, separate unstructured covariance 
structures were estimated for the two treatment groups. For factors involved in 
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significant statistical interactions, we performed the corresponding post hoc t-
tests. Across all analyses, a p-value of less than 0.05 was considered significant. 
All analyses were completed in SAS 9.4 (SAS Institute Inc.; Cary, NC, USA).  
Statistical significance was defined as p < 0.05. 
 
3.4 Results 
 
3.4.1 AhR antagonists reduce pyocyanin-induced stimulation of CYP1a1 mRNA 
abundance but have no effect on pyocyanin-induced suppression of 
adipocyte differentiation  
We demonstrated previously (see Chapter 2) that pyocyanin reduced 
differentiation of 3T3-L1 cells to adipocytes and stimulated adipocyte mRNA 
abundance of CYP1a1, a marker of AhR activation. To define the role of AhR in 
these effects of pyocyanin, we examined effects of three different AhR 
antagonists, 6, 2’, 4’- trimethoxyflavone (TMF), -naphthoflavone (-NF), and 
CH-223191. Our rationale for examining different pharmacologic modes of AhR 
antagonism is based on the actions of these agents to act as partial (TMF, -NF) 
or complete (CH-223191) antagonists [261, 262]. Moreover, we compared effects 
of AhR antagonists on pyocyanin responses to those of TCDD, a potent AhR 
agonist, as a positive control for CYP1a1 activation. 
As reported in Chapter 2, pyocyanin significantly reduced ORO staining as 
a marker of adipocyte differentiation (Figure 3.1A-C, p<0.05). Treatment with the 
three AhR antagonists (alone) had no significant effect on ORO staining (Figure 
3.1A-C). In addition, pretreatment with -NF, TMF, or CH-223191 had no 
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significant effect on pyocyanin-induced reductions in ORO staining (Figure 3.1A-
C).  
Pyocyanin (Figure 3.1D-F, p<0.05) and TCDD (Figure 3.1 D,F; p<0.05) 
resulted in robust activation of CYP1a1, with greater effects of TCDD compared 
to pyocyanin. Exposure to -NF or TMF (alone), but not CH-223191, resulted in a 
significant increase of CYP1a1 mRNA abundance (Figure 3.1D, p<0.05). TCDD-
induced stimulation of CYP1a1 mRNA abundance was antagonized by -NF; 
however, rather than inhibit effects of pyocyanin, combined incubation of 3T3-L1 
cells with pyocyanin and α-NF resulted in a robust, synergistic increase of 
CYP1a1 mRNA abundance (Figure 3.1D, p<0.05). TMF had no significant effect 
on pyocyanin-induced stimulation of CYP1a1 mRNA abundance (Figure 3.1E). In 
contrast, CH-223191 significantly attenuated both pyocyanin- and TCDD-induced 
stimulation of CYP1a1 mRNA abundance (Figure 3.1F, p<0.05). 
 
3.4.2 Validation of the mouse model of adipocyte AhR deficiency  
Previous studies described the generation and characterization of a 
mouse model of adipocyte AhR deficiency [247], focusing on the regulation of 
AhR mRNA abundance in adipose but not in other tissues. To further validate the 
tissue specificity of AhR deficiency in a re-derived model of adipocyte AhR 
deficiency, we used transgenic ROSA26 Cre reporter mice expressing lacZ in all 
cells driven by the adiponectin promoter, with histochemical detection of -
galactosidase activity as an index of AhR deficiency. Following removal of the 
floxed STOP cassette by Cre recombinase, the lacZ reporter gene, which codes 
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for the beta-galactosidase enzyme, is expressed. -galactosidase activity is 
detected using 5-bromo-4-chloro-3-indoyl-beta-D-galactopyranoside (X-gal), 
which forms a dark blue precipitate when cleaved by -galactosidase. Using this 
technique on tissues from this mouse model, BAT, EF, RPF, and SubQ adipose 
tissues from AhRAdQ mice were dark blue, indicating the presence of -
galactosidase and, therefore, expression of Cre (Figure 3.1). In contrast, there 
was no blue color detected in kidney, lungs, stomach, or brains from AhRAdQ 
mice and their floxed littermate controls (Figure 3.1). Blue staining around the 
heart and aorta is likely epicardial fat, which mirrors previous findings of modest 
reductions of AhR mRNA abundance in hearts of AhRAdQ mice [247].  
 
3.4.3 Adipocyte AhR deficiency in male mice attenuates effects of pyocyanin on 
body weight and fat mass 
Using the experimental design from previous studies demonstrating an 
effect of pyocyanin to regulate body weight and fat mass, we administered three 
doses (one week apart) of vehicle (VEH) or pyocyanin (PYO) to AhRfl/fl and 
AhRAdQ male mice. AhRfl/fl male mice exhibited reductions in body weight 
following administration of pyocyanin, which was maintained through study 
endpoint (Figure 3.3A; p<0.05). Similarly, AhRAdQ male mice lost weight in 
response to pyocyanin administration, but the magnitude of pyocyanin-induced 
reductions in body weight was less compared to AhRfl/fl mice (Figure 3.3B). For 
example, AhRfl/fl mice had significant reductions in body weight from day 3 
through the end of the study in response to pyocyanin, while AhRAdQ mice 
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exhibited significant reductions in body weight following the third dose of 
pyocyanin, which were not maintained by study endpoint (Figure 3.3A,B, p<0.05).  
In mice of either genotype administered vehicle, there was no significant 
effect on fat or lean mass compared to baseline (day 0) (Figure 3.4A,B). 
Administration of pyocyanin to AhRfl/fl male mice resulted in a significant 
reduction in body fat compared to baseline on days 14 and 21 (Figure 3.4A, 
p<0.05). Similarly, administration of pyocyanin to AhRAdQ male mice decreased 
body fat compared to baseline on days 7, 14 and 21 (Figure 3.4B, p<0.05). 
Compared to vehicle controls, there were no significant reductions in fat mass of 
either genotype on days 0, 7 or 14 (Figure 3.4A,B). However, on day 21, both 
AhRfl/fl and AhRAdQ mice exhibited significant reductions in body weight and fat 
mass compared to vehicle controls within genotype (Figure 3.4A,B, p<0.05). 
Lean mass was not significantly different from baseline in mice of either genotype 
administered vehicle (Figure 3.4C,D). Administration of pyocyanin resulted in an 
increase in lean mass compared to baseline on days 14 and 21 in AhRfl/fl male 
mice, and on days 7 – 21 in AhRAdQ males (Figure 3.4C,D, p<0.05) . Moreover, 
on day 21 following pyocyanin both genotypes exhibited significant elevations in 
lean mass compared to vehicle controls within genotype (Figure 3.4C,D, p<0.05).  
 
3.4.4 Pyocyanin does not alter glucose tolerance or adipose explant lipolysis of 
AhRfl/fl or AhRAdQ male mice 
Because of the modestly higher body weights of AhRAdQ male mice (VEH) 
compared to AhRfl/fl controls (Figure 3.3A,B), and because pyocyanin reduced 
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body weight, we quantified glucose tolerance. However, pyocyanin had no 
significant effect on glucose tolerance of male mice of either genotype compared 
to vehicle controls (Figure 3.5A-C). Similarly, pyocyanin had no significant effect 
on adipose explant lipolysis in male mice of either genotype compared to vehicle 
controls (Figure 3.6).  
 
3.4.5 Adipocyte AhR deficiency abrogates pyocyanin-induced stimulation of 
adipose CYP1a1 mRNA abundance in male mice 
We previously observed an adipose-selective activation of CYP1a1 mRNA 
abundance in adipose tissue of male C57BL/6J mice following pyocyanin 
administration (see Chapter 2). Similar to previous findings, administration of 
pyocyanin to male AhRfl/fl resulted in a significant elevation of CYP1a1 mRNA 
abundance in adipose tissue, but not liver (Figure 3.7A,B, p<0.05). Moreover, 
pyocyanin-induced elevations of CYP1a1 mRNA abundance were not observed 
in adipose tissue from AhRAdQ male mice (Figure 3.7A).  
 
3.4.6 Adipocyte AhR deficiency augments effects of pyocyanin to decrease 
body weight and fat mass of female mice 
On this genetic background, pyocyanin had no significant effect on body 
weight of AhRfl/fl female mice (Figure 3.8A). Paradoxically, pyocyanin 
administration significantly decreased body weights of AhRAdQ females, with 
significant reductions compared to vehicle controls on day 3 through study 
endpoint (Figure 3.8B, p<0.05).  
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Compared to baseline (day 0), administration of pyocyanin resulted in a 
significant reduction of fat mass in both genotypes on days 7 – 21 (Figure 
3.9A,B, p<0.05). Moreover, fat mass of pyocyanin-treated AhRAdQ females was 
significantly decreased compared to vehicle controls on day 21 (Figure 3.9B, 
p<0.05).  
Lean mass was significantly increased compared to baseline on days 14 
and 21 following administration of pyocyanin to both genotypes (Figure 3.9C,D, 
p<0.05). However, there were no significant differences in lean mass of either 
genotype compared to vehicle controls at any time point examined (Figure 
3.9C,D). 
 
3.4.7 Neither adipocyte AhR deficiency nor pyocyanin influence glucose 
tolerance of female mice, but adipocyte AhR deficiency abolishes effects 
of pyocyanin to stimulate lipolysis of adipose tissue explants  
Despite robust reductions of body weights of AhRAdQ females in response 
to pyocyanin (Figure 3.8B), there was no significant effect of either pyocyanin or 
adipocyte AhR deficiency on glucose tolerance (Figure 3.10A-C). Pyocyanin 
stimulated lipolysis of adipose tissue explants from AhRfl/fl females (Figure 3.11, 
p<0.05). In contrast, there was no effect of pyocyanin on adipose explant lipolysis 
of AhRAdQ females (Figure 3.11, p<0.05).  
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3.4.8 Pyocyanin-induced stimulation of adipose CYP1a1 mRNA abundance is 
mediated by adipocyte AhR 
Similar to males, pyocyanin administration resulted in a significant 
increase of CYP1a1 mRNA abundance in adipose tissue, but not livers of AhRfl/fl 
females (Figure 3.12A,B, p<0.05). In contrast, pyocyanin had no effect on 
CYP1a1 mRNA abundance in adipose tissue from AhRAdQ females (Figure 
3.12A).  
 
3.5 Discussion 
The major findings of this study are as follows:  (1) pyocyanin-induced 
reductions of adipocyte differentiation do not appear to be AhR-mediated, despite 
indices of robust AhR activation by pyocyanin in adipocytes, (2) in male mice, 
adipocyte AhR partially contributes to pyocyanin-induced reductions in body 
weight and fat mass, (3) in female mice, adipocyte AhR deficiency paradoxically 
augments effects of pyocyanin to decrease body weight and fat mass, (4) 
pyocyanin-induced stimulation of CYP1a1 mRNA abundance in adipose tissue is 
adipocyte AhR mediated in both male and female mice. These results indicate 
that pyocyanin stimulates CYP1a1 expression in an adipose-selective manner 
through an AhR mechanism. However, the role of adipocyte AhR in pyocyanin-
induced regulation of body weight and fat mass is sexually dimorphic. Male mice 
appear to partially respond to pyocyanin to decrease body weight and fat mass 
through adipocyte AhR, while females potentially utilize adipocyte AhR to limit 
influences of pyocyanin on the regulation of body weight and fat mass.  
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In agreement with previous findings [270] (see Chapter 2 Figures 2.5 and 
2.6), results from this study demonstrate that pyocyanin stimulates CYP1a1 
mRNA abundance in 3T3-L1 adipocytes as a marker of AhR activation. However, 
it was unclear from previous studies if effects of pyocyanin to reduce adipocyte 
differentiation (see chapter 2) were AhR-mediated. To define the role of AhR in 
effects of pyocyanin at adipocytes, we used three different AhR antagonists: -
NF, TMF, or CH-223191. AhR antagonists competitively bind to AhR, inhibiting 
nuclear translocation. However, several AhR antagonists possess partial agonist 
activity [261]; therefore, finding reliable and effective pharmacologic AhR 
antagonists has been problematic. - NF is a partial agonist of AhR that is able to 
antagonize the receptor at high concentrations by competitive inhibition [262]. 
Similarly, studies have reported partial agonist activity of TMF during prolonged 
exposures, with metabolism of TMF producing weak partial agonism [261]. In this 
study, in which cells had prolonged exposures to AhR antagonists, partial 
agonism by α-NF or TMF is likely as treatment with either antagonist (alone) 
stimulated CYP1a1 mRNA abundance in adipocytes. Moreover, α-NF resulted in 
a synergistic stimulation of CYP1a1 mRNA abundance in the presence of 
pyocyanin, suggesting agonist rather than antagonist effects of the compound. In 
contrast, CH-223191 is a potent pure competitive antagonist of AhR [263-265] 
and was able to antagonize CYP1a1 activation by both pyocyanin and TCDD; 
however, studies have reported that CH-223191 selectively antagonizes 
halogenated aromatic hydrocarbons (HAHs) (TCDD, PCB77, and PCB126) but 
not polycyclic aromatic hydrocarbons (PAHs), flavonoids, and indirubin [265]. 
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Similarly, TMF exhibited preferential inhibition of HAHs [265]. Unlike TCDD and 
PCBs, which contain chloride atoms attached to benzene rings, pyocyanin’s 
structure is not halogenated; therefore, the preferential inhibition of HAHs by 
these antagonists may prove ineffective against pyocyanin’s actions. A limitation 
of this study is reliance on a single mode of AhR interference (pharmacologic) as 
compared to genetic knockdown of the target to define effects of pyocyanin on 
adipocytes. However, our results suggest that while pyocyanin indeed stimulates 
markers of AhR activation in adipocytes that are abolished by pure AhR 
antagonists, the ability of the virulence factor to regulate adipocyte differentiation 
is not AhR-mediated. 
In Chapter 2, we reported that administration of pyocyanin to male and 
female mice resulted in stimulation of CYP1a1 in adipose tissues, but not in liver, 
suggesting an adipose-selective mode of action of the compound. However, it 
was unclear if these effects of pyocyanin were AhR-mediated, and whether they 
were related to pyocyanin-induced regulation of body weight and fat mass. 
Although pyocyanin’s effect to reduce differentiation of 3T3-L1 cells to adipocytes 
does not appear to be AhR-mediated, a change in differentiation was not the 
primary cachectic outcome observed in the in vivo models of chapter 2. We 
validated the mouse model of adipocyte-specific deficiency of AhR (AhRAdQ) and 
used these mice and their floxed littermate controls to determine if pyocyanin’s in 
vivo effects are AhR-mediated. If pyocyanin exerts its cachectic effects through 
AhR, we would anticipate that removing AhR from adipocytes would protect mice 
from pyocyanin-induced reductions in body weight and fat mass.  
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We observed some differences in responses to pyocyanin of male and 
female mice in this study compared to findings from Chapter 2. Specifically, in 
this study AhRfl/fl males lost weight following the first dose of pyocyanin, while 
C57BL/6J males (Chapter 2) required a second dose of pyocyanin to exhibit 
body weight reductions. Moreover, female AhRfl/fl mice of this study administered 
pyocyanin did not exhibit robust effects on body weight and fat mass, compared 
to a pronounced effect of pyocyanin to reduce body weight of C57BL/6J females 
(Chapter 2). These differences in responses to pyocyanin between our studies 
could arise from several potential variables. For example, it is known that there 
are differences in AhR affinity between AhR alleles within different mouse strains 
[382]. There are four variations of the AhR allele in mice, with 10-fold differences 
in affinity and activity of the receptor between the high-affinity Ahrb1 allele present 
in the C57BL/6J strain and the low-affinity Ahrd, which is present in DBA/2 mice 
and is most similar to human AhR [382, 383]. These allelic differences lead to 
large differences in expression of genes, such as CYP1a1 [384].These 
differences result in changes in body mass, fat mass, and fat metabolism 
between mouse strains, with high-affinity allele mice gaining more weight and 
adiposity [382]. Unpublished studies in our lab have demonstrated differential 
induction of CYP1a1 between male C57BL/6J and AhRfl/fl mice following PCB-77 
exposure. The differential response to PCBs and pyocyanin observed between 
these two animal colonies may indicate a difference in the AhR alleles present, 
which could have been introduced into the colony if the AhRfl/fl mice or the 
adiponectin Cre mice possessed different AhR alleles than the C57BL/6J mice 
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purchased directly from Jackson Laboratories. For example, CYP1a1 expression 
in POF of AhRfl/fl  females exposed to pyocyanin is one fold lower than CYP1a1 
expression in POF from C57BL/6J females exposed to pyocyanin for the same 
duration, which could explain why AhRfl/fl  females had less pyocyanin-induced 
weight loss than C57BL/6J females in Chapter 2.  
Our results clearly indicate that pyocyanin induces an adipose-selective 
activation of CYP1a1 mRNA expression, indicative of AhR activation, in both 
male and female mice through adipocyte AhR. These results confirm the mouse 
model of adipocyte AhR deficiency, as pyocyanin-induction of CYP1a1 mRNA 
abundance was abolished in adipose tissue, but not in livers from mice with 
adipocyte AhR deficiency. Pyocyanin is an organic compound that is soluble in 
chloroform or DMSO, and is thus lipophilic. It is likely that pyocyanin induces an 
adipose-selective induction of CYP1a1 mRNA expression because of the 
compound’s sequestration in adipose lipids, similar to other persistent organic 
pollutants (see Chapter 2, Figures 2.5 and 2.6). Adipose tissue accumulation of 
pyocyanin may contribute to more pronounced effects of pyocyanin to activate 
AhR in adipose than in liver of both male and female mice.  
We previously demonstrated the ability of other AhR ligands, including 
coplanar PCBs, to impair glucose homeostasis [247, 385]. Thus, it was important 
to define the physiological relevance of pyocyanin-induced regulation of body 
weight in mice, and whether these effects were adipocyte AhR-mediated. If 
weight loss in pyocyanin-treated mice is healthy, we would anticipate a beneficial 
effect on glucose homeostasis following weight reduction [386, 387]. 
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Unfortunately, despite reductions in body weight of pyocyanin-treated mice, there 
was no change in glucose tolerance. Furthermore, impaired glucose homeostasis 
is commonly reported in human patients and murine models of sepsis, with 
hyperglycemia occurring in the catecholamine-rich hypermetabolic stage of 
sepsis and hypoglycemia resulting in the hypodynamic stage [388-391]. The 
absence of an improvement in glucose homeostasis despite weight loss in 
pyocyanin-treated mice may reflect the impaired glucose tolerance observed in 
the hypermetabolic stage of sepsis [388-391]. 
 Our results suggest that adipocyte AhR plays a sexually dimorphic role in 
the regulation of body weight following pyocyanin exposure. Adipocyte AhR 
partially mediates effects of pyocyanin to regulate body weight of male mice, 
while removal of the receptor potentiated body weight regulation by pyocyanin in 
females. These results suggest a protective role of adipocyte AhR in females that 
may be linked to clearance of pyocyanin, as removal of adipocyte AhR would 
limit CYP1a1 induction and therefore retard pyocyanin clearance. Indeed, 
previous studies demonstrated that male and female whole body AhR knockout 
mice succumbed more quickly to P. aeruginosa infection, which was believed to 
be due to reduced clearance of pyocyanin [270]. In this study, fat mass of female 
mice at baseline was modestly higher than males, suggesting potentially more 
accumulation of pyocyanin in adipose tissue of female than male mice. These 
results suggest that adipose tissue may serve as a primary site for both the 
storage and clearance of pyocyanin. A limitation of this study is that we did not 
measure pyocyanin levels in adipose tissue or plasma. However, since previous 
  121 
studies using the same experimental design did not give rise to detectable levels 
of pyocyanin three weeks after the last injection (see Chapter 2), it is unclear 
whether differences in pyocyanin accumulation in adipose tissue between the 
sexes contributed to sexual dimorphism of the role of adipocyte AhR. 
Regardless, these results suggest that in males, activation of adipocyte AhR by 
pyocyanin contributes to both induction of CYP1a1 (and resultant pyocyanin 
metabolism) and body weight regulation, while adipocyte AhR activation by 
pyocyanin in females may influence pyocyanin clearance (through CYP1a1 
induction). Pyocyanin has physiological effects outside of its role as an AhR 
ligand that could contribute to regulation of body weight in male or female mice. 
For example, pyocyanin produces reactive oxygen species, and oxidative stress 
is a known mechanism of cachexia, particularly in muscle wasting [392, 393]. 
These effects of pyocyanin may not require receptor activation.  
 In conclusion, pyocyanin stimulates CYP1a1 expression in adipose tissue 
of male and female mice, and this effect is AhR-mediated. However, effects of 
pyocyanin to reduce adipocyte differentiation do not appear to be AhR-mediated. 
Moreover, while adipocyte AhR deficiency contributes to pyocyanin’s regulation 
of body weight and fat mass in male mice, removal of the receptor from 
adipocytes of female mice augmented cachexia-like effects of pyocyanin. Future 
studies should focus on mechanisms of sex differences and AhR-dependence of 
the effects of pyocyanin on body weight and fat mass.  
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Figure 3.1. AhR antagonists have no effect on pyocyanin-induced reductions of 
adipocyte differentiation but differentially affect CYP1a1 expression 
 
  
Figure 3.1. AhR antagonists have no effect on pyocyanin-induced 
reductions of adipocyte differentiation but differentially affect CYP1a1 
expression. (A-C) Oil Red O (ORO) absorbance (510nm, day 8 of differentiation 
protocol) of 3T3-L1 adipocytes treated with vehicle (VEH, 0 M), pyocyanin 
(PYO, 100 M), or TCDD (10 nM) following a 1-hour pretreatment with of (A) -
NF (20 μM), (B) TMF (20 μM), or (C) CH-223191 (10 μM). (D-F) mRNA 
abundance of CYP1a1 in 3T3-L1 adipocytes incubated with vehicle (VEH, 0 M), 
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pyocyanin (PYO, 100 M), or TCDD (10 nM) following a 1-hour pretreatment with 
(A) -NF (20 μM), (B) TMF (20 μM), or (C) CH-223191 (10 μM). Data are mean + 
SEM from n = 3-8 wells/treatment. *, P<0.05 compared to 0 M (VEH). #, P<0.05 
effect of antagonist. 
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Figure 3.2. Validation of mouse model of adipocyte-specific AhR deficiency 
 
Figure 3.2. Validation of mouse model of adipocyte-specific AhR 
deficiency. Validation of adipocyte-specific Cre activation by detection of β-
galactosidase activity in tissues from AhRfl/fl and AhRAdQ male mice. Blue staining 
in brown adipose tissue (BAT), epididymal fat (EF), retroperitoneal fat (RPF), and 
subcutaneous fat (SubQ) from AhRAdQ mice indicates adipose-specific activation 
of Cre under the adiponectin promoter. 
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Figure 3.3 Adipocyte deficiency of AhR attenuates weight loss in males 
administered pyocyanin 
 
 
Figure 3.3. Adipocyte deficiency of AhR attenuates weight loss in males 
administered pyocyanin. Male AhRfl/fl and AhRAdQ mice received three 
injections (i.p.) of vehicle (VEH) or pyocyanin (40 mg/kg) one week apart with 
study endpoint occurring 2 weeks after the third injection. Body weights (g) of (A) 
AhRfl/fl males and (B) AhRAdQ males treated with VEH or PYO. , indicates timing 
of ip injection. Data are mean + SEM from n = 8-11 mice/group. *, P<0.05 
compared to VEH.  
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Figure 3.4 Adipocyte AhR does not affect body composition in chronically 
exposed males 
 
 
Figure 3.4. Adipocyte AhR does not affect body composition in chronically 
exposed males. Male AhRfl/fl and AhRAdQ mice received three injections (i.p.) of 
vehicle (VEH) or pyocyanin (40 mg/kg) one week apart with study endpoint 
occurring 2 weeks after the third injection. EchoMRI was performed weekly 
before each injection. (A, B) Percent fat mass (fat mass (g) / body weight (g) x 
100)) of (A) AhRfl/fl  and (B) AhRAdQ males. (C, D) Percent lean mass (lean mass 
(g) / body weight (g) x 100)) of (C) AhRfl/fl  and (D) AhRAdQ males. Data are mean 
+ SEM from n = 8-11 mice/group. *, P<0.05 AhRAdQ VEH compared to AhRAdQ 
PYO. #, P<0.05 compared to baseline PYO. 
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Figure 3.5 Neither adipocyte AhR deficiency nor pyocyanin administration 
regulates glucose tolerance of male mice 
 
Figure 3.5. Neither adipocyte AhR deficiency nor pyocyanin administration 
regulates glucose tolerance of male mice. (A,B) Blood glucose measurements 
for AhRfl/fl (A) and AhRAdQ (B) mice after glucose challenge. (C) Area under the 
curve (AUC) for blood glucose concentrations following administration of glucose 
in females of each genotype administered VEH or PYO (week 3, one week after 
final exposure). Data are mean + SEM from n = 8-11 mice/group. 
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Figure 3.6 . Adipocyte AhR does not influence lipolysis of adipose explants from 
male mice 
 
Figure 3.6. Adipocyte AhR does not influence lipolysis of adipose explants 
from male mice. Lipolysis of epididymal fat (EF) explants as quantified by 
glycerol release at study endpoint, two weeks after the final exposure to 
pyocyanin. Data are mean + SEM from n = 8-11 mice/group.  
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Figure 3.7. Adipocyte AhR deficiency abolishes pyocyanin-induced elevations 
of CYP1a1 mRNA abundance in adipose tissue, but not livers of male mice 
 
 
Figure 3.7. Adipocyte AhR deficiency abolishes pyocyanin-induced 
elevations of CYP1a1 mRNA abundance in adipose tissue, but not livers 
of male mice. Two weeks after final exposure, tissues were harvested from 
AhRfl/fl and AhRAdQ males. mRNA abundance of CYP1a1 in (A) epididymal (EF) 
adipose tissue and (B) liver. Data are mean + SEM from n = 9-12 mice/group. 
*, P<0.05 compared to VEH. #, P<0.05 effect of genotype. 
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Figure 3.8. Adipocyte AhR deficiency augments pyocyanin-induced reductions 
in body weight of female mice 
 
 
Figure 3.8. Adipocyte AhR deficiency augments pyocyanin-induced 
reductions in body weight of female mice. Female AhRfl/fl and AhRAdQ mice 
received three IP injections of vehicle (VEH) or pyocyanin (40 mg/kg) one week 
apart with study endpoint occurring 2 weeks after the third injection. Body 
weights (g) in (A) AhRfl/fl females and (B) AhRAdQ females treated with VEH or 
PYO. , indicates timing of ip injection. Data are mean + SEM from n = 9-12 
mice/group. *, P<0.05 compared to VEH.   
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Figure 3.9. Adipocyte AhR deficiency augments pyocyanin-induced reductions 
in fat mass of female mice 
 
 
Figure 3.9. Adipocyte AhR deficiency augments pyocyanin-induced 
reductions in fat mass of female mice. Female AhRfl/fl and AhRAdQ mice 
received three IP injections of vehicle (VEH) or pyocyanin (40 mg/kg) one week 
apart with study endpoint occurring 2 weeks after the third injection. (A, B) 
Percent fat mass (fat mass (g) / body weight (g) x 100)) in (A) AhRfl/fl  and (B) 
AhRAdQ. (C, D) Percent lean mass (lean mass (g) / body weight (g) x 100)) in (C) 
AhRfl/fl  and (D) AhRAdQ. Data are mean + SEM from n = 9-12 mice/group. *, 
P<0.05 AhRAdQ VEH compared to AhRAdQ PYO. #, P<0.05 compared to baseline 
PYO. 
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Figure 3.10. Neither adipocyte AhR deficiency nor pyocyanin regulate glucose 
tolerance of female mice 
 
 
Figure 3.10. Neither adipocyte AhR deficiency nor pyocyanin regulate 
glucose tolerance of female mice. (A,B) Blood glucose measurements for 
AhRfl/fl (A) and AhRAdQ (B) mice after glucose challenge. (C) Area under the 
curve (AUC) for blood glucose concentrations following administration of glucose 
in females of each genotype administered VEH or PYO (week 3, one week after 
final exposure). Data are mean + SEM from n = 9-12 mice/group. 
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Figure 3.11. Adipocyte AhR deficiency abolishes pyocyanin-induced 
stimulation of lipolysis in adipose explants from female mice 
 
 
 
Figure 3.11. Adipocyte AhR deficiency abolishes pyocyanin-induced 
stimulation of lipolysis in adipose explants from female mice. Lipolysis of 
periovarian fat (POF) explants as quantified by glycerol release at study 
endpoint, two weeks after the final exposure to pyocyanin. Data are mean + SEM 
from n = 9-12 mice/group.  
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Figure 3.12. Adipocyte AhR deficiency abolishes pyocyanin-induced elevations 
of CYP1a1 mRNA abundance in adipose tissue, but not livers of female mice 
 
 
Figure 3.12. Adipocyte AhR deficiency abolishes pyocyanin-induced 
elevations of CYP1a1 mRNA abundance in adipose tissue, but not livers of 
female mice. Two weeks after final exposure, tissues were harvested from 
AhRfl/fl and AhRAdQ females. mRNA abundance of CYP1a1 in (A) periovarian fat 
(POF) and (B) liver. Data are mean + SEM from n = 9-12 mice/group. *, P<0.05 
compared to VEH. #, P<0.05 effect of genotype.  
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Chapter 4 Overall Discussion 
 
4.1 Discussion 
 
4.1.1 Summary 
This dissertation demonstrates a novel role of pyocyanin in the 
pathogenesis of cachexia and adipose wasting. By studying the effects of 
pyocyanin alone, these studies distinguish the virulence factor’s effects in 
isolation from the confounding effects of the other phenazines produced by P. 
aeruginosa. To our knowledge, these are the first studies administering 
pyocyanin via intraperitoneal injection and subsequently measuring the virulence 
factor in plasma and adipose tissue. We suggest that the in vivo model 
developed in this dissertation provides an experimental model of pyocyanin-
induced cachexia. The model reproducibly results in cachexia and adipose 
wasting in two different murine strains. The effects of pyocyanin appear to be 
largely adipose-selective, with activation of CYP1a1 occurring in adipose tissue, 
but not in liver, the primary organ for metabolism of factors such as pyocyanin. 
These findings, coupled with the detection of pyocyanin in adipose tissue after in 
vivo exposure, suggest pyocyanin might behave similarly to other AhR ligands, 
such as the lipophilic persistent organic pollutants that accumulate in adipose 
tissue and exert effects through adipocyte AhR. While some of pyocyanin’s 
cachectic mechanisms, such as lipolysis and weight loss, appear to be partially 
mediated through AhR, pyocyanin also exerts effects independently of the 
receptor. Furthermore, sexually dimorphic effects and variances in AhR 
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responsiveness based on timing of exposure and mouse strain complicate the 
understanding of pyocyanin’s mechanisms. 
 
4.1.2 Pyocyanin contributes to adipose cachexia 
While pyocyanin has largely been studied in bacterial lung infections in 
cystic fibrosis, little is known about pyocyanin’s function in sepsis arising from P. 
aeruginosa infection. There is evidence that pyocyanin activates AhR and 
contributes to the production of reactive oxygen species and inflammation, but its 
actions at adipocyte AhR remain unknown. We previously demonstrated that 
AhR ligands reduce adipocyte differentiation and augment adipocyte 
inflammation [225]. Furthermore, AhR appears to regulate body weight [247]. As 
a putative AhR ligand released during bacterial infections, pyocyanin represents 
a novel target in the study of weight loss and lipoatrophy of septic cachexia. 
Using in vitro and in vivo approaches, the studies in Chapter 2 attempted to 
address this gap in the literature by examining the ability of pyocyanin to activate 
adipocyte AhR and contribute to cachexia by inducing weight loss, changes in 
body composition, and inflammation.  
Using 3T3-L1 cells and adipocyte-derived stem cells (ADSCs), we 
determined that pyocyanin can activate adipocyte AhR and reduce adipocyte 
differentiation at a concentration of 100 M in two different adipocyte model cell 
systems. In murine adipose explants, this same concentration of pyocyanin 
stimulated basal lipolysis. These in vitro studies demonstrated the ability of 
pyocyanin to alter adipocyte function and development through mechanisms 
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potentially linked to AhR activation. However, pyocyanin had differing effects on 
pre-/differentiating adipocytes and mature adipocytes. In order to elucidate 
pyocyanin’s physiological effects on body weight and adipose mass, and to 
determine if systemically-administered pyocyanin would influence adipocytes, we 
developed an in vivo model of pyocyanin-induced cachexia using intraperitoneal 
injection.  
With this model, we studied the acute and chronic effects of pyocyanin on 
adipose cachexia in male and female C57BL/6J mice. Acutely, pyocyanin 
administration increased systemic inflammation and decreased body 
temperature, which coincided with trembling and reduced locomotive activity. 
Therefore, pyocyanin may contribute to the hypothermia, shaking, and 
disorientation observed in septic patients. Even with normal body temperature 
and behavior restored 24 hours post-injection, pyocyanin-treated animals lost 
weight. This sustained weight loss could potentially be explained by pyocyanin’s 
effects on the adipocyte and lipid metabolism, as pyocyanin was detected in 
plasma and visceral adipose tissue 24-hours after exposure. Pyocyanin reduced 
respiratory exchange ratio (RER), energy expenditure, activity, and food intake. A 
reduction in RER indicated a shift towards the utilization of fat for fuel, a hallmark 
of septic cachexia [120, 159, 160]. Moreover, when ADSCs were harvested from 
the stromal vascular fraction of mice 24-hours following injection with pyocyanin, 
stem cells from both EF and SubQ depots exhibited reduced differentiation to 
adipocytes. These studies suggest that pyocyanin induces weight loss and 
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adipose cachexia through acute increases in inflammation and fat mobilization 
and reductions in stem cell adipocyte differentiation.  
Chronically, pyocyanin resulted in significant weight and fat loss. 
Pyocyanin largely affected the mass of visceral fat, with reductions in EF and 
RPF tissue weight corresponding with an adipose-selective activation of AhR. 
Interestingly, these chronic effects were not related to adipocyte differentiation, 
as ADSC from adipose tissue of mice administered pyocyanin exhibited normal 
adipocyte differentiation. Sustained adipose-selective activation of CYP1a1 two 
weeks after the final exposure suggests that, like other lipophilic AhR ligands, 
pyocyanin may be sequestered in the adipocyte lipid droplet, permitting 
persistent activation of adipocyte AhR.  
Furthermore, pyocyanin had sexually dimorphic effects on adipose tissue. 
Females lost more weight than males, and ADSCs from females administered 
pyocyanin had increased expression of AhR and TNF- compared to controls, 
effects that persisted three weeks after the last pyocyanin injection. While 
ADSCs from chronically-treated males had unaltered gene expression, 
pyocyanin augmented basal lipolysis of EF explants in these males. Therefore, 
chronic pyocyanin exposure induces weight loss and adipose cachexia with 
sexually dimorphic mechanisms, with stimulated lipolysis in males and increased 
adipocyte inflammation in females. These divergent mechanisms of cachexia 
may contribute to the sex differences observed in sepsis survival [15, 16]. 
Overall, our findings indicate pyocyanin can alter adipocyte differentiation 
in vitro and in vivo, promote lipolysis, and augment inflammation, contributing to 
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weight loss and adipose cachexia via sexually and temporally dimorphic 
mechanisms. Therefore, future research should focus on understanding these 
potentially AhR-mediated mechanisms in order to develop novel treatment 
strategies for cachexia following P. aeruginosa infection in sepsis as well as 
other disease states, including cystic fibrosis.   
 
4.1.3 Pyocyanin’s effects on adipose tissue are partially mediated through AhR 
In Chapter 2, we established that pyocyanin, a Pseudomonas aeruginosa 
virulence factor, can activate adipocyte AhR in vitro and in vivo. The adipose-
selective activation following pyocyanin treatment indicated a role of pyocyanin in 
adipose cachexia. Male and female C57BL/6J mice chronically exposed to 
pyocyanin lost body weight and fat mass with augmentations in lipolysis and 
inflammation. The studies in chapter 3 attempted to elucidate the mechanism of 
pyocyanin’s role in adipose cachexia, which we believed to be mediated through 
adipocyte AhR. To address pyocyanin’s mechanism of action on the adipocyte, 
we utilized in vitro and in vivo methods of interfering with the actions of adipocyte 
AhR.  
 Pyocyanin was shown to activate AhR and CYP1a1 and reduce adipocyte 
differentiation in 3T3-L1 cells in Chapter 2. To determine if these effects occurred 
through adipocyte AhR, we utilized AhR antagonists to block pyocyanin’s binding 
to the receptor. Cells were pretreated with -NF (20 μM), TMF (20 μM), or CH-
223191 (10 μM) prior to exposure to 100M pyocyanin. None of the AhR 
antagonists blocked pyocyanin’s ability to reduce adipocyte differentiation. 
However, CH-223191 did prevent pyocyanin’s induction of CYP1a1 mRNA 
  140 
abundance. Interestingly, -NF pretreatment with pyocyanin resulted in a robust 
synergistic activation of CYP1a1 mRNA abundance. Synergistic activation of 
CYP1a1 has been previously demonstrated in zebrafish embryos co-treated with 
-NF and 6-Formylindolo[3,2-b]carbazole (FICZ), a potent AhR agonist [394]. 
The synergistic effect between pyocyanin and -NF could be explained by (1) 
partial agonism by -NF and (2) reduced metabolism of pyocyanin. Previous 
studies have reported partial agonist activity of -NF and TMF [261, 262], which 
are supported by results from our studies. Alternatively, inhibition of CYP1a1 by 
-NF in zebrafish embryos has been shown to increase the half-life and levels of 
FICZ by preventing its metabolism [394]. Therefore, by blocking metabolism of 
pyocyanin through CYP1 enzymes, -NF could maintain elevated in vitro 
concentrations of pyocyanin, resulting in continued AhR activation and CYP1a1 
transcription.  
CH-223191 attenuated CYP1a1 activation by both pyocyanin and the 
potent AhR agonist TCDD. However, CH-223191 has been demonstrated to 
selectively antagonize halogenated aromatic hydrocarbons but not polycyclic 
aromatic hydrocarbons, flavonoids, and indirubin [265]. Unlike TCDD, which 
contains chloride atoms, pyocyanin is not halogenated; therefore, CH-223191 
may not effectively inhibit pyocyanin’s actions on the adipocyte due to its 
structure. These studies suggest that pyocyanin is an adipocyte AhR agonist, but 
its effect to reduce adipocyte differentiation does not appear to be AhR-mediated. 
However, pyocyanin is likely a weak AhR agonist, and the partial agonism by 
many of the available AhR antagonists complicates the interpretation of the in 
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vitro findings. Future studies should test methods of antagonizing AhR other than 
competitive inhibition, including siRNA and isolating stromal vascular cells 
harvested from AhR knockout mice, to fully understand pyocyanin’s mechanism 
of action. If the cachexia induced by pyocyanin is not AhR-mediated, other 
mechanisms, such as the production of reactive oxygen species, will be explored 
as described below in the future directions.  
To determine if pyocyanin’s effects on weight loss, fat loss, lipolysis, and 
inflammation occur through AhR, we repeated the chronic exposure studies from 
Chapter 2 in a mouse model of adipocyte-specific deficiency of AhR. Although 
pyocyanin’s in vitro effect on adipocyte differentiation does not appear to be AhR-
mediated, adipocyte differentiation was not a major contributor to pyocyanin-
induced adipose cachexia of Chapter 2. We hypothesized that pyocyanin’s ability 
to reduce body weight and fat mass and increase adipose explant lipolysis in vivo 
is AhR-mediated and would be attenuated in mice lacking AhR in adipocytes 
(AhRAdQ) as compared to their floxed littermate controls (AhRfl/fl).  
 In males, deficiency of adipocyte AhR diminished the amount of weight 
lost following chronic pyocyanin exposure, indicating a partial effect of adipocyte 
AhR to regulate pyocyanin’s effect on body weight. This weight loss was not 
healthy, as no improvements in glucose tolerance were observed in the 
pyocyanin-treated mice experiencing weight loss. Moreover, pyocyanin’s 
adipose-selective activation of CYP1a1 was blocked in AhRAdQ males. 
 On the other hand, AhR deficiency in female mice potentiated pyocyanin’s 
effect to initiate weight loss. Pyocyanin stimulated lipolysis of adipose explants in 
  142 
tissues from AhRfl/fl females, which was mitigated in AhRAdQ females, indicating 
that adipocyte AhR mediates pyocyanin’s effect on lipolysis. Despite this effect to 
reduce lipolysis, AhRAdQ females lost more weight than their floxed littermate 
controls, demonstrating another mechanism contributes to pyocyanin’s effect on 
weight loss. The effects of pyocyanin described in Chapter 2, including an acute 
reduction of RER and chronic induction of inflammation and AhR activation in 
ADSCs from pyocyanin-treated females, could contribute to this weight loss in 
AhRAdQ females. Moreover, oxidative stress contributes to cachexia [392, 393], 
and pyocyanin’s production of reactive oxygen species may lead to weight loss 
independent of receptor activation.  
 These results suggest that while pyocyanin is an AhR ligand capable of 
activating CYP1a1 in an adipose-selective manner, its role in cachexia is not 
entirely mediated through adipocyte AhR. Although AhR deficiency protects 
males from weight loss and females from increased lipolysis, pyocyanin is still 
able to exert effects on cachexia in the absence of adipocyte AhR in both sexes.  
 
4.2 Limitations of the present study 
The results of this dissertation suggest that while pyocyanin is an AhR 
ligand capable of activating CYP1a1 in an adipose-selective manner, its role in 
cachexia is not entirely mediated through adipocyte AhR. Although adipocyte 
AhR appears to partially mediate weight loss and lipolysis, pyocyanin is still able 
to exert effects on cachexia in the absence of adipocyte AhR in both sexes. 
Oxidative stress is a known mechanism of cachexia [392, 393]. Therefore, 
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pyocyanin’s other physiological effects, namely its ability to produce reactive 
oxygen species, could contribute to the weight loss and fat wasting observed in 
these studies. The lack of measurements for oxidative stress, inflammasome 
activation, and apoptosis is a limitation of these studies. Such measurements, 
described below in the future directions, would allow a more complete 
understanding of pyocyanin’s mechanism of adipose cachexia.   
Additionally, the study of adipose cachexia is complicated by the obesity 
paradox, in which fat mass offers protection against sepsis [186-188]. If 
pyocyanin behaves similarly to other lipophilic, aromatic AhR ligands, pyocyanin 
could be sequestered in adipose tissue [52]. Increased adiposity could lead to 
greater adipose burden of pyocyanin in close proximity to adipocyte AhR. In 
cachexia, pyocyanin could be liberated from adipose tissue to exert systemic 
effects, similar to the mechanism observed with PCB-77 upon weight loss [52]. In 
consideration of these important roles of fat mass, it might have been more 
beneficial to match mice across study, strain, and sex for fat mass (as a percent 
of body weight) as opposed to age. 
Any therapeutics created to target pyocyanin’s actions on the adipocyte 
will only be efficacious in treating septic patients with P. aeruginosa infection, as 
this is the only bacterium to produce pyocyanin. Therefore, pyocyanin is unlikely 
to play a role in sepsis originated from other types of infection, such as E. coli. 
However, P. aeruginosa infection is also incredibly prevalent in cystic fibrosis 
patients, with 80% of cystic fibrosis patients colonized with the bacteria [395]. For 
this reason, much of the literature on pyocyanin focuses on its effects in the lung. 
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Cystic fibrosis patients also suffer from weight loss and wasting [396-398]; 
therefore, these findings could be applied to cystic fibrosis patients infected with 
P. aeruginosa who are losing weight. In fact, understanding pyocyanin’s 
mechanisms in the regulation of body weight and lipid homeostasis would have 
clinical relevance for many disease states associated with P. aeruginosa 
infection. 
 
Variations in AhR Responsiveness 
 Interpreting pyocyanin’s mechanism is complicated by different effects 
across length of exposure, sex, and strain, which could be explained by 
variations in AhR responsiveness. Response to AhR ligands is widely variable 
between species and within strains of the same species [399-402]. These 
variations in response can be partially explained by allelic differences in the AhR 
gene, with high- and low-affinity alleles producing a 10-fold difference in AhR 
ligand binding affinity and CYP1a1 expression levels [382, 383]. Unpublished 
studies in our lab have previously indicated differential induction of CYP1a1 
expression by PCB-77 between male C57BL/6J and AhRfl/fl mice on a C57BL/6J 
background. Analysis of the AhR alleles present in each animal colony is 
necessary for appropriate comparisons across these strains.  
Sex differences in AhR response to ligands have been described by our 
laboratory [403] and others [378-380]. In rats, females are more sensitive to 
TCDD toxicity than males [400]. On the other hand, in C57BL/6J mice, males 
have been shown to be the more sensitive sex to TCDD-induced toxicities [379, 
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404]. Interestingly, in male and female mice treated with TCDD, females had 
relatively higher expression of CYP1a1 [379] despite previous studies indicating 
that CYP1a1 may be repressed by estrogen receptor  (ER) [405]. In these 
studies, there was a sexually dimorphic effect on the time at which maximal 
response to TCDD occurred, with the female response occurring earlier than the 
male’s [379]. Moreover, mice exhibit sexually dimorphic TCDD wasting, as males 
lose more weight and possess greater inflammatory cytokine expression than 
females exposed to the same dose of TCDD [400]. This can be partially 
explained by the effect of sex hormones on sensitivity to AhR ligands, with 
estrogen providing resistance against TCDD and testosterone augmenting 
sensitivity to TCDD toxicity [404]. The variation in the magnitude and timing of 
AhR responsiveness between strains and between sexes provides context for 
the divergent effects seen in the acute and chronic studies of Chapter 2 as well 
as between sexes and mouse strains in both chapters.  
 
Inhibition of AhR 
Elucidating if pyocyanin’s effects are mediated through AhR has proven 
difficult due to problematic methods of inhibiting AhR activity. We used three 
different AhR antagonists to understand the role of AhR in pyocyanin’s in vitro 
effects on adipocytes because several antagonists, including -NF and TMF, 
have partial agonist activity [261, 262]. Indeed, partial agonist activity was 
evident in our results, as both of these antagonists increased CYP1a1 mRNA 
abundance when incubated alone with 3T3-L1 cells. Interestingly, treatment with 
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-NF and pyocyanin resulted in a synergistic activation of CYP1a1. Studies have 
previously reported synergistic CYP1a1 activation following co-treatment with -
NF and AhR ligands  [394, 406, 407]. This synergism could result from partial 
AhR agonism by -NF coupled with CYP1 enzyme inhibition by -NF leading to 
increased concentrations of AhR ligands as a result of reduced metabolism [394, 
406, 407]. Depending on the concentration, -NF is able to either antagonize 
AhR or activate the receptor by weak agonism or negative feedback from CYP1 
inhibition [394].  
In contrast, CH-223191, considered to be a competitive AhR antagonist 
[263-265] without partial agonist activity, was able to block pyocyanin’s induction 
of CYP1a1. However, CH-223191, as well as TMF, have been shown to 
selectively antagonize halogenated aromatic hydrocarbons (HAHs), such as 
TCDD, PCB77, and PCB126, but not polycyclic aromatic hydrocarbons (PAHs), 
flavonoids, or indirubin [265]. Although pyocyanin is aromatic, it lacks halogen 
atoms; therefore, these antagonists may be less effective at blocking all of the 
actions of pyocyanin mediated through AhR. This structural selectivity could 
explain why CH-223191 was able to attenuate pyocyanin’s induction of CYP1a1 
but not its reduction of adipocyte differentiation. Further, antagonists that may 
work on a strong agonist such as TCDD may not be as effective on weak 
agonists, such as pyocyanin. Future studies should implement other methods of 
interrogating AhR, including siRNA, to test the ability to antagonize pyocyanin’s 
effects. Furthermore, similar to the adipose derived stem cells used in Chapter 2, 
stromal vascular cells from AhR knockout mice could be harvested and treated 
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with pyocyanin during differentiation. However, this method is problematic due to 
potential role of endogenous AhR in adipocyte differentiation [219, 225].  
 
4.3 Future directions and conclusions 
The studies described in this dissertation are the first to investigate 
pyocyanin’s ability to activate AhR on adipocytes as well as its putative role in 
cachexia resulting from P. aeruginosa infection. Because P. aeruginosa is a 
leading cause of sepsis, and septic cachexia currently lacks an efficacious 
treatment, it is important to understand the contribution of pyocyanin to adipose 
wasting and its mechanisms of action. Characterizing pyocyanin’s physiological 
effects on adipose tissue are not only critical for understanding adipose cachexia, 
but also allow for the development of novel therapeutic strategies for treating 
cachexia and improving outcomes in critically ill patients.  
Several questions remain to fully understand pyocyanin’s mechanism of 
action to regulate body weight, fat mass, and potentially septic cachexia. First, 
the physiological effects of pyocyanin are not completely understood, and the 
toxicity of this compound is unknown. Although trypan blue staining of pyocyanin-
treated 3T3-L1 cells was normal, the ability of pyocyanin to initiate apoptosis in 
adipocytes is unknown.   
Second, more information is needed on pyocyanin binding to AhR and 
subsequent metabolism. Previous studies in liver cytosolic fractions determined 
the inhibition constant (Ki) of pyocyanin was 5.4M compared to a Ki of 40nM for 
TCDD [270]. Understanding pyocyanin’s ability to bind AhR is further complicated 
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by the fact that the three-dimensional structure of AhR remains unknown. Studies 
have suggested pyocyanin is metabolized by AhR [270], but the metabolism of 
pyocyanin remains to be elucidated, and this dissertation is the first report of 
pyocyanin metabolites in vivo. These metabolites may be biologically active and 
could act at AhR, at another receptor, or through non-receptor mediated 
mechanisms, such as the production of reactive oxygen species. Furthermore, 
detection of pyocyanin in adipose tissue suggests the virulence factor may be 
sequestered between lipids in the triacylglycerol droplets of adipocytes, similar to 
other AhR agonists [52]. If pyocyanin accumulates in adipose tissue, cachexia 
and weight loss could release the virulence factor into systemic circulation, 
allowing action at a distinct receptor. This liberation of pyocyanin from adipose 
tissue could explain the sensitization effect of pyocyanin, where greater effects 
are observed upon second injection.  
 This dissertation reveals a potential pathophysiologically relevant role of 
pyocyanin in weight loss, adipose wasting, and inflammation that could contribute 
to cachexia following infection with P. aeruginosa. However, future studies are 
needed to more fully identify a role for pyocyanin as a cachexia-inducing, 
bacterial-derived virulence factor. Future directions could compare the levels of 
pyocyanin quantified in plasma and adipose tissue within this study to levels that 
are observed either systemically or in adipose tissue during infection with P. 
aeruginosa. These comparisons would facilitate an understanding of the 
pathophysiological relevance of the findings of this dissertation as well as inform 
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the dose and frequency of pyocyanin exposure in future experimental studies 
aimed at elucidating mechanisms of pyocyanin.  
Furthermore, it is important to understand the pharmacodynamics and 
pharmacokinetics of pyocyanin, as there is limited information on the compound.  
For example, it is suggested to harvest plasma from exposed animals at time 
points earlier than 24-hours, as implemented in the acute study in Chapter 2. 
Collecting plasma at these earlier timepoints would allow the use of metabolomic 
analyses to determine metabolism of pyocyanin in the blood, similar to the 
methods used on urine that was collected one-hour post-injection. Sub-
mandibular bleeds would permit collection of blood at several time points after 
pyocyanin injection. Coupled with urine collection, metabolomic analyses on 
these samples would yield a more complete understanding of pyocyanin’s 
metabolism and excretion, which is poorly understood but has important 
implications in understanding the pharmacodynamics of the compound. 
Additionally, use of a HemaVet hematology system would permit analysis of the 
white blood cell counts of pyocyanin-exposed mice, complementing the plasma 
inflammatory cytokine panel performed in Chapter 2. 
Pyocyanin’s effect on adipose tissue warrants future study to develop a 
more comprehensive understanding of the virulence factor’s role in adipose 
cachexia. We previously demonstrated a role of endogenous ligands of AhR to 
regulate body weight and adipocyte size [247]; furthermore, reduced adipocyte 
size is reported in cachexia [136, 142, 143]. Therefore, adipose tissue samples 
taken from pyocyanin-treated mice in these studies should be sectioned and 
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adipocyte size quantified. Given pyocyanin’s effect to induce loss of body weight 
and fat mass, we would anticipate smaller adipocyte size in pyocyanin-treated 
animals.  
Furthermore, this dissertation describes the first studies examining levels 
and effects of pyocyanin in adipose tissue, revealing a novel area of study within 
the field of cachexia, sepsis, and P. aeruginosa infection. RNA sequencing and 
microarrays for inflammation lipid metabolism in adipose tissue on samples from 
pyocyanin-treated animals would yield a wealth of information. Due to 
pyocyanin’s ability to increase ROS [331], future studies should quantify levels of 
superoxide and hydrogen peroxide, as well as the activity of superoxide 
dismutase (SOD) and catalase (CAT), and glutathione peroxidase (GSH). 
Studies have also identified malondialdehyde (MDA) as a marker of oxidative 
stress following intranasal administration of pyocyanin [321]. Additionally, the 
NLRP3 inflammasome has been indicated as a mechanism of adipose cachexia 
in sepsis and burns [195, 408]. Pyocyanin has been shown to inhibit the NLRP3 
inflammasome in macrophages [334]. However, pyocyanin’s influence on the 
inflammasome in vivo has not been studied. Future studies should investigate 
adipose NLRP3 inflammasome activation following pyocyanin exposure.  
 Another novel area of study is the impact of pyocyanin on the gut 
microbiome. Previous studies have demonstrated pyocyanin’s antibiotic and 
antifungal properties [310, 315, 322, 324]. Therefore, if pyocyanin reaches the 
intestines during P. aeruginosa infection, it could impact the microbiome by killing 
off beneficial gut bacteria. The intraperitoneal injection utilized in the animal 
  151 
model of cachexia in these studies could expose the gut microbiome to 
pyocyanin. Alternative methods of exposure, such as oral gavage, could 
introduce pyocyanin to the digestive tract. If patients infected with P. aeruginosa 
are exposed to pyocyanin in their intestines, which is plausible given its detection 
in plasma, adipose, and urine, changes in gut microbiota could impact cachexia 
and outcomes of septic patients. Studies have demonstrated the ability of AhR 
ligands, including PCB-126, to increase intestinal inflammation and disrupt the 
gut microbiome by reducing bacterial diversity and altering gut metabolites [409, 
410]. Gut microbiota, which modulate the innate and adaptive immune system 
and maintain gut-barrier function, are disrupted by sepsis to become a 
“pathobiome” characterized by colonization of deleterious and opportunistic 
bacteria [411, 412]. Treatments targeting the microbiome have demonstrated 
protection against gut-derived sepsis by P. aeruginosa [413]. Therefore, a clear 
link exists between gut bacteria and bacterial sepsis. Furthermore, cachexia has 
recently been linked to changes in the microbiome. Leukemic cancer cachexia 
has been shown to negatively impact the gut microbiome even when the cancer 
occurs outside of the intestines [414]. The gut microbiome has been identified as 
a new therapeutic target for muscle wasting [414-416]; however, the connection 
between adipose wasting and the microbiome remains to be explored.  
Moreover, we propose more rigorous methods of studying pyocyanin’s 
effects in the context of P. aeruginosa infection. P. aeruginosa is the only 
bacterium known to produce pyocyanin. However, there are several mutant 
strains that either over-produce, under-produce, or lack production of pyocyanin. 
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Moreover, the P. aeruginosa PA14 strains 09480 (increased production of all 
phenazines) and phn1/2 (no production of any phenazines) [270] could be used 
to distinguish the effect of all P. aeruginosa phenazines versus that of pyocyanin 
alone. The phzM mutant strain of P. aeruginosa contains a mutation in the 
phenazine biosynthesis gene phzM required for pyocyanin production; therefore, 
phzM mutants have nondetectable pyocyanin production [417] and will enable 
distinction between pyocyanin-dependent versus independent effects of bacterial 
sepsis to regulate adipose tissue mass, inflammation, and body weight.  
Initial pilot studies would determine the optimal number of P. aeruginosa 
colony-forming units (CFUs) for IP injection to induce mid-grade sepsis 
associated with reductions in body weight and fat mass (similar to results 
administering pyocyanin alone). We would continue to utilize IP injection to 
induce sepsis because other methods, such as CLP, induce polymicrobial 
sepsis, and the presence of many other pathogenic bacteria would confound the 
study of the effects of P. aeruginosa and pyocyanin. This study design would 
elucidate the impact of pyocyanin in the context of P. aeruginosa infection as 
opposed to in isolation, as in the present studies. These studies would define the 
relative contribution of pyocyanin to adipose septic cachexia induced by P. 
aeruginosa and determine if these effects are AhR-mediated.  
To define the role of adipocyte AhR in the effects of pyocyanin, we would 
use AhRfl/fl and AhRAdQ mice. Male and female mice of each genotype would 
receive intraperitoneal (IP) injection of vehicle, pyocyanin alone, wild type (WT) 
P. aeruginosa, phzM mutant P. aeruginosa, or phzM mutant P. aeruginosa + 
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pyocyanin to induce sepsis. Additionally, we anticipate that IP injection of 
bacteria producing pyocyanin (WT P. aeruginosa, phzM mutant P. aeruginosa + 
pyocyanin, and pyocyanin alone) to AhRfl/fl mice would activate AhR in 
adipocytes, contributing to reductions in body weight and fat mass associated 
with increased inflammation in adipose tissue. If these effects of pyocyanin are 
AhR-mediated, then they would be attenuated in AhRAdQ mice. Conversely, if an 
increase in inflammation is seen in AhRAdQ mice following sepsis and pyocyanin 
injection, this could be due to the detoxifying capabilities of AhR. This interesting 
result would suggest that adipocyte AhR contributes to clearance and 
degradation of pyocyanin through hydroxylation and excretion. 
If pyocyanin’s effects are not mediated through adipocyte AhR, the whole 
body AhR knockout (KO) mouse model could be used to further study 
pyocyanin’s actions. Previous studies have investigated P. aeruginosa infection 
in whole body AhR KO mice and found that AhR KO mice are more susceptible 
to P. aeruginosa infection, which was believed to be linked to reduced clearance 
of pyocyanin [270]. However, body weight and fat mass changes were not 
quantified in this study, and pyocyanin itself has not been studied in whole body 
AhR knockout mice. 
The ultimate goal of the work presented in this dissertation is to discover 
novel interventions for the treatment of sepsis and adipose cachexia. As 
previously discussed, there is currently no FDA-approved medication for the 
treatment of sepsis or cachexia. Furthermore, due to growing rates of antibiotic 
resistance in sepsis-causing bacteria, new treatment strategies should aim to 
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target other pathways of infection, including compounds released by bacteria, 
such as pyocyanin, that mediate inflammation and cachexia. Of particular interest 
are nutrition therapies due to the lack of current efficacious nutritional 
approaches to preventing weight loss and fat loss in critically ill patients. If 
pyocyanin’s effects on adipose cachexia are AhR-mediated, AhR antagonists, 
such as resveratrol, could be used as a nutritional intervention. The plant 
polyphenol resveratrol is an AhR antagonist capable of attenuating the toxic 
effects of AhR ligands [418-420]. Previous studies in our laboratory have 
demonstrated resveratrol’s ability to protect against PCB-77 impairment of 
glucose homeostasis by improving insulin signaling in adipose tissue [418]. 
However, interventions that inhibit the CYP1 enzymes could inhibit the 
metabolism and excretion of pyocyanin, permitting its toxic effects to persist. 
If pyocyanin’s effects are not AhR-mediated, alternative studies could 
elucidate dietary therapeutics to alleviate septic cachexia, such as omega-3 fatty 
acids, probiotics, and antioxidants. Omega-3 polyunsaturated fatty acids have 
been studied as a treatment for cachexia to promote weight gain and prevent 
wasting. Furthermore, omega-3s have been studied in the context of P. 
aeruginosa infection, and studies have found omega-3s can modulate 
inflammation and increase survival in chronic pneumonia [421, 422]. Additionally, 
therapeutics targeting the microbiome could prove efficacious for the treatment of 
septic cachexia. Oral administration of probiotic Bifidobacterium longum to mice 
prevented against gut-derived sepsis by P. aeruginosa [413]. Synbiotics, a 
combination of probiotic bacteria and prebiotic fiber, have been demonstrated to 
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improve intestinal homeostasis in leukemic mice with cachexia [414]. A 
combination of Lactobacillus reuteri and inulin improved the gut microbial 
ecosystem, reduced hepatic cancer cell proliferation and muscle wasting, 
improved cachexia, and prolonged survival in mouse models of cancer cachexia 
[414]. Lactobacillus reuteri alone was also found to reduce systemic inflammation 
and muscle wasting in murine cachexia [416]. These effects of probiotics on 
cachexia, while promising, have focused solely on muscle wasting. Therefore, 
the study of probiotic interventions in adipose wasting represents a gap in the 
current literature that portends therapeutic benefits for cachectic patients.  
Lastly, studies have suggested the use of antioxidant co-therapy in sepsis 
due to the contribution of oxidative stress to sepsis pathogenesis, namely 
augmented inflammation, increased risk of shock, and organ failure [352]. 
Retrospective clinical studies in septic patients revealed a protective effect of 
vitamin C against organ dysfunction and risk of shock and mortality [423]. 
Moreover, antioxidants have emerged as a promising therapeutic strategy in 
cancer cachexia [424]. Given the multifactorial nature of cachexia, combination 
treatment strategies are the most promising. In fact, a combination of omega-3 
fatty acids, polyphenol-rich diet, and antioxidants in cancer patients with cachexia 
was shown to increase lean body mass, reduce ROS, IL-6, and TNF-α, and 
improve quality of life in a phase II nonrandomized study [425].   
In conclusion, this dissertation demonstrates the in vitro and in vivo effects of 
pyocyanin to activate adipocyte AhR and contribute to adipose wasting and 
cachexia. These studies expand the scope of current knowledge of sepsis and 
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cachexia by describing the role of a sepsis-causing bacterial virulence factor on 
adipocyte differentiation, lipolysis, inflammation, weight loss, and adipose 
wasting. Taken together, these data suggest that pyocyanin exerts effects both 
through adipocyte AhR and independently of the receptor. These findings reveal 
novel targets for the treatment of cachexia, which could reduce sepsis mortality 
and improve outcomes in patients infected with P. aeruginosa. 
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